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Increasing lines of evidence place platelets as having a central role in liver disease. 
Platelets are recruited to the liver and, depending upon stage and type of liver injury 
play varying roles ranging from driving liver fibrosis to aiding regeneration. However 
the molecular basis and consequences of platelet activation in the liver are less clear. 
The work presented in this thesis demonstrates for the first time that platelet 
activation via CLEC-2 is important in the pathogenesis of liver disease. In chronic 
human diseases (CLD) such as Primary Biliary Cirrhosis, and Alcoholic Liver disease 
I have demonstrated that the ligand for CLEC-2, podoplanin is upregulated on portal 
venules and increases proportionately to disease activity. I also note podoplanin 
staining on macrophage populations in CLD. Furthermore I show that this enhanced 
podoplanin expression may be a useful predictor of portal venous thrombosis, and 
correlates with MELD score for some categories of disease.   
In acute liver injury, CLEC-2-depended platelet activation has a profound effect on 
disease development. Here podoplanin expression occurs upon Kupffer cells in both 
humans and mice. Using carbon tetrachloride and paracetamol to induce acute liver 
injury in mice, I show that macrophage-expressed podoplanin activates platelets via 
CLEC-2. This interaction worsens liver injury, I next show that by blocking this 
interaction (using either CLEC-2 or podoplanin-deficient mice, or by using a function-
blocking podoplanin antibody) liver recovery from toxic liver injury was remarkably 
enhanced. This was dependent upon enhanced hepatic neutrophil recruitment in a 
TNFa dependent fashion.  
 
This work explains how platelets manipulate the sterile inflammatory response to 
acute, toxic liver injury and importantly highlights a mechanism that could be targeted 
therapeutically in human acute liver failure. 
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1.  Introduction 
1.1.  The burden of liver disease is increasing 
Mortality from liver disease is increasing. The clear majority of the burden of liver 
disease is due to chronic liver disease (CLD) and deaths due to CLD and its 
complications have been increasing annually. Between 1980 and 2013 liver disease 
deaths increased 4-fold (primarily due to alcohol excess)(1), this fact becomes 
particularly poignant when one compares this to other causes of death which are 
generally declining(2). Median survival of patients with end stage or decompensated 
liver disease is poor, approximating only 20 months(3), and the only cure at this 
stage remains orthotopic liver transplantation. 
Acute liver failure (ALF) is at one end of the liver disease spectrum. Although far less 
common than chronic liver disease, it remains a life threatening illness with little in 
the way of specific therapy(4). The abrupt loss of immunological and metabolic 
function that accompanies acute or fulminant liver failure results in encephalopathy, 
coagulopathy and often multiple organ failure. Fulminant acute liver failure is thus 
defined as 'a severe but potentially reversible liver injury with the onset hepatic 
encephalopathy within 8 weeks of the injury, in a patient without antecedent liver 
disease'. Depending on onset of encephalopathy in relation to when jaundice was 
first noted ALF is subdivided into hyper-acute, acute and subacute(5). ALF in the 
developed world has an incidence between 1 and 6 cases per million of the 
population per year and overall mortality from ALF is about 40%(6). In the west, 
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paracetamol overdose remains the commonest cause of ALF, whilst viruses account 
for the vast majority of cases in developing countries(5,7,8). 
Improvement in the quality of intensive or supportive care over time has resulted in a 
reduction in the mortality associated with ALF. However other than for some viral 
hepatitides, specific therapies are generally lacking. N-acetyl cysteine (NAC) in 
paracetamol overdose is an example of one of the few specific therapies available 
and although NAC is efficacious if used early in paracetamol overdose, the 
effectiveness of this compound decreases markedly in delayed presentations(9). 
There is therefore a need for specific therapy for ALF, particularly in certain scenarios 
such as a delayed paracetamol overdose, where NAC administration is of limited 
value(10) or other acute liver injuries such as alcoholic hepatitis where a recent study 
reveals that none of the current treatments extend patient survival(5,11). 
Chronic liver disease is the result of iterative bouts of liver damage. Multiple 
aetiologies can drive this ‘repetitive’ or persistent damage and these vary 
geographically; for instance alcohol, fatty liver disease and hepatitis C account for the 
majority of cases of chronic liver disease in the west(12) whilst hepatitis B is the 
primary cause in the Asia-Pacific area(12). Other causes include genetic conditions 
such as Wilsons disease, or autoimmune pathologies such as autoimmune hepatitis, 
primary sclerosing cholangitis and primary biliary cirrhosis. An important point to note 
is that despite the varied aetiologies that initiate chronic liver disease there are 
remarkable pathological and immunological similarities in how liver disease 
progresses(12,13). The continuum of chronic liver disease thus starts from repetitive 
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hepatocellular injury (due to a variety of aetiologies) which then causes cellular 
necrosis and loss; the liver is designed to counteract this cellular loss by 
regeneration(14), however the iterative nature of the injury in chronic liver disease 
impairs this process resulting in hepatic fibrosis, progressive loss of liver function and 
the development of liver cirrhosis which is characterized by the development of 
severe liver fibrosis with ‘regenerative' hepatic nodules(12). Liver cirrhosis is thus 
'end stage liver disease' and can be complicated by hepatocellular cancer or 
'decompensation’ which results in potentially uncontrollable or repetitive bleeding, 
infections and encephalopthy; the only effective cure at this stage is liver 
transplantation(13). 
I will now briefly discuss the microscopic structure of the liver followed by the different 
forms of human liver injuries pertinent to this thesis: 
1.2.  Structure of the liver 
The liver is a unique organ as it receives oxygenated blood directly from the heart as 
well as deoxygenated blood from the gut via the portal vein, blood from these two 
sources mixes in the liver sinusoids(15). The portal circulation delivers nutrient and 
antigen rich blood to the liver; the microscopic functional unit of the liver [the liver 
acinus (fig 1.1)], containing sinusoids lined with specialized endothelium, innate 
immune cells and bile ducts is key to allowing the liver to serve its metabolic and 
immunological functions (fig 1.1) (16)  
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Figure 1.1 Structure of the liver acinus:  
Deoxygenated blood from the gut rich with nutrients and pathogens drains into the liver via 
the portal vein whilst oxygen rich blood from the heart enters via the hepatic artery; blood 
from both these sources mixes within the liver sinusoids. The biliary canaliculi lined by 
cholangiocytes drain the hepatocyte secreted bile in the opposite direction to the blood flow 
into small bile ducts which eventually merge to form the larger intra and then extra hepatic 
biliary system. The hepatic artery, portal vein and associated bile duct are referred together 
as the portal triad, and are on the portal side of the acinus. Specialized sinusoidal 
endothelium (lacking a basement membrane and tight junctions) comprised of sinusoidal 
endothelium cells lines the liver sinusoids. These cells are organized like sieve plates with 
multiple fenestrations, which aid nutrient extraction from the blood. Liver macrophages or 
Kupffer cells reside within the sinusoids surveying the blood for pathogenic bacteria whilst 
simultaneously helping to maintaining immunological tolerance to harmless antigens. 
Between the sinusoidal endothelium and hepatocytes is the space of Disse; excess 
extracellular fluid is believed to drain to the liver lymphatics through this space and it contains 
liver stellate cells and fibroblasts. Blood exits the sinusoids through the central vein which is 
on the centrizonal side of the acinus. Multiple central veins merge together to give rise to the 
hepatic veins which provide venous drainage back to heart. Image taken from Eksteen et 
al(16) 
 5 
The hepatocytes that lie along the sinusoids have different metabolic functions 
starting from the portal to centrizonal end of the acinus; this phenomenon is termed 
metabolic zonation(17). The hepatocytes closet to the portal triad receive the highest 
amount of oxygen and form the zone 1 or periportal hepatocytes; they thus have a 
different set of metabolic functions to the ones nearest the central vein (zone 3 or 
centrizonal hepatocytes) which receive blood with lower levels of oxygen. The zone 1 
hepatocytes carry out oxygen dependent functions such as fatty acid oxidation and 
sulfation(17), whilst the zone 3 ones have a richer concentration of the cytochrome 
P450 (CYP) enzymes, and hence are the first ones to be damaged by toxic 
byproducts of xenobiotics(18). 
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Figure 1.2 Metabolic zonation of the liver:  
Zone 1 hepatocytes receive the highest oxygen concentration on the periportal side. Zone 3 
hepatocytes (in the centrizonal area) contain the highest concentrations of CYP enzymes 
and also receive the lowest concentration of oxygen and are thus more prone to hypoxic 








1.3.  Major classes of liver injury studied 
1.3.1.  Alcoholic liver disease 
Alcoholic liver disease is the commonest cause of chronic liver disease in the 
West(20). The spectrum alcoholic liver disease encompasses is wide; starting with 
simple liver steatosis in its early stages, to alcoholic hepatitis with advancing 
consumption and eventually alcoholic cirrhosis which is end stage liver disease. 
Steatosis or fatty liver is an early change seen in the livers of heavy drinkers and 
begins in the peri-venular or zone 3 hepatocytes, Recent evidence suggests that 
continued and heavy alcohol exposure, influences the transcription factors that are 
associated with lipid metabolism. This results in enhanced lipogenesis and lower 
levels of fatty acid oxidation and thus hepatic steatosis(21). Continued alcohol 
consumption drives episodes of acute hepatic inflammation (often on a background 
of steatosis, early fibrosis or even established cirrhosis)(22). These episodes of 
inflammation are termed alcoholic hepatitis and range from mild to life threatening 
with the hepatic histology at this point showing ballooning of hepatocytes, 
neutrophilic infiltration and the characteristic Mallory-Denk inclusion bodies(20). 
About 30-35 percent of heavy drinkers proceed to develop end stage alcoholic liver 
disease or alcoholic liver cirrhosis(20). 
1.3.2.  Non-alcoholic fatty liver disease 
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the 
metabolic syndrome(23). Similar to alcoholic liver disease NAFLD again exists as a 
histological spectrum starting from steatosis to hepatic necroinflammation [termed 
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non-alcoholic steatohepatitis or NASH(24)] and eventually to fibrosis and 
cirrhosis(25). The diagnosis of NAFLD is based on clinico-pathological criteria which 
require at least the present of steatosis and exclusion of other causes of liver 
disease(25). NAFLD represents one of the fastest growing causes of liver 
disease(25,26)  
1.3.3.  Autoimmune liver disease 
Autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing 
cholangitis (PSC) are the three main forms of immune mediated liver disease, there 
is variation amongst these according to the initiating autoimmune damaging insult, 
pattern of histological damage and thus final clinical phenotype(27). 
AIH is a classical autoimmune condition, exhibiting many features one would 
associate with autoimmunity including female preponderance, seropositivity and 
response to immunosuppressive therapy(27,28). AIH is divided into subtypes (types 
1 to 3) on the basis of type of autoantibodies found in the serum. The 
histopathological findings are fairly uniform amongst the different subtypes; a plasma 
cell rich lymphocytic infiltrate in the portal and periportal areas leading to interface 
hepatitis is characteristic(27). In parallel with other forms of liver disease if the 
damage progresses unchallenged, periportal fibrosis followed by broader fibrotic 
septa and ultimately cirrhosis with regenerative nodules results(29). 
PBC and PSC affect the bile ducts and thus comprise the autoimmune 
cholangiopathies. PBC characteristically affects the small interlobular bile ducts 
causing a non-suppurative and destructive cholangitis whereas in PSC the immune 
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injury affects the medium sized and extra hepatic bile ducts causing obliterative 
fibrosis and multifocal bile duct stricturing(27). Although both of these conditions 
exhibit autoimmune features (PSC less so than PBC) such as auto reactive T and B 
cell responses and the presence of characteristic antibodies (AMA-antimitochondrial 
antibodies) in PBC or the presence of non-specific antibodies including atypical 
ANCA and association with other autoimmune diseases such as inflammatory bowel 
disease in PSC(27), the response to immunosuppressive medication is 
disappointing. 
All three conditions are progressive and if untreated may lead to the need for liver 
transplantation(27), whilst most cases of AIH respond to immunosuppressive therapy 
such as corticosteroids and azathioprine(27); the only licensed therapy for PSC and 
PBC is ursodeoxycholic acid (UDCA). UDCA is a hydrophobic bile acid that has an 
effect in the cholangiopathies by protecting cholangiocytes (bile duct lining cells) from 
direct cytotoxicity of hydrophobic bile acids, stimulation of hepatobiliary secretion and 
reducing bile acid-induced hepatocyte apoptosis(30). Immunosuppressive medication 
in contrast to its role in AIH has little efficacy (for a variety of reasons) in PBC and 
PSC and thus is not routinely used(27). 
1.3.4.  Paracetamol induced fulminant liver failure 
Paracetamol metabolism and the resultant liver injury are both discussed in greater 
detail in section 4, suffice to say that as paracetamol is metabolized by enzymes of 
the cytochrome system (present in maximal concentrations in the zone 3 or the 
centrizonal hepatocytes-fig 1.2), the toxic byproducts of this metabolism in 
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paracetamol overdose cause a characteristic centrizonal (zone 3) pattern of liver 
necrosis. 
1.4.  Inflammatory cells drive disease pathogenesis in acute and 
chronic liver disease 
In acute liver injury the initial hepatic insult is followed by innate immune system 
activation(31). Liver resident and infiltrating innate immune cells including 
macrophages, neutrophils, natural killer cells, cytotoxic T cells and dendritic cells, 
interact with stromal cells and these collectively survey and monitor the hepatic 
environment for damage or infection(32,33). The function of this system is to clear 
dead/dying cells, enable repair and regeneration and guide a return to hepatic 
homeostasis(34). Most bouts of liver damage result in short lived episodes of liver 
inflammation or acute hepatitis. These mostly sub-clinical episodes spontaneously 
remit with little or no long-term sequelae. The hepatic inflammatory response can 
however on occasion instead of healing the liver, itself cause vast amounts of 
hepatocellular loss, worsening the initial injury and then potentially acute fulminant 
liver failure(4). The reasons this happens can sometimes be traced back to the 
nature or potency of the injurious stimuli (i.e. massive paracetamol overdose or 
overwhelming viral infection), but similar insults often drive different outcomes in 
different patients; the reasons for this variability are not completely understood and 
are likely to be multifactorial. The innate immune response can worsen the initial liver 
injury by enhancing liver cell death pathways such as necroptosis, necrosis, 
apoptosis and autophagy(35). Such detrimental innate immune system activation 
 11 
during acute liver injury often invokes a systemic inflammatory response driving a 
sepsis like immune paresis(35), The final result of this is multiple organ failure and 
accelerated hepatocyte loss resulting in the metabolic, immune and coagulopathic 
collapse characteristic of ALF(5). 
On the other hand, repetitive low grade liver insults result in iterative bouts of low 
grade inflammation and subsequently healing. Iterative patterns of liver damage and 
resultant inflammation result in the development of a stromal microenvironment 
comprised of a neomatrix, where interactions particularly between activated 
fibroblasts and macrophages(13) result in dysregulated cytokine production(36) and 
contribute to leukocyte positioning, recruitment and persistence, driving the 
fibrogenesis that results in chronic liver disease(13). Iterative inflammation therefore 
gradually drives the destruction of the liver macro and micro architecture, 
development of fibrosis, loss of hepatic function, and end stage liver disease which is 
characterized by liver cirrhosis and hepatocellular cancer (HCC)(13). 
Macrophages in particular have critical roles in both acute and chronic liver disease. 
The hepatic macrophage population, comprising both resident hepatic (Kupffer cells 
KCs) and blood derived macrophages (monocyte derived macrophages (MoMf))(37) 
accounts for the vast majority (almost 80%) of the total number of macrophages in 
the body(38). In mice, although Kupffer cells have traditionally been thought to 
perpetuate the initial toxic insult by releasing factors such as TNFa and CCL2 which 
initiate the immune response to paracetamol induced liver injury(38), depleting KCs 
results in a massive aggravation in paracetamol induced liver injury suggesting that 
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they overall likely play a protective role(39). The protective role of macrophages is 
also seen in human paracetamol injury where low levels of M-CSF (macrophage 
chemoattractant) is associated with poor outcomes overall(38). The macrophage role 
extends beyond acute liver injury; macrophages have divergent roles in chronic liver 
injury being important in driving both progression and resolution(40). Macrophage 
heterogeneity within the injured liver is consequent upon distinct pathways of 
activation which themselves are driven by specific cytokines and cellular interactions, 
particularly with fibroblasts(13). Large numbers of macrophages accumulate within 
the livers of patients with chronic liver disease; studies reveal that CD14highCD16+ 
macrophages are particularly important(38). This particular population is recruited to 
the liver by CX3CL1 and then undergoes transendothelial migration via VAP-1(41). In 
humans CD14highCD16+ macrophages secrete pro inflammatory and profibrotic 
cytokines such as TNFa, IL-8 and Il-1b and activate collagen producing stellate 
cells(40), thus driving fibrosis. Murine models of fibrosis have arguably been more 
comprehensively dissected than the human versions, here hepatic macrophage 
infiltration is driven by chemokine pathways which may drive fibrosis such as CCL2-
CCR2(42) and CCL1-CCR8(43) or inhibit it such as CX3CL1-CX3CR1(44). The 
macrophage role in resolution of of fibrosis becomes apparent with the emergence of 
Ly6Clow restorative macrophage population on cessation of injury; this population 
secretes various metalloproteinases (9, 12 and 13) which then aid reduction of 
fibrosis(45). 
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Another derivative of the myeloid compartment of cells is the neutrophil. After 
paracetamol induced liver damage neutrophils accumulate within the livers of both 
mice and humans(38,46). This is driven by the expression of DAMPs (damaged 
associated motif patterns) or alarmins, macrophages further enhance neutrophilic 
recruitment to the liver by sensing the expression of DAMPs by injured hepatocytes 
and secreting neutrophil recruiting cytokines. This process is part of the 'sterile 
inflammatory response' to liver injury(47) and is discussed in greater detail in chapter 
4. The infiltration of neutrophils is also seen within the livers of patients with chronic 
liver disease and chronically injured murine livers(38,48), in fact most liver diseases 
exhibit a degree of neutrophil co-localization. Although their role in acute liver injury 
and processes such as pathogen clearance and immune cell recruitment are well 
described and have traditionally been thought of as deleterious to the liver(38,49), 
recent work highlights a restorative or reparative role for neutrophils after a toxic liver 
injury(50). 
1.5.  Is there a role for platelets in liver disease? 
Although there is a striking difference between the final clinico-pathological features 
of acute and chronic liver disease, there are parallels between how they develop, 
most notably at the level of the initial necroinflammatory and innate immune 
response to injury. Manipulating the innate immune system may thus help in the 
treatment of both acute and chronic liver disease. Platelets represent a unique part of 
the innate immune system with well described functions in haemostasis, and 
arguably less familiar but equally relevant functions as immune cells(51). Platelets 
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interact with many of the key cellular protagonists of acute and chronic liver disease 
including myeloid cells, sinusoidal endothelial cells, lymphocytes and stromal 
cells(15,52) and unsurprisingly therefore the platelet role in liver pathology has been 
under much scrutiny over the last decade. Platelets have now been shown to 
contribute to almost all aspects of liver pathobiology including acute and chronic 
hepatitis, liver regeneration and the development of fibrosis(53). Although the specific 
molecular basis of these interactions is yet to be comprehensively be 
established(32). Manipulating platelet function to modulate the innate immune 
response during liver inflammation may be valuable in the treatment of both acute 
and chronic liver disease(52,54). With the growing burden of liver disease and the 
limited treatments currently available, establishing a definitive role of platelets in the 
different stages of liver disease, to then potentially use antiplatelet therapy which is 
already widely available, becomes particularly relevant. 
1.6.  Platelets and haemostasis 
The traditional paradigm of platelet function revolves around how platelets maintain 
vascular integrity at points of endothelial disruption through haemostasis. Having 
been extensively studied in cardiovascular science; the archetypal platelet role 
starting from adhesion to the damaged vessel wall culminating in activation and 
aggregation in concerto with the clotting cascade has been extensively 
described(53). The initial interaction with the damaged vessel wall is between platelet 
(GP) 1b-V-IX with von Willebrand factor (vWF). Formation of a thrombus starting 
from the initial weak GP1b-vWF interaction requires a rapid upregulation of autocrine 
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and paracrine signaling to amplify and sustain the platelet response(53,55). Central 
to this is the GP VI receptor. Platelets flowing at high velocities and under the 
considerable shear stress found in medium and large arteries thus use GP1b to 
tether to exposed vWF, this slows them down sufficiently to allow a meaningful 
collagen GP VI interaction (56,57). When collagen interacts with GP VI an ‘inside-out’ 
signal is generated which then institutes a conformational change in platelet 
integrins. The relevant platelet integrins 𝛼2𝛽1 and GP IIbIIIa, switch from a resting 
low affinity state to a high affinity state and bind to collagen resulting in stable platelet 
adhesion(56). The next stage of platelet activation is dependent on recruitment and 
activation of more platelets from the circulation. Release of soluble mediators and 
their interaction with G protein coupled receptors (GPCRs) is the key mechanism 
here(58). 
After a GPVI dependent platelet monolayer develops at the site of vascular injury, 
local concentrations of potent platelet activating molecules including adenosine 
diphosphate (ADP), thromboxane A2 (TXA2) and thrombin increases(57). These 
molecules act on GPCRs, drive positive feedback loops and upregulate their own 
production resulting in rapid activation and recruitment of platelets to the growing 
thrombus(58). ADP is stored within the platelet dense granules in high concentrations 
and is released on platelet activation(58). Thus, released ADP acts on the platelet 
GPCRs: P2Y2 and P2Y12, resulting in further platelet activation, characteristic shape 
change and positive feedback which accentuates platelet responsiveness to other 
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platelet activators such as TXA2(58). The thienopyridine clopidogrel exerts its anti-
thrombotic action by irreversibly binding an inhibiting P2Y12. 
Thrombin which is produced by the exposure of tissue factor to plasma coagulation 
factors on platelet and endothelial cell surfaces is amongst one of the most powerful 
platelet activators(58). Thrombin receptors are called protease activated receptors 
(PARs); mouse platelets express PAR 3 and 4, whilst human platelets express PAR 
1 and 2 (59). 
TXA2 is produced from arachidonic acid through the action of cyclooxygenase-1 
(target of low dose aspirin) (60). TXA2 activates platelets via its actions on the TXA2 
receptor (TP). This second phase of platelet activation requires a rapid and 
coordinated response of platelets to soluble mediators, and the versatility and thus 
responsiveness of the GPCR system is critical to this phase(58). 
The major platelet receptors (with their corresponding ligands) are detailed in table 







Receptor Ligand Receptor type 
PAR1 (only in 
human) 
Thrombin, PAR1 peptide (synthetic) G protein-coupled 
receptor 
PAR4 Thrombin, PAR4 peptide (synthetic) G protein-coupled 
receptor 
P2Y1 ADP G protein-coupled 
receptor 
P2Y12 ADP G protein-coupled 
receptor 
TP TxA2, U46619 (synthetic) G protein-coupled 
receptor 
GPVI Collagen, laminin, CRP (synthetic), 
convulxin (snake toxin), JAQ1 (antibody) 
Immunoglobulin 
α2β1 Collagen Integrin 
α6β1 Laminin Integrin 
GPIb-XI-V vWF, ristocetin (snake toxin) Leucine-rich 
αIIbβ3 Fibrinogen, vWF Integrin 
P2X1 ATP Ca2+ channel 
CLEC-2 Podoplanin, rhodocytin (snake toxin) C type lectin-like 
Table 1.1 Overview of the key receptors expressed in platelets (57). 
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Most classes of major platelet receptors have a prominent role in mediating 
haemostasis (61) and it is pertinent to therefore note that the vast majority are linked 
to and activate similar downstream pathways, this often begins with phospholipase C 
(PLC) 𝛽(60,62). PLC- 𝛽 has a variety of roles and induces numerous intracellular 
responses; critical ones include cytoskeletal rearrangements, Ca2+ dependent Rap1b 
(Ras-related protein Rap-1b) activation and DAG-dependent protein kinase C (PKC) 
activation. Rap1 then induces activation of the fibrinogen receptor and 𝛼 IIb 𝛽 3 
integrin (GPIIb-IIIa) whilst PKC triggers platelet granular secretion(60) (platelet 
granular secretion is discussed later). GPIIb-IIIa is the main and final receptor for 









1.7.  ITAM receptors and their ligands 
The focus of this thesis is the role platelet activation via the C-lectin like receptor-2 
(CLEC-2) plays in liver disease. CLEC-2 belongs to the ITAM group of receptors; 
these receptors signal intracellularly through immunoreceptor tyrosine-based 
activation motif represent a significant mechanism for platelet activation(63). CLEC-2, 
GPVI and Fc RIIA belong to this class of receptor, Fc RIIA however is present only 
on human platelets and absent from murine platelets. I will therefore discuss what is 
already known about the roles of such ITAM receptors in health and disease and why 
ITAM (and associated signaling pathway) blockade may be of relevance in liver 
disease. 
1.7.1.  CLEC-2 and Podoplanin 
CLEC-2 (fig 1.3) is encoded by the CLEC 1b gene on chromosome 12; this gene is 
within the Dectin-1 gene cluster where genes for six other C-type lectin receptors are 
also present(64). C-type lectin receptors are important pattern recognizing receptors 
(PRRs) which recognize molecular patterns on pathogens and initiate the intracellular 
signaling cascades critical to the cellular innate immune response to infection. CLEC-
2 was thus originally identified as being present on immune cells and is present albeit 
in small amounts on a subpopulation of inflammatory dendritic cells (60,64). Using a 
combination of mass spectrometry and affinity chromatography to the snake venom 
toxin rhodocytin, Watson et al demonstrated the presence of CLEC-2 on platelets 
(65) identifying it as the key receptor via which rhodocytin elicited platelet activation. 
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Figure 1.3 The structure of the CLEC-2 receptor:  
CLEC-2 exists as a homodimer on the surface of the platelet. It dimerizes once it binds its 
ligand and then signals intracellularly initially via Src (proto-oncogene tyrosine-protein 
kinase) and Syk (spleen tyrosine kinase) kinases, which then recruit and activate SLP-76 










Experiments demonstrating that tumor cells could cause platelet activation (which in 
turn facilitated cancer expansion) in a manner similar to rhodocytin led to the 
identification of the only known endogenous ligand for CLEC-2: podoplanin (66). 
Podoplanin is a 43kDA protein and was initially identified as a key protein in 
maintaining the glomerular filtration barrier; it was named podoplanin due to its 
presence on glomerular epithelial foot processes or podocytes (67). Podoplanin 
expression is rather more ubiquitous in its expression than CLEC-2. It is widely 
expressed on a variety of mammalian cells and has several names which reflect its 
discovery in different species including aggrus, T1 𝛼and gp36 in humans, gp38 or 
OTS-8 in mice, E-11 antigen in rats and gp40 in canine cells(68). Podoplanin is 
observed on lymphatic endothelium(69) , kidney podocytes (67) and type-1 
pneumocytes(68). Podoplanin expression changes during embryonic development, 
starting at high concentrations in the developing nervous system in the embryo to 
then being restricted to the choroid plexus in adults(68, 70) thus suggesting that it 
may have functions both in embryonic development and adult nervous system 
function. 
In addition to activating platelets via CLEC-2, podoplanin itself is linked to the actin 
cytoskeleton of the cell via the ERM (ezrin, radixin and moesin) proteins(71). Over 
expression of podoplanin, phosphorylates the ERM proteins thus exposing additional 
sites for actin and other proteins(69). This pathway may explain some of the effects 
podoplanin has on cellular motility and why it has been extensively studied in the 
context of cancer invasiveness and metastases, this is further discussed in chapter 3. 
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Figure 1.4 Schematic diagram illustrating the structure of Podoplanin:  
This basic schematic of podoplanin illustrates that podoplanin interacts with the cytosolic 
ERM proteins via a cytoplasmic amino acid tail (the three key amino acids for this interaction 
are K, K and R-coloured in pink). This interaction with ERM proteins enables podoplanin to 
influence cell migration by causing rearrangement of the actin cytoskeleton. Glycosylation of 
residue threonine 34 in the extracellular domain is necessary to support binding to CLEC-






1.7.2.  GPVI and its ligands 
The observation that collagen dependent platelet activation is blocked by tyrosine 
kinase inhibitors led to the discovery of GPVI(72). GPVI is the platelet collagen 
receptor and belongs to the Ig superfamily of surface receptors with two Ig 
domains(72). Although GPVI exist in both monomeric and dimeric forms, the 
monomeric forms inherently low affinity to collagen precludes binding at physiological 
concentrations(72). Binding of dimeric GPVI to collagen causes cross linking of the 
two dimers and thus phosphorylation of a conserved ITAM region within the FCR- -
chain (72). The gene for GPVI is located on chromosome 19, and in addition to 
collagen GPVI can also bind to laminin and adiponectin. Although the physiological 
relevance of these interactions is not immediately clear (66), laminin appears to have 
a role in facilitation platelet spreading through 𝛼6𝛽1 (73). Given the central role this 
receptor plays in the beginning of platelet activation it would seem sensible to 
assume that a GPVI deficiency would give rise to a substantial bleeding diathesis. 
Observations in patients with compound heterozygous mutations for the GPVI 
receptor however reveal that upto a 50% reduction in GPVI levels does not 
appreciably alter bleeding risk(72). This may be due to the recent observation that 
platelets have some constitutively active 𝛼2𝛽1 which can bind to fibrillar collagen 
without the need for the ‘inside-out’ signal GPVI provides(74) , or more likely the 




1.7.3.  ITAM signaling 
Both CLEC-2 and GPVI signal via the ITAM sequence characterized by Yxx(I/L)x(6-
12)Yxx(I/L). Upon receptor activation, the ITAM sequence is tyrosine phosphorylated 
by receptor associated src kinases. Dual ITAMs then serve as a docking site for SH2 
containing proteins including Syk tyrosine kinase (60)(75). CLEC-2 is different to the 
other ITAM receptors as it exists as a homo-dimer on the platelet surface, and 
dimerizes on meeting its extracellular ligand-podoplanin thus providing the dual ITAM 
scaffolding required for syk docking (76). Once bound, Syk undergoes both 
autophosphorylation and further phosphorylation by Src family kinases (57). 
Activated Syk then starts a signaling cascade involving linker for T cells (LAT) and 
the SH-2 domain containing leucocyte protein of 76kDa (SLP-76). This results in 
recruitment and activation of PLC 2 (70), Tec family kinases(57,60) and PI3K-
dependent signaling (60)(77) , calcium influx and then platelet activation. 
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Figure 1.5 ITAM signaling:  
Once the ITAM receptor GPVI or the hemITAM receptor CLEC-2 are activated, PI3K 
activation ensues; PI3K coverts PIP2 to PIP3 within the platelet plasma membrane. PIP3 
then activates Akt, which then phosphorylates GSK3. GSK3 phosphorylation serves to 
suppress platelet activation in GP VI (thus acting as a negative feedback pathway) but 
actually enhances platelet activation in CLEC-2. PI3K generated PIP3 also activates MEK 
and ERK, PLCg2 and recruits Btk and Tec to the plasma membrane to induce calcium 





1.7.3.1.  The coagulopathy of liver disease: could therapeutic blockade of ITAM 
mediated platelet activation avoid contributing to bleeding risk? 
GPCR signaling as discussed above has a critical role in effective haemostatic plug 
formation, however individual platelet ITAM receptor removal/blockade appears not 
to worsen the bleeding risk in a similar fashion to GPCR blockade (60,70,78). Mice 
with CLEC-2 deficient platelets do not exhibit prolongation of tail bleeding times 
(57,65). Thus, in keeping with the fact that the CLEC-2 ligand-podoplanin has not 
been reported as being expressed on structures or cells where it may facilitate 
thrombus formation such as vascular endothelium, platelets or exposed sub-
endothelial matrix (57). This limited role of CLEC-2 in thrombosis and homeostasis 
has however been debated, as May et al demonstrate defective thrombus formation 
in mice treated with a CLEC-2 depleting antibody (79), this may have been due to the 
filter blotting assay used by May et al to assess clot formation; other groups have 
found no discernible increase in bleeding times with the same antibody but using 
non-filter assays (80,81). Similarly, no appreciable bleeding diathesis is noted with a 
selective GPVI deficiency (82). This aspect of individual ITAM receptor blockade 
makes blocking one of these receptors a particularly attractive method of abrogating 
platelet activation in patients where the bleeding risk is substantial, such as in 
patients with acute liver failure with associated disseminated intravascular 
coagulation. Although the bleeding risk that accompanies the ‘coagulopathy’ of 
chronic liver disease is overstated(83), it would regardless seem sensible to exhibit 
caution when manipulating platelet function in these patients until a definitive role for 
platelet function and haemostasis can be established in CLD; again, highlighting a 
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case for targeting ITAM receptor driven platelet activation. Blocking Syk signaling 
(downstream of ITAM receptors CLEC-2 and GPVI) using Syk deficient mice or small 
molecular inhibitors such as PRT060318 again does not prolong tail bleeding 
times(64) , which is interesting as in vivo experiments with mice deficient in both 
GPVI and CLEC-2 results in profound defects in haemostasis and arterial thrombus 
formation(57). It thus seems likely that these haemostatic defects in the double 
deficient mice are thus due to a combination of loss if adhesion plus activation 
compared to a complete block of the signaling pathway(64). 
1.7.3.2.  Role of ITAM receptors in maintenance of vascular integrity and 
inflammation 
Platelets have an important role in the maintenance of vascular endothelium. This is 
greater than merely mediating healing at points of damage or disruption. Studies in 
thrombocytopaenic rabbits(84) and humans(85) demonstrate endothelial thinning, 
increased permeability and abnormal capillary fenestrations. The maintenance of 
endothelial integrity becomes particularly important during situations of increased 
leukocyte movement such as during inflammatory processes or within lymph nodes 
for the development of adaptive immunity. Herzog et al recently demonstrated the 
role of platelets in maintaining high endothelial venue integrity (HEV) in lymph 
nodes(86). Here platelets (via CLEC-2) interact with podoplanin expressing 
fibroblastic reticular cells (FRCs), which then causes a localized release of 
sphingosine-1-phosphate (S1P) from platelets. This platelet derived S1P then 
maintains vascular integrity by increasing VE-cadherin expression on HEV cells (86). 
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Similarly, during models of lung inflammation , Boulaftali et al note that inhibiting 
GPVI or removing CLEC-2 from platelets results in a breakdown of the vascular 
barrier causing intra-alveolar haemorrhage (78). Interestingly it was noted that 
blocking GPCR signaling had no effect on the maintenance of vascular integrity in 
the same model (78). It is pertinent to note that there in order for there to be bleeding 
or a breakdown in vascular integrity during thrombocytopaenia, a 'second hit' of 
inflammation after thrombocytopenia is needed (87). George et al imaged the 
cutaneous Arthus reaction, and demonstrated in real time the breakdown of vascular 
integrity in thrombocytopaenic mice during inflammation and the increased leukocyte 
movement this brought(87). It is likely that the increased trafficking of leucocytes that 
accompanies inflammation essentially ‘punches’ holes in the endothelium which are 
then rapidly sealed by platelets in an ITAM dependent fashion, perhaps through a 
combination of suppressing further inflammation or releasing endothelium healing 
vasoactive factors (75). 
The main leukocytes responsible for the inflammatory bleeding that accompanies 
thrombocytopaenia are probably neutrophils, as depleting neutrophils or blocking 
their migrating ability reduces such haemorrhage (88). Whether the vasculoprotective 
effects of platelets during leukocyte trafficking extend beyond 'healing' the 
endothelium to actively manipulating leukocyte effector activity, such as by 




1.7.3.3.  Role of CLEC-2 in lymphatic development 
The separation of lymphatic and blood vessels during embryogenesis as well as the 
maintenance of this separation during adult life is highly dependent on platelets, 
specifically the ITAM signaling pathway beginning with CLEC-2(70). During 
embryogenesis, blood within the developing vasculature comes into contact with 
podoplanin expressing lymphatic endothelium; this interaction initiates platelet ITAM 
signaling via CLEC-2 resulting in the separation of lymphatic vessels from blood 
vasculature (75). The role downstream molecules including Syk and SLP-76 play in 
mediating blood lymphatic separation was established using chimeric mice over 10 
years ago(91). Subsequent experiments using mutant mice models with conditional 
deficiencies of CLEC-2 and Syk within the megakaryocytic cell lineage demonstrate a 
similar phenotype of abnormal blood-lymph secondary to erroneous lymphatic 
development(70), the fact that this phenotype was not replicated on inducing a Syk 
deficiency in any of the other haematopoietic lineages confirms the specific role of 
platelets in this process(70). 
It is interesting to note that CLEC-2 signaling on platelets is not only essential for the 
initial development of the lymphatic system but also in the maintenance of the 'blood-
lymph barrier’ in later life(92). This holds particular relevance to the liver as the low 
shear, non-injured (during health) environment of the liver sinusoids is not dissimilar 
to the low flow, low shear environment at the lymphovenous junction; additional 
parallels between both environments is the lack of dependence on integrins for either 
thrombosis(93) or cellular recruitment(15). 
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1.8.  Platelets beyond homeostasis (53) 
It is increasingly being recognized that platelets play a complex role beyond their role 
as cellular mediators of thrombosis; the platelet ITAM receptors illustrate this point 
well. Contribution of platelets to diverse processes including atherosclerosis(63), 
infection(94), lymphangiogenesis(70), acute lung injury(95) has now been described. 
An emerging theme from recent work is how intricately platelets interact with 
inflammatory cells and influence the outcome in inflammatory reactions (96). I shall 
next therefore briefly review what is known about how platelets participate in 
inflammatory processes in general. 
1.8.1.  The platelet secretome dictates function (53) 
Soluble mediators contained within these cells help account for some of the other 
observed roles that platelets play in pathophysiological processes; the ‘platelet 
secretome’ which is arguably context specific (97) helps shape the outcome of 
platelet activation. Platelets contain a plethora of biologically active proteins, most of 
these inflammatory and immune mediators are preformed and stored in the alpha, 
dense and lysosomal granules within the platelet cytoplasm (63). 
The least abundant lysosomal granules contain glycohydrolases and degradative 
enzymes (63). Dense granule constituents range from the vasoactive peptide 
serotonin to calcium and pyrophosphate (98), these granules thus contribute to 
platelet activation, aggregation and modulation of systemic vascular tone (63). The α-
granules are the most abundant granule in platelets; they are synthesized in 
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megakaryocytes prior to the mature platelets 'budding' off. Proteomic analysis has 
confirmed the presence of hundreds of proteins within α-granules (52). The diverse 
contents include proteins destined to be expressed on the platelet surface and also 
soluble proteins that are released into the extracellular space (63) . Hence α-granules 
secrete fibrinogen and von Willebrand factor (vWf), adhesive proteins which mediate 
platelet-platelet and platelet-endothelial interactions and therefore are critical to 
primary and secondary haemostasis (99,100). P-selectin, which translocates from α-
granules to the platelet surface following platelet activation is a critical 
immunomodulatory molecule and participates in platelet interactions with endothelial 
cells, monocytes, neutrophils, and lymphocytes. Furthermore, α-granules contain a 
variety of mediators that induce recruitment, activation, chemokine secretion, and 
differentiation of other vascular and hematologic cells (99,100). 
An interesting but contentious point is whether platelet activation results in a non-
specific degranulatory event causing the platelet to release all of its inflammatory 
payload or whether a more selective profile of cytokine release can be triggered by 
different activating signals. There is evidence to suggest that depending on the initial 
stimulus, certain granules are preferentially released. Italiano et al suggest that 
distinct populations of pro and anti-angiogenic factor containing α-granules exist, 
whose secretion is differentially regulated by different stimuli (97). Given the 
contrasting and varied pathology mediated by platelets, selective granule secretion 
remains an exciting avenue for further study. Mechanistically this may explain why 
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platelets behave in different ways mediating seemingly contrasting roles in liver 
injury(52). 
1.8.2.  Platelet sequestration in tissue contributes to inflammation 
Platelets can bind to the endothelium in the absence of collagen exposure or 
endothelial denudation(101) , this occurs only if either (or both) the platelet or the 
endothelium in activated. Indeed bidirectional activation is characteristic of systemic 
inflammatory states such as hypercholestrolaemia(102). Platelet and endothelial 
activation is also seen during the sepsis associated systemic inflammatory response 
and underlies many of the clinically relevant sequelae including microvascular 
thrombosis and organ dysfunction(103) . A similar consumptive coagulopathy with 
concomitant small vessel obstruction is seen in the haemolytic uraemic syndrome 
where the shiga toxin renders both platelets(104) and the endothelium highly 
thrombogenic(105). Acute lung injury represents an organ specific manifestation of 
platelet activation aiding inflammatory cell recruitment thus driving endothelial and 
tissue damage. Projahn et al and Stokes et al [as cited by Boulaftali et al(75,95)] 
state that these interactions can potentially be mediated by a variety of platelet 
receptor-ligand pairs including P-selectin-PSGL-1, GPIb α -Mac1, CD40L-CD40, and 
α IIb β 3-ICAM1. 
1.8.3.  Platelets are the gatekeepers to innate and adaptive immunity 
The ability of platelets to interact with endothelial and inflammatory cells makes them 
ideally suited to be part of the 'first response' to invading microbes. Platelets 
effectively focus haemostatic and immune responses to help prevent pathogen 
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invasion in situations where physical barriers such as the skin are breached(63). It is 
unsurprising therefore that platelets secrete and express molecules which are directly 
microbicidal, such as CXCL4, thymosin-β4, and CCL5 (RANTES)(106), but also 
modulate and initiate immune responses (both innate and adaptive)(107). Toll like 
receptors (TLR) which have critical role in antigen capture and initiation of the innate 
immune response are found on platelets (108) . Of these, platelet based TLR 4 may 
arguably be the most important by driving TNFα production, LPS induced 
thrombocytopaenia (109) , mediating neutrophil adhesion and NET formation (110). 
Platelets have the capability to bridge the acute phase response to infection(63) to 
adaptive immunity by expressing immunostimulatory molecules like CD154(107) and 
secreting chemokines including CCL3 (MIP 1α) and CCL5(111). These molecules 
are known to help induce antiviral CD 8 T-cell production(112) (central to viral 
mediated hepatotoxicity) and mediate T-cell activation(113). Platelets additionally 
regulate and in many cases, are critically important in mediating tissue 
regeneration(52), angiogenesis, wound healing, cancer and lymphangenesis. Given 
the diverse systemic and organ specific roles of platelets-some of which are 
highlighted above, it is perhaps unsurprising that increasingly evidence suggests that 
platelets play a profound role in the hepatic environment. 
1.9.  Platelets and liver disease: what is already known?(53) 
The platelet role in inflammation is entirely context dependent and varies according 
to pathophysiological stage of the reaction, organ involved etc.(89), it is thus 
important to establish these parameters prior to studying platelets in inflammatory 
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disease, this holds particular relevance when one examines the contribution of these 
cells to inflammatory processes within complex organs such as the liver. The platelet 
role to liver pathology is pleiotropic and sometimes seemingly contradictory 
especially when comparing liver disease specific platelet contributions(53). 
Platelets enter the injured liver and interact with hepatic sinusoidal endothelium 
influencing effector cell recruitment and activation (15). These cellular interactions 
can result in the granular release of a range of platelet contained bioactive proteins 
as discussed above (52). Using these bioactive molecules platelets are able to drive 
diverse, even seemingly opposite hepatic processes ranging from necro-
inflammation and fibrosis to liver repair and regeneration. Such variation is also 
observed in other organs (89) and is partly explained by the very nature of 
inflammation, which is a multistep, pleiotropic process with platelets varying in their 
contribution in a disease and stage specific manner. Strategies to block platelet 
activation can be platelet specific (low dose aspirin, clopidogrel and platelet 
depletion) or can also affect other cell types (cilostizol, rho kinase inhibitors and 
protease activated receptor blockade)(53). The latter must be taken into account 
when defining a role for platelets in liver disease and crucially these effects may 
explain discrepancies in the observed platelet effect in models of liver damage(53). 
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Table 1.2 Summary of the roles platelets play in different liver injuries(53)  
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1.9.1.  The interaction between platelets and liver sinusoidal endothelium 
governs hepatic leukocyte recruitment 
Hepatic sinusoids are lined by unique fenestrated endothelial cells, which are 
exposed to only minimal shear stress (15) and have scavenger like functions (126). 
Additionally, the unique phenotype of sinusoidal endothelium characterized by 
paucity of P-selectin expression (both constitutive and inflammation-induced) and low 
levels of VWF(15) help set hepatic vasculature apart from the majority of other 
endothelial beds and render the liver a specialized environment for platelet-
endothelial interactions(53). The combinations of signals which govern recruitment of 
immune cells across the sinusoidal bed are distinct from those reported in other solid 
organs(15,127) and platelets may compensate for the lack of expression of 
attachment factors such as selectins to assist in leukocyte recruitment during 
inflammation. Studies in viral models of murine hepatitis(113,116,128), human liver 
regeneration and ischaemia-reperfusion injury(129), demonstrate platelet 
sequestration within hepatic sinusoids. in vitro  studies with human hepatic sinusoidal 
endothelial endothelial cells (HSEC) demonstrate that platelet adhesion is partly 
integrin (GPIIb/IIIa and αVβ3) mediated(15) with the precise location of hepatic 
platelet adhesion varying dependent on the type of injury. For instance, in ischaemia-
reperfusion injury platelets are selectively sequestered to the periportal and midzonal 
sinusoidal endothelium(15). Bound platelets activate isolated HSEC to express 
CXCL-8 and CCL-2 thereby promoting neutrophil and lymphocyte recruitment (fig 
1.3)(15). Studies in rats have revealed that platelet-driven leukocyte recruitment 
results in hepatic damage during systemic endotoxaemia and that platelet-endothelial 
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interactions precede and drive leukocyte adherence(130). Furthermore, leukocytes 
themselves can also recruit platelets to the liver. Models of ischaemia-reperfusion 
injury in mice reveal the ability of CD4 T-cells to activate endothelial cells thus driving 
platelet recruitment to the liver sinusoids (Figure 1.3). The end result is a self-
perpetuating cycle of microvascular dysfunction and hepatocellular injury(131). A 





Figure 1.6 Platelet-HSEC-lymphocyte interactions during liver injury: 
A and B) Activated platelets bind to the endothelium causing the endothelium to upregulate 
and secrete CXCL 8 and CCL2. These chemokines recruit T cells and neutrophils to the 
endothelium. C) T cells use the platelets to bind to the endothelium. Platelets use CD44 to 







1.9.2.  Platelet interactions with myeloid cells 
Platelet interaction with myeloid cells, particularly macrophages and neutrophils, has 
been extensively investigated in the context of cardiovascular disease, thrombosis 
and atherosclerosis(132–134). As Mantovani et al however point out, the role 
platelets play in innate immunity and inflammation via interaction with myeloid cells is 
frequently overlooked(135). These inflammatory and immune interactions are highly 
relevant to liver disease because (as already mentioned above) neutrophils and 
macrophages play central roles in liver injury, fibrogenesis and 
regeneration(40,136,137). Although the accepted paradigm is that regardless of 
initial insult, neutrophils recruited to the site of liver damage exacerbate liver damage, 
recent evidence suggests that they may also have anti-inflammatory and restorative 
properties(138); For example, platelets have recently been shown to physically 'pave 
the way' for neutrophils to enter the liver during sterile liver injury to aid 
repair(50)(Table 1.2). The macrophages role in liver disease has been touched upon 
above. Platelets have an important role in regulating macrophage differentiation and 
recruitment; platelet derived CXCL4 and microparticles induce patterns of 
macrophage activation consistent with tissue repair(139) and matrilysis(140), 
respectively. in vitro studies using human cells demonstrated the ability of platelet 
derived CXCL4 to induce differentiation of blood monocytes to tissue 
macrophages(141). These macrophages then switch to a pro-inflammatory 
phenotype on interacting with activated platelets at sites of tissue inflammation(142). 
In the liver, Kupffer cell-platelet interactions are important determinants of the 
outcome in liver ischaemia-reperfusion injury. During the early period of an ischaemic 
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insult, platelets sequester in the liver with most adhering to Kupffer cells(117) most 
likely through the interactions between platelet CLEC-2 and macrophage podoplanin 
which is up-regulated under inflammatory conditions. The interaction between 
platelets and Kupffer cells provides bidirectional signals which together drive tissue 
injury; reducing platelet-Kupffer cell binding ameliorates hepatic inflammation in 
steatotic livers of rodents (90,143). During ischaemia-reperfusion injury platelet-
Kupffer cell interaction precedes and initiates leukocyte accumulation, sinusoidal 
dysfunction and the iterative inflammation which eventually results in liver failure (32). 
 
1.9.3.  The roles of platelets in specific liver diseases (53) 
1.9.3.1.  Viral Hepatitis: are platelets a primary mediator of viral hepatitis (53) 
The generation of virus specific T cells is an important determinant of the outcome of 
viral hepatitis. Lang et al described how platelets aggravate viral hepatitis in mice 
through the secretion of serotonin that results in hepatic sinusoid microcirculation 
failure, delayed viral clearance and enhanced cytotoxic T-cell (CTL) mediated liver 
damage (128). Several other murine studies also demonstrate that depleting platelets 
attenuates CTL mediated liver damage (114); platelet reconstitution is able to restore 
intrahepatic T cell accumulation and cytotoxicity. The need for platelet activation is 
shown by studies in which reconstituting platelet-depleted mice with platelets 
rendered resistant to activation by treatment with prostaglandin E1 (PGE1) did not 
restore T cell mediated liver damage(116) (Table 1.3). Blocking GPIIb/IIIa and αVβ3 
reduces platelet-sinusoidal binding in vitro  by about 50%(15), suggesting that other 
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molecules and mechanisms promote platelet binding to hepatic sinusoids including 
platelet based CD44 binding to sinusoidal hyaluronan(32). (Figure 1.6)(53). 
1.9.3.2.  Contribution of platelets to non-alcoholic fatty liver disease 
The hepatic manifestation of the 'metabolic syndrome' is non-alcoholic fatty liver 
disease (NAFLD)(23). Platelets already have well described roles in the vascular 
complications of the metabolic syndrome and atherosclerosis; a role for platelets in 
NAFLD is also beginning to emerge. Mean platelet volume (MPV), a surrogate 
marker of platelet turnover is consistently higher in patients with NAFLD(144) and 
there is a direct correlation between MPV and histological severity of hepatic 
inflammation and fibrosis(145). in vivo murine studies support a role for platelets in 
fatty liver disease(146). These studies however need to be interpreted with caution 
as the antiplatelet drug (cilostizol) demonstrated to have the most marked effect on 
reducing hepatic steatosis, inflammation and fibrosis in mice on high fat/high calorie 
or choline-deficient diets(146), has numerous 'non-platelet' effects. Data regarding 
antiplatelet therapy and liver disease in humans is generally lacking but a large 
recent cross-sectional analysis suggests that regular aspirin use may be associated 
with a lower prevalence of NAFLD(53,147). 
1.9.3.3.  Dual roles for platelets in cholestatic liver injury 
Depletion of platelets protects against cholestasis-induced hepatic inflammation and 
injury suggesting that platelet interactions within the micro-vasculature may be 
important in cholestasis induced liver damage(121). A variety of strategies designed 
to block platelet function have similar effects in acute murine cholestatic injury. Rho-
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kinase inhibitors reduce liver damage in bile duct ligation models of cholestasis(122) 
whilst platelet depletion reduces hepatic necro-inflammation in response to alpha-
naphthylisothiocyanate (ANIT)-mediated cholestatic liver injury(123) However, as 
with other injury models, the role of platelets in cholestatic liver injury evolves with the 
development of chronicity. Although perpetuating acute inflammation early on, in the 
late stages of cholestasis, platelet activation is hepatoprotective. Thus, inducing 
thrombocytopaenia in mice during the latter stages of chronic cholestasis worsens 
liver function by causing hepatic fibrosis(148)(Table 1.3). Studies in PAR-4 (protease 
activated receptor) deficient mice suggest that it is probably platelet activation 
resulting in platelet MMP secretion and fibrolysis that underlies their observed 










Table 1.3 Summary of the contribution of key platelet-derived mediators to the 
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1.9.4.  Liver regeneration and fibrosis: two sides of the same platelet? 
1.9.4.1.  Platelets drive liver regeneration and inhibit fibrosis 
Platelets are critical regulators of liver regeneration. After hepatic resection, platelets 
sequester at the resection margins and orchestrate complex processes necessary for 
functional hepatic architecture(149). The first suggestion that platelets may have a 
role in liver regeneration came from studies in rats, where thrombocytosis was 
observed to aid liver regeneration via hepatocyte derived growth factor (HGF)(150). 
Subsequently, it has been shown that platelets are potent mediators of liver 
regeneration; thrombopoietin induced thrombocytosis experiments have 
demonstrated improved survival in rodent models of partial hepatectomy (PH) 
ordinarily lethal (eg 90% hepatectomy)(149) or situations where regeneration has 
been traditionally been thought of as undermined such as cirrhosis(151). Additionally, 
thrombocytopaenia inhibits liver regeneration in partially hepatectomized mice(129). 
Platelet-mediated hepatic regeneration is dependent on their ability to bind to 
sinusoidal endothelium, interact with Kupffer cells and traverse the space of Disse to 
interact with the hepatocytes as described below(152) and shown schematically in fig 
1.7. in vitro  studies with cultured HSEC reveal that platelets promote endothelial 
production of IL6 and vascular endothelial growth factor (VEGF) via sphingosine 1-
phosphate. These two proteins simultaneously inhibit apoptosis and stimulate 




1.9.4.2.  But platelets can also drive fibrosis 
Liver repair and regeneration requires both pro- and anti-proliferative signals to 
coordinate tissue repair. Platelets play a dual role: in addition to their ability to 
suppress fibrogenesis and drive hepatic mitogenesis, under certain conditions 
platelets have the potential to diminish hepatocyte regeneration and exacerbate 
fibrosis(140,155). 
Rodent studies reveal that platelets lysates have the potential to drive the release of 
profibrotic factors by hepatic stellate (HSC) in vitro (156). A platelet-derived cytokine 
implicated in liver fibrosis is CXCL4. Hepatic CXCL4 levels increase proportionately 
to fibrotic burden and CXCL4-/- mice display markedly less hepatic fibrosis in 
response to injurious stimuli than their WT counterparts(157). Similar findings have 
been reported in human chronic liver disease; patients with advanced fibrosis have 
high intrahepatic and serum concentrations of CXCL4(157). A schematic 






Figure 1.7 The platelet role in regeneration and fibrosis:  
A) Regeneration; Platelets stimulate liver regeneration by three simultaneous interactions 1) 
Kupffer cells: on binding platelets, Kupffer cells become activated and produce TNFα and 
IL6. 2) Hepatocytes: Platelets directly stimulate hepatocyte growth and proliferation via HGF, 
IGF-1 and VEGF. 3) Sinusoidal endothelial cells: activated platelets produce S-1-P, which 
promotes liver regeneration via akt and ERK1/2 phosphorylation. B) Fibrosis; Platelets 




1.9.5.  Therapeutic implications of platelets in liver disease 
Platelets have diverse roles in liver patho-biology. Defining the stage and disease 
specific molecular contributions will help us to devise sensible treatment strategies 
using antiplatelet drugs. The ultimate goal of studying platelets in liver disease thus is 
the potential of this work to yield new therapies of the treatment of acute and chronic 
liver disease. With the large amount of anti-platelet drugs already in use, evidence for 
how antiplatelet therapy may impact liver disease is beginning to emerge. Recent 
work for instance suggests that aspirin reduces the risk of liver fibrosis in patients 
who have been transplanted for hepatitis C(158) Mechanistically, aspirin and 
clopidogrel inhibit dense granule release, blocking serotonin among other small 
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molecules. These drugs also inhibit the expression of a -granule-stored proteins that 
are involved in heterotypic interactions between platelets/ leukocytes and the 
endothelium including P-selectin and CD40L(159) Reducing platelet activation alters 
how immune-mediated chronic hepatitis progresses, impacting even cancer 
development(159). 
1.10.  Project aims 
The overarching hypothesis behind this project was that 'platelet activation via CLEC-
2 has a role in driving liver damage’. Establishing the role of platelets role in liver 
disease is critical to designing sensible and rational platelet targeting therapy in the 
management of such patients. I chose the ITAM receptor CLEC-2 specifically in this 
regard as abrogating individual ITAM receptors does not appreciably increase 
bleeding risk in mice (64) and human patients with advanced acute or chronic liver 
disease often exhibit marked coagulopathy. Although as mentioned above this risk 
particularly in association with chronic liver disease is often overstated(83). 
Therefore in order to address this hypothesis, this project had the following specific 
aims: 
1) To assess whether chronically and acutely injured human livers express the 
requisite ligand for CLEC-2 mediated platelet activation: podoplanin. Here I also 
aimed to document whether platelets sequester to the liver during human liver 
diseases and whether such co-localization varies with disease type and stage, and 
importantly whether platelets are able to sequester to podoplanin expressing areas. I 
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also established whether podoplanin expression varies between type and extent of 
hepatic injury seen. Lastly as podoplanin is known to mediate inflammatory hepatic 
thromboses(94) I assessed whether they may be a link between podoplanin 
expression and portal venous thrombosis. 
       2) to ascertain the functional relevance of the CLEC-2:podoplanin axis in 
mediating or perpetuating acute inflammatory liver damage such as that seen with 
toxic agents including carbon tetrachloride and paracetamol. Here I blocked this axis 
using a combination of mutant mice and function-blocking antibodies. 
       3) to establish if there is any role for the CLEC-2 podoplanin axis in chronic liver 
injury specifically the development or regression of fibrosis and the development of 
fatty liver disease. Here I used the chronic carbon tetrachloride model to induce 
fibrosis and study regression of fibrosis. I also used the methionine choline-deficient 
diet in mice to induce fatty liver disease and determined to consequences of CLEC-2-




2.  Materials and methods 
 
2.1.  Human tissue 
All tissue used for this thesis was collected at the Queen Elizabeth Hospital 
Hepatobiliary Unit in Birmingham, obtained with prior written, informed patient 
consent and approved by our local research ethics committee. Normal liver tissue 
was from hepatic resection margins and donor tissue that was surplus to requirement 
for transplantation. Diseased liver tissue from explanted livers with drug induced liver 
injury (DILI), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), 
alcoholic liver disease (ALD) and autoimmune hepatitis (AIH) was obtained from 
patients in the Birmingham liver transplant programme. Limited patient details for 
each of the liver samples obtained were available to clinical staff in the Centre for 
Liver Research. These included Model for End stage Liver Disease (MELD) scores 
which were calculated from patient blood taken immediately pre-transplant using the 
following equation. 
𝑀𝐸𝐿𝐷 = 3.78 ∗ 𝐼𝑛[𝑠𝑒𝑟𝑢𝑚𝑏𝑖𝑙𝑖𝑟𝑢𝑏𝑖𝑛(𝑚𝑔/𝑑𝑙)] + 11.2 ∗ 𝐼𝑛[𝐼𝑁𝑅] + 9.57






2.1.1.  Liver tissue section preparation 
Fresh liver when obtained from liver explant specimens was as per lab protocols cut 
into 1cm3 cubes, and immediately placed into liquid nitrogen for snap freezing. The 
cubes were then stored at - 80° C until needed. OCT TissueTek mount was used to 
embed the liver cubes and 7𝜇m section were cut using a cryostat (Bright OTF). The 
freshly cut sections were then mounted on 0.01 % Poly-L-Lysine (Sigma, UK) coated 
microscopy glass slides (Leica, UK). The slides were then fixed in acetone (NHS 
supplies) and stored at -20° C until needed. 
2.1.2.  PCR 
Tissue for quantitative polymerase chain reaction (qPCR) was obtained from frozen 
cubes of diseased or normal livers as detailed above. The process is described 
below. 
2.2.  Murine tissue 
Eight to twelve week old wild type (WT) C57BL/6J mice were purchase from HO 
Harlan OLAC Ltd. (Bicester, U.K.). Multiple genetically modified mice were used in 
this study and the mutant mice strains are detailed in table 2.1. All genetically 
modified mice were bred from in-house colonies at the University of Birmingham 
Biomedical Services Unit (BMSU), these colonies were maintained by the 
Birmingham Platelet Group. All animals were housed at the BMSU in conditions free 
from specific- pathogens. All experiments were performed in accordance with UK 
 51 
Home Office regulations, under the remit of an appropriate HO project license and 
were ethically approved by the local research ethics committee. 
 
Table 2.1 mouse strains used in this project 
2.3.  Methods 
2.3.1.  Induction of murine liver injury 
2.3.1.1.  Carbon tetrachloride 
Acute 
Carbon tetrachloride (CCl4) (Sigma, UK) was administered intraperitoneally to induce 
hepatic necroinflammation. For the acute models, CCl4 was administered dosed by 
weight at 1ml/Kg. CCl4 was dissolved in mineral oil (Sigma, UK) in a 1:4 ratio (1 part 
CCl4 to 4 parts solution or 1 part CCl4 to 3 parts mineral oil). The mixture was made 
up in glass containers due to the ability of CCl4 to act as a solvent and dissolve 





























the mineral oil/CCl4 mixture and thus the pressures required to administer the 
mixture, only luer lock syringes were used for the procedure. For the acute CCl4 
intoxication models the dose was only administered once. Mice were harvested at 
the end point of the experiment via cardiac puncture (schedule 1 procedure) under 
deep sedation. Whole blood was obtained via cardiac puncture and livers were 
harvested in their entirety as described below. 
Chronic 
For the chronic models, as per our previously used lab protocol I initially used the 
same dose as for the acute models i.e. 1ml/kg. This resulted in some animals losing 
too much weight and thus needing to be culled before adequate hepatic fibrosis 
could be established. So I repeated the experiment using a lower dose of CCl4 (0.6 
ml/Kg) again made up by dissolving in mineral oil (again 1:4), this dose has been 
described in the literature(160). Control mice were given only mineral oil. Mice were 
injected with mineral oil or CCl4 twice a week, for 7 weeks to induce fibrosis. To 
minimize concomitant hepatic necroinflammation mice were taken at 72 hours after 
the last injection of CCl4. 
To study the resolution phase and allow for reversal of fibrosis; after 7 weeks of 
biweekly CCl4 injections the treatment was stopped. Mice were then left with no 
further treatment for three weeks prior to culling them. Mice were harvested at the 
end point of the experiment via cardiac puncture (schedule 1 procedure) under deep 
sedation. Whole blood was obtained via cardiac puncture and livers were harvested 
in their entirety as described below. 
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2.3.1.2.  Paracetamol induced liver injury 
Paracetamol (Sigma, UK) was dissolved in PBS. This necessitated heating the 
solution to 60℃, with continued stirring. The solution was cooled to 37℃ prior to 
injecting intraperitoneally into the mice. The final dose used 350mg/kg and a 
maximum of 350ul of solution was injected per animal. Mice were monitored closely 
after injection and we found that they exhibited an antalgic gait, reduced feeding and 
reduced movement at around 6-8 hours’ post injection. This was transient and by 24 
hours all mice spontaneously improved. Mice were harvested at the end point of the 
experiment via cardiac puncture (schedule 1 procedure) under deep sedation. Whole 
blood was obtained via cardiac puncture and livers were harvested in their entirety as 
described below. 
2.3.1.3.  Methionine Choline deficient diet 
To study the development of steatohepatitis and fibrosis mice were administered the 
methionine choline deficient (MCD) diet(161). This lipogenic was obtained from 
Harlan-teklad laboratories, and was used to completely replace the chow the mice 
were normally fed. Mice had free access to chow and were weighed and monitored 
daily. They all exhibited greasy coats and a degree of overgrooming at the start of 
the diet but within two weeks this reverted to normal behaviour in most of the animals 
placed on the diet. The end point for this experiment was 6 weeks on the diet, 35% 
weight loss on the diet or excessive grooming leading to wounds. Mice were 
harvested at the end point of the experiment via cardiac puncture (schedule 1 
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procedure) under deep sedation. Whole blood was obtained via cardiac puncture and 
livers were harvested in their entirety as described below. 
2.3.1.4.  Therapeutic interventions used in the murine models 
Etanercept 
Etanercept antibody was obtained from Amgen and injected intravenously where 
indicated at a dose of 10mg/Kg, diluted in sterile PBS. Control animals received PBS 
alone. 
Neutrophil depletion 
Neutrophil depletion was achieved using a specific alpha Ly6G antibody (1A8). The 
use of a selective alpha Ly-6G antibody for the purposes of neutrophil depletion has 
described previously(162,163). The antibody was obtained from Bioxcell, West 
Lebanon, NH, USA. Where indicated mice were pretreated (24 hours prior to either 
APAP or CCl4 injection) with 200 𝜇g of 1A8 in phosphate buffered saline (PBS) 
intravenously. Control animals were given PBS alone. 
Anti-podoplanin antibody 
We used a function blocking anti-podoplanin antibody to abrogate CLEC-2 
dependent platelet activation in out murine experiments. An IgG anti mouse 
monoclonal, specific podoplanin IgG targeting antibody (8.1.1) was raised in Golden 
Syrian hamsters (made in house by Margaret Goodall). This was injected at a dose 
of 5𝜇g/gm intravenously (diluted again in PBS). Control animals received isotype 
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matched control antibody (Purified IgG, golden Syrian hamster-again made in house) 
diluted in PBS. 
2.3.1.5.  Experimental end point 
Mice were sacrificed under deep anaesthesia using isoflurane. Up to 1 ml of whole 
blood was obtained from each animal via cardiac puncture using a 25g x 5/8” gauge 
needle which was directly inserted into the heart. Blood was transferred to eppendorf 
tubes and allowed to clot at room temperature for 1 hour. The clotted blood was 
centrifuged at 15000 RPM for 15 minutes, the supernatant was removed and 
centrifuged again at 15000 RPM for 15 mins (Sorvall Legend Micro 17 Centrifuge). 
The supernatant harvested at this point was either sent for measurement of serum 
alanine transaminase (ALT) levels or immediately frozen down to -80℃ for storage. 
Where blood platelet isolation was required (see macrophage isolation assays below 
section 2.8.3) syringes were pre-coated/prefilled with acid-citrate dextrose (ACD) as 
an anticoagulant (100µl of ACD per 900µl of whole blood). This anticoagulated blood 
was kept at room temperate prior to being used for platelet isolation (see section 
2.8.4). Where whole blood counts of cells were required anticoagulated mouse blood 
was analyzed using ABX pentra 60 blood counter (Horiba medical, France). 
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2.4.  Tissue Preparation 
2.4.1.  Liver harvesting 
After being bled via cardiac puncture, mice were next subjected to a schedule 1 
procedure (cervical dislocation). The liver was then dissected out and care was then 
to harvest in its entirety (fig 2.1). The liver was then divided into 3 sections labelled 
as lobes A-C below (fig 2.1). 
 
Figure 2.1 Method of liver lobe isolation:  
Once dissected out lobe A was placed in 4% formaldehyde (for paraffin embedding and 
sectioning-see below). Lobe B was immediately snap frozen by being placed in liquid 
nitrogen after extraction, the lobe was then stored at -80℃ 
 until required. This lobe was used either for preparing frozen sections for confocal 
immunofluorescent microscopy or for providing tissue for PCR or for hydroxyproline assays 
(all described below). Lobe C was placed into ice cold RPMI supplemented with glutamine 
(Sigma-Aldrich, UK), this entire lobe was used for isolating and staining intrahepatic 







2.4.2.  Histology 
Lobe A of the liver which was initially suspended in formalin, was next trimmed to 
remove fibrous/tough parts of the liver capsule, and then resuspended in fresh 4% 
formaldehyde after being placed in a plastic cassette (Wheaton, UK). These were 
then embedded in paraffin according to the following protocol: 
 
Figure 2.2 Procedure for wax embedding of liver tissue 
 
5 𝜇m sections were cut from paraffin embedded tissue and then fixed onto 
microscope slides (X-tra Adhesive, Leica). 
2.4.3.  Haematoxylin and Eosin staining 
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Paraffin embedded liver sections (mouse) (made as described above) were ‘de-
waxed’ as detailed in figure 2.3. All reagents were purchased from Leica 
microsystems, Peterborough, UK. 
 
Figure 2.3 Method to de-wax paraffin sections 
 
 
'Dewaxed' mouse sections as described in fig 2.3, or frozen human liver sections 
(that had been stored at -20ºC) were thawed and stained with haematoxylin and 
eosin as described in fig 2.4. 
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2.4.4.  Picrosirius red staining 
Paraffin sections were de-waxed and hydrated as detailed above in figure 2.3. The 
slides were next laid out in a humidified chamber and wax squares drawn around the 
sections. 5% phosphomolybdic acid solution (PMA-Sigma, UK) was used to cover 
the tissue sections. The slides were placed on the rocker for 5 minutes, following 
which the PMA was tapped off and the slides placed into a pre-made picrosirius-red 
dye (0.1%, Sigma UK) bath. The bath was placed on a rocker for 30 minutes, at 
which point slides were removed and excess picrosirius red tapped off. The slides 
were now dipped sequentially in 0.1M HCl and then dH20 (1-2 seconds each), and 
then 3 batches of fresh ethanol (for 2 minutes each). Slides were then left in clearene 
(Leica, UK) for 5 minutes and mounted in DPX (Sigma, UK). 
2.4.5.  Van Gieson stain 
Mouse paraffin sections were dewaxed as described in fig 2.3 stained with Van 








2.4.6.  Immunohistochemistry 
Both mouse and human sections were stained using immunohistochemistry (IHC) to 
visualize protein expression or infiltrating leucocyte patterns. For fluorescent IHC, 
only frozen sections were used (both mouse and human). These frozen sections 
were removed from -20ºC storage and allowed to thaw before staining. For certain 
antibodies, paraffin sections were recommended for optimum visualization. All 
paraffin sections were obtained from mice, and had to undergo an antigen retrieval 
procedure prior to staining. 
2.4.6.1.  Antigen retrieval 
The sections were de-waxed as described in section 2.3. They were then placed in a 
plastic bucket containing 990ml of distilled H20 and 10 ml of high pH antigen retrieval 
solution (Vector, UK), and placed in a microwave (Sanyo, Japan) and heated at high 
power for 10 minutes. The solution containing the slides was then allowed to rest at 
room temperature for 10 minutes following which cold water was added to bring the 
temperature of the solution down to room temperature. The slides were then placed 
in TBS (tris buffered saline, Ph 7.6, Sigma, UK) for 5 minutes. 
Once the antigen retrieval procedure was completed (in the case of paraffin sections) 
or the frozen sections had thawed, a common IHC staining pathway as described 




2.4.6.2.  Staining protocol 
The slides were initially placed in a blocking solution for 20 minutes to block 
endogenous tissue peroxidase (Dako, UK). The slides were next washed twice in 
TBS for 5 minutes each. A wax pen was then used to draw a well around the tissue 
section. 100 𝜇l of 20% casein solution and 1 drop of horse serum (both Vector, UK) 
were then placed within the wax well-ensuring complete coverage of the section, and 
the slides were placed in a humid chamber on slow rocking for 30 minutes. The 
casein solution was then tapped off, and 75 𝜇l of solution containing the primary 
antibody (made up to the appropriate concentration using TBS) was placed within the 
wax well, the slides were incubated with the primary antibody for 60 minutes (with 
slow rocking). The primary antibody was then washed off, by washing the slides in 
TBS and 0.05% tween (Sigma-aldrich, UK). All secondary antibodies used had 
already been commercially adsorbed and were again made up to the appropriate 
concentrations using TBS. 75 𝜇l of secondary antibody solution was placed on the 
sections for a 45 minute incubation (with slow rocking) and then washed off as 
described above. The primary and secondary antibodies used, species, clones and 
concentrations are detailed in table 2.6. 
If the desired secondary antibody to be used was linked to horse-radish peroxidase 
(HRP), the slides were then developed using a peroxidase substrate (Vector, UK). 
The substrate was 3, 3’-diaminobenzidine tetrahydrochloride (DAB SK-4100) (Vector) 
and made up as per the manufacturer’s instructions. Briefly 2 drops of buffer stock 
solution, 4 drops of DAB stock solution and 2 drops of hydrogen peroxide solution 
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were added to 5 mls of dH2O. 150 𝜇l of the resulting solution was added to the 
section containing the HRP linked antibody and the slide developed to the required 
intensity usually (60 seconds to 2 minutes). The slides were then washed as 
described above, and counterstained with filtered Mayer’s haematoxylin for 20 
seconds. The slides were then sequentially washed in cold and then warm water (2.5 
mins each), following which they were dehydrated in alcohol and clearene, then 
mounted in DPX (Sigma). 
2.5.  Microscopy 
2.5.1.  Brightfield 
Photographs of stained tissue were taken using a Zeiss Axioscope microscope using 
brightfield illumination and then analyzed using Axiovision software (Carl Zeiss, UK). 
2.5.2.  Confocal 
Confocal microscopy was used define the nature of the cellular infiltration that 
occurred in acute and chronic human and murine liver damage. Sections cut using a 
cryotome and stored at -20ºC were thawed at room temperature. The tissue sections 
were drawn around with a wax pen, following which the tissue was covered with 
blocking solution (100𝜇l of 20% casein solution, and a drop of horse serum (both 
vector)). The sections were then gently rocked in moisture chamber (covered with foil 
to block exposure of the fluorescent antibodies to light thus minimising potential 
bleaching). The blocking solution was then tapped off and the primary antibody made 
upto the appropriate concentration (in TBS) was added to the section, the slide was 
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then placed back into the moisture chamber and allowed to rock for 60 minutes. The 
slides were then washed twice in TBS with 0.05% tween as described above and 
incubated in the rocking chamber with the fluorescent secondaries (if indicated) at 
the appropriate concentrations for 30 minutes. The slides were then washed again, a 
hoechst 33258 stain was next used to stain the nuclei (2 minutes) and then the 
stained section was mounted using Prolong Diamond Anti-fade Reagent (Invitrogen, 
Paisley, UK). A LSM510 microscope (Zeiss) was used to acquire the pictures, the 
software used for acquisition was Zeiss LSM software. 
2.5.2.1.  Isotype controls 
To set the fluorescence detection levels of the LSM510 appropriately (specifically the 
amount of fluorescence detected by each channel), we always prepared a section 
control within which the primary antibody was omitted, conjugated secondary 
antibodies were added as with the other sections. The laser emission strength of the 
microscope was then set to a level where only minimal fluorescence was detected on 
the isotype control. This ensured that non-specific background fluorescence was 
minimized. I have included an isotype control sample in chapter 3, figure 3.2 to 
illustrate this. Isotype control images obtained on the confocal microscope have not 
been repeated throughout. 
2.6.  Quantitative PCR 
RNA was extracted from human livers using a RNEasy kit (Qiagen, UK) and cDNA 
was generated using a High capacity cDNA reverse transcription kit (ThermoFisher, 
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UK) according to manufacturer’s instructions. Quantitative analysis of Podoplanin 
mRNA expression was performed using Taqman Fluorogenic 5' nuclease assays 
using gene-specific 5' FAM labelled probes (PDPN gene; aliases A-GGRUS, gp36, 
gp40, gp38, HT1A-1, OTS8, PA2.26, T1A, T1A-2, T1A2, TI1A: Hs00366766_m1, 
Applied biosystems UK) run on a ABI Prism 7900 sequencer with 18s;SFRS4 used 
as internal control. Differential expression levels were calculated according to the 2-
ΔΔCt method. 
Component Concentration at which used 
Taqman 2x master mix 
(Applied Biosystems)  
1x  
 





RNAse free water Up to 10μl  
 
cDNA  100 μg/ml  
 
Table 2.2 Materials used for qPCR reaction 
 
2.7.  TNFa ELISA 
Serum from mice or supernatant from cell cultures/assays (section 2.8.3) was used 
for ELISA. The TNF-𝛼 ELISA was conducted using the manufacturers instructions 
(Thermo Fisher Scientific, 88-7324). An ELISA plate (Corning Costar 9018), was 
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incubated overnight with 100𝜇l/well of capture antibody. The wells were washed with 
wash 250𝜇l of wash buffer three times, and then 200𝜇l of ELISPOT diluent was 
added to each well. The plate was set to rest at room temperature for 1 hour. Next 
the standards were made up to the appropriate concentrations and placed in order of 
increasing dilution (2 fold) in the plate, along with the standards (100𝜇l of sample per 
well-each sample placed in triplicate) and incubated for 2 hours (fig 2.6) 
 
Figure 2.6 ELISA well set up:  
The standards were placed in order of increasing dilution from A through to H, H had no 
detectable standard (diluent control only). The remaining wells were used for samples, each 







The wells were then aspirated/washed as previously described and the plate 
incubated with detection antibody for 1 hour. After another aspiration/wash cycle, 
avidin-HRP was added to each well and the plate incubated at room temperature for 
30 minutes. The plate was then aspirated, washed and then the tetramethylbenzidine 
(TMB) substrate solution was added to each well, the plate was covered and 
incubated at room temperature for 15 minutes, next 50𝜇l of stop solution was the 
added to each well. The plate was read at 450nm on a versamax plate reader and 
analyzed using Softmax pro software. The standard curve was plotted using PRISM 
7.0 software. 
2.8.  Isolation of murine leukocytes 
2.8.1.  Preparation of leukocyte suspension from murine liver 
Lobe C prepared as described in figure 2.1, was immediately placed into 3 mls of ice 
cold RPMI. The lobe was then weighed and dissociated (GentleMACS dissociator) in 
a gentleMACS C tube (Miltenyi Biotec). The programme used was spleen_04_01. 
The homogenate from the tube was then filtered using a 70𝜇m cell strainer (Falcon) 
into a 20ml Falcon tube. The filtrate was made up to 10mls using cold RPMI and then 
centrifuged at 2000 rpm for 5 minutes, the pellet was then resuspended in 10 mls of 
RPMI and the process repeated. After two washes, the pellet was resuspended in 
10ml of RPMI. The cell suspension was then divided into two volumes of 5 mls each. 
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For each sample 7 mls of optiprep solution (at room temperature) was used. 160 mls 
of optiprep solution (enough for 10 animals) was prepared as follows [42.6 mls of 
Optiprep (Sigma) + 117.4 mls PBS]. 
5ml of the cell suspension was layered upon 7 mls of the prepared optiprep solution 
in a 15ml corning tube. Thus for each sample, two layered cell suspensions were 
created. These were then centrifuged at 1000 rpm for 25 mins with no brake. The 
cells at the interface of both tubes were extracted and combined; the cells were then 
washed twice and then resuspended in RPMI. This solution was now the leukocyte 
suspension. 
2.8.2.  Flow cytometry 
2.8.2.1.  Live dead stain 
The leukocyte suspension obtained above was washed in and then re-suspended in 
1ml of PBS. A live-dead stain (Zombie NIR-Biolegend) was made up in DMSO as per 
the manufacturer’s instructions and 1µl of dye was added per ml of cell suspension. 
The cells were incubated at room temperature protected from light for 30 mins. The 
cell suspension was then washed twice in MACS buffer and then resuspended in 1ml 
MACS buffer (PBS+1mM EDTA+2%FCS). 
2.8.2.2.  Flow cytometric staining 
The live-dead stained cell suspension was aliquoted into round bottomed 
polypropylene FACS tubes (corning) as detailed below: 
100µl for cells alone 
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100µl for isotype matched controls 
200µl for combination tubes 
Compensation beads (AbD serotec) were used for single colour controls. A single 
drop of the bead solution was suspended in 100µl of PBS to which the fluorophore 
containing antibody was added. The volumes of each antibody for single colour 
control used are detailed in tables 2.3-2.5. 
The volumes of fluorescent antibodies and isotope matched controls added per tube 
is detailed below. 
T-cell combination: 
 
5µl anti-CD3-PB  
5µl anti-CD4-PE  
5µl anti-CD45-PerCPCy5.5  
5µl anti-CD8a-APC  
T-cell IMCs: 5µl hamster IgG2-PB  
5µl rat IgG2a-PE  
5µl rat IgG2b-PerCP-Cy5.5  
5µl rat IgG2a-APC  
Table 2.3 T-cell panel and IMCs: 


















5µl anti-CD3-PB  
2µl anti-F480-FITC  
10µl anti-CD11b-PE  
5µl anti-CD45-PerCPCy5.5 
5µl anti-Gr-1-APC  
 






5µl hamster IgG2-PB  
2µl rat IgG2a-FITC  
10µl rat IgG2b-PE  
5µl rat IgG2b-PerCP-Cy5.5  
5µl rat IgG2b-APC  
Table 2.4 Myeloid Cell panel and IMCs: 



























5µl Hamster IgG2-PB 
5µl IgM V450 
5µl IgG2a-PB 
5µl Rat IgG2a-BV510 
2µl Rat IgG2a-FITC 
10µl Rat IgG2b-PE 
5µl Rat IgG2b-PerCPCy5.5 
5µl Rat IgG2c-APC 
Table 2.5 Pro-fibrotic and restorative macrophage panel and corresponding 
IMCs: 




The stained samples were next incubated at 4℃ under foil for 30 mins. The stained 
cells were then washed again and resuspended in 400µl of macs buffer. 50µl of 
AccuCheck counting beads (invitrogen, UK) were added per tube. The samples were 
vortexed to ensure homogenous distribution of cells and beads, and then acquired 
using the CyAn FACS Analyser (Dako, Denmark) using Summit v4.3 software. Data 
were analysed using FlowJo software [Version 8.7(TreeStar)]. The gating strategies 
are shown in the relevant sections. 
Cells per gram was worked out using the following formula: 
𝑐𝑒𝑙𝑙𝑠/𝑔𝑚 =(counted cells on flow scatter plot X total counting beads in 50µl of 
accucheck solution)/(counted beads on flow scatter plot X weight of liver lobe) 
2.8.3.  Hepatic macrophage isolation 
To isolate macrophages for in vitro  studies we used Blomhoff’s principle of selective 
plastic adherence(164). Once the leukocyte suspension was obtained as detailed 
above in section 2.8.1, it was washed again and this time made up to 6 mls using 
Dulbecco’s modified eagle medium (DMEM-Gibco) supplemented with fetal bovine 
serum (FBS, Gibco, UK) and penicillin/streptomycin/glutamine (PSG, Gibco, UK). 
The solution gently vortexed to ensure uniform distribution of leukocytes throughout 
the solution, and then 1ml of solution was added per well in a 6 well plate (Corning). 
The plate was incubated for 2 hours at 37℃ in a 5% CO2 atmosphere. Non-adherent 
cells were then gently washed off with PBS. To confirm that the remaining cells were 
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macrophages a fluorescent F4/80 (FITC conjugated, ebioscience) antibody was used 
(fig 4.6). 
Once adequate a number of cells had seeded in each well (gauged using phase 
contrast microscopy), 1ml of DMEM (with or without lipopolysaccharide-LPS 
100ng/ml, Sigma) supplemented with FBS (Gibco) and PSG (Gibco) was added to 
each well. In experiments where platelets (isolation described in section 2.8.4) were 
added, these were layered on 6 hours after the macrophages had been incubated at 
37℃ in a 5% CO2 atmosphere. 
Macrophages were either isolated from wild type mice or when podoplanin deficient 
macrophages were required, these were isolated from Vav1-iCre+pdpnfl/fl mice. 
2.8.4.  Isolation of platelets from murine whole blood 
Blood was obtained from an anaesthetized mouse as described above, via cardiac 
puncture using a 25-gauge needle with a 1 ml syringe containing 100µl of acid citrate 
dextrose (ACD, Sigma). The whole blood was transferred to an eppendorf tube and 
centrifuged for abut 7 mins at 1000rpm using a Sorvall centrifuge. The top phase 
(platelet rich plasma-PRP) was removed and 200µl of modified Tyrode’s buffer (ph 
6.6) was added to the remaining blood in the eppendorf tube. The eppendorf was 
then centrifuged again, this time for 5 mins at 1000rpm- and the upper phase was 
removed again. The process was repeated until the upper phase became clear (and 
thus had no or very little platelets). 
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5µl of platelet rich plasma was removed for gauging platelet counts [ABX pentra 60 
blood counter (Horiba medical)]. 1 μg/ml of prostacyclin was then added per ml of 
PRP (to prevent platelet aggregation prior to use), the PRP was then immediately 
centrifuged for 5 minutes at 2750 rpm, the supernatant was now discarded and the 
pellet resuspended in Tyrode’s buffer (pH 7.3). Platelets from multiple mice (of the 
same strain) were pooled together to achieve the final requisite concentration; 300µl 
of 1 x 10^8 platelets/ml was added per well of 6 well plate (where platelets were 
indicated). 
Platelets were isolated from WT mice; where CLEC-2 deficient platelets were 
required, these were isolated from PF4CreCLEC1bfl/fl mice. 
2.9.  Hydroxyproline assay 
Between 50 and 100mg of murine hepatic tissue was cut from murine liver blocks 
stored at -80°C (preparation of these blocks is described above in fig 2.1). The exact 
weight of the sample was noted prior to addition on 0.5ml of dH2O, and the sample 
homogenized with a hand held homogenizer (Polytron MR 2100). The homogenate 
was topped up to 1ml with distilled dH2O. Next 125𝜇l of 50% trichloroacetic acid was 
added and the solution incubated on ice for 30 minutes. The solution was next 
centrifuged to precipitate out protein (the supernatant was discarded); following 
which the protein precipitate was placed in sealed borosilicate tubes containing 500 
𝜇l of 6N hydrochloric acid (HCL), overnight at a temperature of 120°C. The next day 
the lids were taken off the tubes to allow the HCL to evaporate. The following day the 
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remaining precipitate was resuspended in 250𝜇l of double distilled H2O, and then 
filtered using a 0.45 𝜇m nylon containing polypropylene costar centrifuge tube 
(Corning, Fisher scientific). 50µl of the filtered solution was transferred to glass tubes; 
and the hydroxyproline standards were prepared. 950µl of ddH20 was added to the 
filtered solution to make up a total volume of 1ml. Next 500µl of Chloramine-T was 
added and the resultant solution incubated at room temperature (RT) for 20 min. 
Following this incubation 500µl of dimethylaminobenzaldehyde-perchloric acid 
solution was added and the solution vortexed and then incubated in the fume 
cupboard at 65oC for 15 min. Finally 200µl of solution was pipetted into ELISA plate 
wells in triplicates and read at 561nm. The hydroxyproline was expressed as μg 
hydroxyproline per gram liver. 
2.10.  Biochemical liver function assays 
Whole mouse blood collected at cardiac puncture was centrifuged at 15,000 rpm for 
15 minutes twice as described above to isolate serum. 100μl of serum from the final 
supernatant was removed and placed in a 13mm false-bottomed sample tube 
(Sarstedt) the remainder as discussed above was frozen down for long term storage 
at -80°C. Serum was assayed for alanine transaminase (ALT) levels by the clinical 
biochemistry team at Birmingham Women's Hospital using clinical analysers. 
2.11.  Statistical analysis 
Where possible (if there were greater than 5 variables in each group) normality for 
each group was tested using the Kolmogorov-Smirnov test (with the Dallas-
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Wilkinson-Lillie for corrected P value) or D'Agostino-Pearson omnibus test. If the two 
groups exhibited a gaussian distribution a parametric unpaired t test was conducted 
to compare the two groups. If the groups did not exhibit a gaussian distribution (this 
was the case for the majority of our samples) the difference between the medians of 
the two groups was assessed using the two-tailed Mann- Whitney non-parametric 
sum of ranks test. 
Where the relationship between a scalar dependent variable and an explanatory 
variable was modelled (for instance MELD score vs intrahepatic podoplanin 
concentration), linear regression analysis with a line of best fit was used. 
The statistics programme GraphPad Prism version 7.0 was used to calculate P 
values. These are detailed in each figure according to the following criteria for 




2.12.  Antibodies and isotype controls used 





























Rat IgG2a, I (anti-KLH) 
 
APC 0.2 mg/ml FC BD 
Biosciences 




PE 0.2 mg/ml FC BD 
Biosciences 




APC 0.2 mg/ml FC BD 
Biosciences 




PerCP-Cy5.5 0.2 mg/ml FC BD 
Biosciences 
F4/80 FITC 0.5 mg/ml FC Biolegend 
Rat IgG2a 
 
FITC 0.5 mg/ml FC Biolegend 
Ly6G BV510 0.2 mg/ml FC Biolegend 
Rat IgG2a 
 
BV510 0.2 mg/ml FC Biolegend 
Ly6C APC 0.2 mg/ml FC Biolegend 
Rat IgG2c 
 
APC 0.2 mg/ml FC Biolegend 
DX5 V450 0.2 mg/ml FC BD 
Biosciences 
Rat IgM V450 0.2 mg/ml FC BD 
Biosciences 





PB 0.2 mg/ml FC BD 
Biosciences 
CD61 (human) Alexa Fluor® 
647  
 
1µg/ml IHC Biolegend 
CD41 (mouse) BV605 1µg/ml IHC Biolegend 
Podoplanin (mouse 8.1.1) 
Uncconjugated 
- 0.5 µg/ml IHC ebioscience 
 
Syrian Hamster IgG 
 
- 0.5 µg/ml IHC ebioscience 
HRP conjugated rabbit Anti-
Syrian Hamster IgG H&L 
 
N/A 1µg/ml IHC Abcam 
Podoplanin (human 8.1.1) 
Unconjugated 
- 0.5 µg/ml IHC ebioscience 
Goat Anti-mouse IgG H&L 
 
Cy3 1µg/ml IHC abcam 
CLEC-2 (human) Unconjugated - 1µg/ml IHC Biorbyt 
HRP-conjugated anti rabbit Ig 
 
N/A Pre-diluted IHC Vector 
HRP-conjugated anti rat Ig 
 
N/A Pre-diluted IHC Vector 
HRP-conjugated anti mouse Ig N/A Pre-diluted IHC Vector 
CD68 (human) FITC 1µg/ml IHC Biolegend 
CD45 (human) Alexafluor 647 2µg/ml IHC Biolegend 
CD31 (human) FITC 2µg/ml IHC Biolegend 
F4/80 (mouse) FITC 1µg/ml IHC Biolegend 
F4/80 (mouse, unconjugated) - 1µg/ml IHC Biolegend 
Rat IgG2a, κ 
 
- 1µg/ml IHC Biolegend 
Anti-neutrophil elastase antibody 
(mouse, unconjugated) 
N/A 0.5µg/ml IHC Abcam 
Rabbit IgG, polyclonal 
 
N/A 1µg/ml IHC Abcam 
 
Table 2.6 : Details of antibodies used for flow cytometry and 
immunohistochemistry (with corresponding isotype matched controls) 
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3.  Podoplanin is upregulated in acute and chronic human 
liver injury 
 
3.1.  Introduction 
Podoplanin (PDPN) is a 36- to 43-kDa sialomucin-like transmembrane glycoprotein 
and the only known endogenous ligand for CLEC-2 (70). Podoplanin has 
homologues in humans, mice, rats, dogs, and hamsters(68). Under normal 
physiological conditions spatial and cellular localization of podoplanin precludes 
access to platelet CLEC-2 and it thus cannot activate platelets, however during 
specific phases of embryological development and certain pathological conditions, a 
variety of cells up regulate podoplanin and allow platelet activation(69,165). 
Podoplanin is ubiquitously expressed on multiple cell types, and this expression is 
driven by a variety of transcriptional pathways including ones pertinent to normal 
development such as Prox-1 and others which are pathological including pro-
inflammatory and pro-tumorigenic mechanisms(69). Table 3.1 (69) summarizes 









Beginning day E9, becomes 
restricted to choroid plexus in 
adult mouse 
No specific function reported during 
development; high PDPN expression 
in brain tumors 
Heart Starts E9, expression 
continues in adults 
Required for normal heart 
development, specifically for EMT in 
epicardium-derived cells 
Lungs Appears in foregut on day E9 
before lung buds; 
subsequently restricted to 
alveolar type I epithelial cells 
Required for lung development; 
specifically the effective maturation of 
alveolar type I epithelial cells 
Intestine Expressed on day E9 in 
foregut; continued expression 
in lamina propia 
No specific function determined 
Lymphoid 
organs 
Present in spleen 4 days 
postnatally; in adult, 
expression by FRCs, LECs, 
and FDCs in lymph node and 
spleen, and thymic medullary 
epithelial cells 
Required for proper formation and 
organization of lymph nodes and 
spleen; necessary for efficient DC 
migration to and within lymph nodes; 
highly expressed by stroma and 
some T cells in ectopic lymphoid 
tissue 
Table 3.1 Podoplanin expression and function(69) : 
 Summary of how site and timing of podoplanin expression inform podoplanin 





Podoplanin is expressed on lymphatic endothelium (in both mice and humans) and is 
used as an immunohistochemical marker for lymphatic vessels in both species(68). 
Since intact platelets normally do not enter the lymphatic vasculature, lymphatic 
podoplanin (during normal adult physiology) does not activate platelets (92). An 
exception is at lymphovenous junction in the thoracic duct where lymphatic fluid from 
the body is returned to the vascular system, here the lymphonvenous valve prevents 
back flow from the thoracic duct to the lymphatic vessels. As blood platelets come 
into direct contact with lymphatic podoplanin at the lymphovenous junction, platelet 
aggregation occurs and these aggregates are critical to the maintenance of barrier 
integrity between lymphatic and blood vessels integrity in neonatal but adult mice 
(92). Podoplanin first appears on PROX-1 positive lymphatic cells at embryonic day 
11.5(75), and mice that are deficient in podoplanin, in keeping with their CLEC-2 
deficient counterparts exhibit anomalous lymphatic development and blood lymph 
mixing(166). Podoplanin is also required to maintain the lymph-blood barrier and 
lymph node integrity in adult mice(167).The role the CLEC-2/podoplanin axis plays 
lymphatic development has already been discussed in greater detail above (chapter 
1). 
Podoplanin has important roles in the development of multiple other organ systems. 
As mentioned in the table above the embryonic heart starts expressing podoplanin 
around day 9 and lack of podoplanin expression is associated with a multitude of 
cardiac developmental abnormalities including septal hypoplasia and 
underdevelopment of the pulmonary vein(168). Podoplanin is also important within 
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neonatal lungs, and supports lung inflation after birth(69) . Lymphatic vessels are 
crucial to lung inflation in the neonate, as mice with genetic deletions for the 
lymphangiogenic factor CCBE1 or VEGFR3 function, fail to develop lymphatic 
vessels and die shortly after birth due reduced lung compliance and thus post-natal 
lung inflation(169); as podoplanin is critical to the development of the lymphatic 
vasculature this may in part explain which podoplanin/CLEC-2 deficient mice exhibit 
high rates of perinatal mortality (70,170). In addition podoplanin knockout (pdpn-/-) 
mice may not be able to inflate lungs after birth because podoplanin is required for 
the development of type 1 alveolar cells, these cells cover the majority of the lung 
surface and are crucial for the development of alveoli(171). Podoplanin also begins 
to be expressed within the central nervous system specifically on the neuro-
epithelium around day 9-10 (69). Interactions between this neurally expressed 
podoplanin and platelet CLEC-2 promotes aggregation and adhesion of platelets, 
which then guides the development or ‘patterning’ of cerebral vasculature thus 
preventing haemorrhage during cereal development(172). 
In addition to its role in developmental of various organ systems as detailed above, 
podoplanin expression varies with a variety of pathological processes/injuries and the 
CLEC-2/podoplanin axis here has roles can facilitate healing or in certain situation 
perpetuate further damage. 
The podoplanin-CLEC 2 axis has an important role in facilitating wound healing. 
Podoplanin is expressed by keratinocytes at the edge of wounds. Asai et al found 
that keratinocyte expressed podoplanin interacted with platelet CLEC-2 after skin 
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injury in mice resulting in reduced migration of normal human epidermal 
keratinocytes (NHEKs) via podoplanin mediated inhibition of keratinocyte migration 
(due to loss of E-cadherin). This influenced wound healing in a RhoA dependent 
mechanism, thus highlighting the role for this axis in wound healing (173). 
The platelet role in propagating cancer by facilitating metastatic spread has been 
extensively studied (174). Podoplanin itself has been extensively studied in the 
context of cancer, especially as it is expressed by lymphatic vessels and increased 
lymphangiogenesis is associated with poor outcomes after malignancy(69). 
Podoplanin is unregulated by a number of cancers including heard and neck 
squamous cell carcinomas, malignant mesotheliomas and various central nervous 
system tumours (69,175). Podoplanin co-localizes with the ezrin, radixin and moesin 
(ERM) family proteins; ERM proteins link membrane proteins to the actin 
cytoskeleton thus having the ability to translate signals from the cell surface into 
conformational changes in the cellular cytoskeleton influencing cellular processes 
including adhesion and migration(176). Studies in epithelial cells reveal that an over 
expression of podoplanin results in increased ERM phosphorylation, which gives 
these cells a more mesenchymal appearance, with increased filopodia and 
decreased stress fibres. Thus unsurprisingly studies demonstrate that expression of 
podoplanin correlates with increased cellular motility(68,69). Such increased cellular 
motility may explain why podoplanin expression in several cancers (177,178) 
correlates with a more aggressive and thus invasive phenotype. However others 
have found that in other contexts including lung squamous and uterine cancer the 
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opposite appears to be true; higher podoplanin expression in primary tumours 
correlates with lack of lymphatic invasion and better patient survival(179,180). With 
the findings above in mind, it is unsurprising therefore that functional in vivo studies 
report conflicting roles of the CLEC-2 podoplanin axis in facilitating tumor spread; an 
anti-podoplanin antibody has been demonstrated to reduce the number of metastatic 
lung nodules in murine models of metastatic cancer(181) but similar findings were 
not replicated in CLEC-2 deficient chimeric mice(165). 
Recent evidence identifies podoplanin as a crucial player in various aspects of 
immune system functioning (90,182). Kerrigan et al reported that during inflammatory 
states macrophages up regulate podoplanin(90). In fact a recent study identified a 
number of other cells within the injured liver including distinct stromal populations that 
may thus also provide ligand for CLEC-2 dependent platelet activation(183). 
Podoplanin also has a critical role in adaptive immunity, beyond its role in 
maintenance of high endothelial vein integrity during lymphocyte trafficking (86). 
Acton et al describe the importance of podoplanin expression by stromal scaffolds 
(lymphatic endothelial and fibroblastic reticular cells) in activating dendritic cells 
(DCs) via CLEC-2, thus allowing enhanced DC motility across stromal surfaces and 
facilitating the adaptive immune response (182). Lastly the CLEC-2/podoplanin axis 
also plays an important role in driving thrombosis during inflammation as an eloquent 
study by Hitchcock et al details; here they find that CLEC-2 and podoplanin play an 
important role in facilitating inflammatory thrombosis in the liver during salmonella 
infection(94). 
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3.2.  Aims of this chapter 
As we hypothesized that platelet activation via CLEC-2 plays a role in liver damage, 
we sought to examine whether the ligand for CLEC-2, podoplanin was expressed in 
the liver. It is important to establish whether expression increases after, or during 
liver injury and indeed whether the type of liver disease influences podoplanin 
expression. In order for platelet activation to occur, podoplanin must be accessible to 
CLEC-2 expressing platelets thus we next sought to define the patterns of platelet 
sequestration in the damaged liver and critically whether this sequestration was 
associated with podoplanin expressing cells. Lastly, we wished to examine whether 
podoplanin expression within the inflamed liver provided a stimulus for hepatic 
thrombosis and if expression varied with severity of liver disease. Thus the specific 
aims for this chapter were as follows: 
1. To establish the pattern of podoplanin expression in the non-injured and injured 
human liver. 
2. To examine whether platelets sequestered to podoplanin expressing cells during 
human liver disease. 
3. To correlate podoplanin expression with clinical markers of human liver disease 
including severity as gauged by MELD scores and occurrence of clinically relevant 
thrombosis (specifically portal venous thrombosis). 
 86 
3.3.  Podoplanin is minimally expressed within the liver during 
normal physiology 
Podoplanin expression was fairly limited within normal non-injured human liver. Most 
of this expression in non-injured liver was confined to the portal tracts on lymphatic 
vessels (fig 3.1) 
 
Figure 3.1 Podoplanin expression is minimally expressed in the non-injured human 
liver:  
Podoplanin was visualized using indirect immunohistochemical staining with DAB 
substrate(arrows, brown) on frozen human liver sections. Representative image of non-
injured donor tissue is shown with podoplanin antibody (left panel) or Isotype matched 
control (right panel) original magnification 20x . Arrows indicate positive staining on lymphatic 


















We next used confocal microscopy to determine whether podoplanin expression in a 
non-injured liver was associated with platelets. We found that platelets (using CD61 
as a marker) were found to reside within hepatic sinusoids but did not associate with 
podoplanin expressing cells or structures in uninjured normal liver (representative 
images in fig 3.2). Podoplanin expression was in keeping with our DAB stain 




Figure 3.2 Minimal colocalisation of platelets and podoplanin in the normal liver:  
An explanted frozen non-injured human liver section is shown. The nuclei are stained with 
hoechst-grey, CD61+ platelets are green and podoplanin is purple. Image representative of 
at least 5 different livers. 10x magnification. Isotype control was negative (bottom image). 








3.4.  Podoplanin expression increases dramatically during acute and 
chronic human liver disease 
Once we had established the basal expression of podoplanin in uninjured human 
liver samples, we then examined tissues from diseased patients to assess the 
patterns of expression in acute and chronic liver injury. 
3.4.1.  Podoplanin expression in acute liver injury 
The livers we studied for acute human liver injury sample studied were from 
explanted livers from patients with acute fulminant liver failure due to paracetamol 
overdose. An upregulation of podoplanin was noted in these acute drug induced liver 
injuries. Again the staining was observed in a predominantly periportal distribution 
but in far greater amounts than what was noted in non-injured livers. The distribution 
of this upregulated podoplanin was concentrated within periportal areas (blue arrows 
fig 3.3) with very minimal expression by hepatocytes or other parenchymal cells. The 
morphology of positively stained structures was indicative of the thickened 
endothelial lining of lymphatic vessels (see higher magnification image examples in 
fig 3.3). In addition we noted that podoplanin was also expressed upon cells of the 
inflammatory infiltrate(see black arrows in fig 3.3). 
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Figure 3.3 Podoplanin is upregulated in paracetamol induced acute human liver injury:  
Representative images from frozen human liver sections stained with podoplanin specific 
antibody(brown staining) in a standard indirect immunochemical protocol. Images are from 
representative cases of paracetamol toxicity and are shown at A) 10x, or B) 20x original 
magnification. Isotype control staining (IMC) is shown in panel C. Positive staining on 
lymphatic vessels (blue arrows) and infiltrating mononuclear cells (black arrows) is present. 



















To identify the immune cells that stained positively for podoplanin in acutely injured 
livers I performed confocal microscopy on sections stained with fluorescent 
antibodies. Figure 3.4 shows representative examples of this staining and illustrates 
that CD68+ macrophages in the parenchyma (green staining) also express 
podoplanin (blue stain, dual stain-sea blue indicated by arrowheads on Figure 3.4). 
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Figure 3.4 Hepatic macrophages upregulate podoplanin after APAP induced liver 
injury in humans:  
A) Representative images from frozen human liver sections stained with podoplanin specific 
antibody(brown staining) in a standard indirect immunochemical protocol. Images are from 
representative cases of paracetamol toxicity and are shown at 40x, or B) Representative 
confocal images from the same human liver section presented at either 20x or 63x 
magnification. Podoplanin (blue) expression on hepatic macrophages-arrows (CD68-
macrophages-green) (CD45-leukocytes-red, DAPI-white). Podoplanin expressing 



































3.4.1.1.  Platelets sequester to podoplanin expressing macrophages during 
paracetamol-induced acute liver injury. 
To ascertain whether podoplanin expression in the acutely injured liver could 
potentially provide ligand for and thus activate platelets we next undertook confocal 
microscopy to study platelet distribution after paracetamol overdose. We found that 
platelets sequestered to podoplanin expressing macrophages here (fig 3.5) within 
portal areas and also sinusoids. Podoplanin (green) expressing macrophages (red) 
clearly exhibit platelet (CD61-blue) sequestration. Figure 3.5 is representative of all 
samples of paracetamol overdose we studied. 
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Figure 3.5 Platelets sequester to podoplanin expressing macrophages in APAP injured 
human liver:  
A frozen section from an explanted APAP injured human liver is shown. The nuclei are 
stained with hoechst-grey, CD41 (platelet) is blue, podoplanin is in green and CD68 
(macrophages) is red. Image is representative of at least 4 different livers. 63x magnification. 
Composite image bottom shows macrophages (CD68) expressing podoplanin to which are 







3.4.2.  Podoplanin expression in chronic liver injury 
Chronic liver disease (CLD) as discussed in the section 1.3, is the result of iterative 
insults to the liver. Although there are similarities in the initial immunological 
processes that drive both acute and chronic liver disease, the final outcomes vary 
considerably. Having established the expression of podoplanin in the acutely injured 
liver we next proceeded to examine if this was different in chronically injured human 
livers. 
3.4.2.1.  Alcoholic liver disease 
Livers from patients with alcoholic cirrhosis (ALD) demonstrated a significant 
upregulation of podoplanin within periportal areas compared to the picture in normal 
or acutely injured livers. Here podoplanin was expressed on both vessels in the 
portal areas and upon cells of the inflammatory infiltrate (see higher magnification 
images in fig 3.6). The staining on vessels appeared more intense (darker) than 
acutely injured samples and was accompanied by a lower intensity stain with a more 
'stromal' appearance around portal vessels and biliary structures and areas of 
ductular reaction (arrows panel D figure 3.6). No staining was seen with isotype-
matched control antibodies (Panel F, fig 3.6) 
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Figure 3.6 Podoplanin is upregulated in periportal areas in alcoholic liver disease: 
Representative images from frozen human liver sections stained with podoplanin specific 
antibody(brown staining) in a standard indirect immunochemical protocol. Images are from 
representative cases of ALD and are shown at 10x magnification. A-B) Demonstrate 
podoplanin expression in periportal areas, on vessels (arrows). C,E) podoplanin expression 
is seen around bile ducts (arrows). D) Podoplanin expression is seen areas of ductular 
reaction (arrows). F) Isotype matched control was negative. Images are representative of at 






We next used a CLEC-2 -specific antibody to establish whether there was any CLEC-
2 expression in alcoholic liver disease. Interestingly we observed that CLEC-2 -
expressing platelets or structures appeared to sequester to cells within the 
inflammatory infiltrate (panel C fig 3.7). We also noted enhanced CLEC-2 staining of 





Figure 3.7 Expression of CLEC-2 in alcoholic cirrhosis: 
Frozen sections of explanted livers from patients with end stage liver disease (cirrhosis) due 
to alcohol were stained using a CLEC-2 primary antibody and DAB (brown, arrows) 
secondary stain. Sections were counterstained with hameotoxylin (nuclei-purple), 20X or 40X 
magnification. A-B) Demonstrate increased CLEC-2 expression within biliary structures. C-D) 










Confocal microscopic analysis with fluorescent antibodies was also performed. In 
alcoholic liver disease, similar to our findings in acute liver injury we found that 
podoplanin was upregulated upon macrophages (fig 3.8) but also upon periportal 
vessels (fig 3.9). The morphology of these vessels seemed distinct to lymphatic 
vessels so I dual stained these sections with podoplanin and CD31 (marker of 
vascular endothelium) (fig 3.9). We demonstrate that in chronic human liver disease 
due to alcohol podoplanin is upregulated upon vascular endothelium (fig 3.9). The 
morphology and location of these vessels was consistent with portal venules. Notably 
the enhanced stromal DAB stain we observed (fig 3.6) earlier was replicated in our 
confocal images (fig 3.9). 
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Figure 3.8 Macrophages in alcoholic liver disease express podoplanin:  
A frozen liver section from a patient with alcoholic cirrhosis section is shown. The nuclei are 
stained with hoechst-grey, podoplanin is in green and CD68 (macrophages) is red. Image is 
representative of at least 4 different livers. 100x magnification. Composite image bottom right 






Figure 3.9 Portal veins express podoplanin in alcoholic liver disease:  
A frozen liver section from a patient with alcoholic cirrhosis section is shown. The nuclei are 
stained with hoechst-grey, podoplanin is in blue and CD31 (vascular endothelium) is in 
green. Image is representative of at least 4 different livers. 20x magnification. Composite 









3.4.2.2.  The expression of podoplanin in autoimmune liver disease 
The pattern of podoplanin expression detected immunochemically in autoimmune 
liver disease (AIH) was similar to that seen in alcoholic cirrhosis. Thus we saw 
podoplanin expression around portal vessels with high intensity (blue arrows) and a 
lower intensity ’stromal’ stain (fig 3.10, panel A-C). No staining was seen with 
isotype-matched control antibodies (Panel D, fig 3.10). However a notable difference 




Figure 3.10 Podoplanin is upregulated in autoimmune human liver disease: 
Representative images from frozen human liver sections stained with podoplanin specific 
antibody(brown staining) in a standard indirect immunochemical protocol. Images are from 
representative cases of AIH and are shown at 20x magnification. Sections were 
counterstained with hameotoxylin (nuclei-purple), A-C) Demonstrate increased podoplanin 
expression (brown) in periportal areas, on vessels (blue arrows)and inflammatory cells (black 










3.4.2.3.  Non-alcoholic steatohepatitis 
Compared to alcoholic liver disease less overall podoplanin expression was seen in 
human non-alcoholic steatohepatitis (NASH). Expression was seen periportally, on 
infiltrating mononuclear cells and periportal vessels. On the whole a lower intensity of 
podoplanin stain uptake particularly in the stromal areas was seen compared to what 
we observed in ALD and PSC. Podoplanin was seen on periportal vessels (fig 3.11, 
panel A arrows, panel B asterisk, panel C arrow and panel D arrows) and cells of the 
inflammatory infiltrate (fig 3.11, panel B arrows). Minimal expression on steatotic 
hepatocytes was seen (fig 3.11, panel C asterisks). 
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Figure 3.11 Podoplanin is upregulated in periportal areas in non-alcoholic fatty liver 
disease:  
Representative images from frozen human liver sections stained with podoplanin specific antibody 
(brown staining) in a standard indirect immunochemical protocol. Sections were counterstained with 
hameotoxylin (nuclei-purple), 20X magnification. A) podoplanin expression in periportal areas on cells 
of the inflammatory infiltrate (arrows) B) A single enhancing portal vessel is seen (asterisk), multiple 
areas of podoplanin expression are seen within the inflammatory infiltrate (arrows). C) Wider angle 
views reveal steatotic hepatocytes (asterisks) do not express podoplanin, podoplanin expression is 
seen periportally (arrow) D) Numerous periportal vessels expressing podoplanin are seen (arrows). E) 











CLEC-2 expression was also harder to discern in NASH, however broadly followed 
the same pattern as what has been seen previously with ALD. Hence CLEC-2 
expression was again seen in neo biliary structures and on platelets sequestering to 
areas of inflammatory infiltrate (fig 3.12). 
 
Figure 3.12 CLEC-2 expressing platelets sequester to the injured liver during NASH: 
Representative images from frozen NASH human liver sections stained with CLEC-2 specific 
antibody (brown staining) in a standard indirect immunochemical protocol. Sections were 
counterstained with hameotoxylin (nuclei-purple), A) CLEC-2 expression within biliary 
structures is seen-arrows (20x). B) CLEC-2 expression on platelets sequestering to 











3.4.2.4.  Primary biliary cirrhosis 
The immunochemical staining pattern for podoplanin expression in PBC was much 
different than we observed with other chronic diseases. A much greater quantity of 
cells expressing podoplanin was seen (fig 3.13 panels A-E). Thus we saw high 
intensity dark staining of portal vessels (fig 3.13), a very intense stromal stain 
(particularly around biliary structures 3.13, A-B) and enhanced vascular staining 
within areas of inflammatory cell accumulation along fibrous septa (fig 3.13, panel D). 
Confocal microscopy also revealed that we saw an increased accumulation of 
platelets within PBC livers (blue staining fig 3.14). However it was interesting to note 
that this staining did not localize in proximity to green-stained podoplanin positive 
structures (fig 3.14) 
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Figure 3.13 Podoplanin is upregulated in primary biliary cirrhosis (PBC): 
Representative images from frozen PBC human liver sections stained with a podoplanin specific 
antibody (brown staining) in a standard indirect immunochemical protocol. Sections were 
counterstained with hameotoxylin (nuclei-purple), 10X or 20X magnification. A-B) Peri-biliary 
podoplanin expression areas (arrows-brown). C,D,E) Periportal vessel (asterisk) and the portal 
infiltrate podoplanin expression (arrows) F) Isotype matched control was negative. Image is 













Figure 3.14 Platelets do not sequester to podoplanin expressing areas in PBC:  
Frozen sections of explanted livers from patients with PBC were stained using a podoplanin 
antibody (green), hoechst nuclear stain (grey) and CD41 platelet stain (blue). Image 








3.4.2.5.  Primary sclerosing cholangitis 
Podoplanin expression in explanted livers from patients with primary sclerosing 
cholangitis (PSC) again followed a similar pattern to other liver diseases with most of 
the podoplanin being expressed within the portal tracts, with no expression on the 
hepatocytes themselves. The staining was the most pronounced amongst all the 
diseases we studied. Notably the stromal stain intensity was greatest in PSC (fig 
3.15, panel A and B, asterisks). A significant amount of podoplanin expression was 
noted on periportal vessels (fig 3.15, panel A-D, black arrows). High magnification 
images confirm that the podoplanin was upon the endothelial vessel lining and not 
just the vessel wall (fig 3.15, panel E arrows). Another difference in pattern of 
expression to other liver pathologies studies was the presence of podoplanin on 
larger periportal vessels, with little or no peri-billary podoplanin expression. 




Figure 3.15 Podoplanin is upregulated in primary sclerosing cholangitis (PSC): 
Representative images from frozen PSC human liver sections stained with a podoplanin specific 
antibody (brown staining) in a standard indirect immunochemical protocol. Sections were 
counterstained with hameotoxylin (nuclei-purple), 10X, 20X or 40X magnification. A-B) podoplanin 
expression in a portal vessels (black arrows) (10x). C,D) Podoplanin expression is seen on periportal 
vessels ( black arrows) and the portal infiltrate (blue arrows) (20X). E) High magnification (40X) picture 
a vessel confirms endothelial podoplanin expression (arrows). F) Isotype matched control staining was 















In PSC we again noted podoplanin expression upon vascular endothelium 
(CD31+vessels) (fig 3.16, blue arrows) and upon leukocytes (as characterized by 
CD45+ cells) (fig 3.16, white arrows) 
 
Figure 3.16 Vascular endothelial cells and leukocytes express podoplanin in PSC 
livers:  
Frozen sections of explanted livers from patients with PSC were stained using a podoplanin 
antibody (red), CD31 (vascular endothelium) (green) and a CD45 (pan leukocyte marker) 
stain (magenta). Vascular endothelium that expressed podoplanin appears yellow in 
composite figure (blue arrows), leukocytes expressing podoplanin are highlighted with black 
arrows. Image representative of at least 6 livers. 10x magnification. 
 
 
To confirm what leukocytes may be up regulating podoplanin we stained for 
macrophages using a CD68 marker and found that similar to acute liver injury 






Figure 3.17 Macrophages express podoplanin in PSC: 
Frozen sections of explanted livers from patients with PSC were stained using a podoplanin 
antibody (green), hoechst nuclear stain (grey) and CD68 macrophage stain (red). 
Macrophages expressing podoplanin appear yellow in composite figure. Image 






3.5.  Clinical correlation between podoplanin and disease severity 
The data above confirm that podoplanin is upregulated during both chronic and acute 
liver disease. In very acute injuries such as fulminant liver failure secondary to drugs 
(paracetamol overdose) podoplanin upregulation was primarily seen upon 
macrophages. In chronic variants of human liver disease however, podoplanin 
appears in peri-portal areas on both periportal vessels and inflammatory cells. Where 
there was evidence of macrophage podoplanin, I observed that platelets sequestered 
to these podoplanin expressing macrophages, thus potentially providing an avenue 
for CLEC-2-dependent platelet activation. I will explore the functional consequences 
of this interaction in the subsequent chapters, whilst the role of podoplanin in chronic 
human liver disease is considered in the sections below. 
3.5.1.  Podoplanin mRNA is increased in damaged livers 
To support my immunohistochemical findings I quantified the amount of podoplanin 
mRNA in injured human livers by qPCR. Figure 3.18 below confirms that compared 
to non-injured control livers, chronically injured livers expressed significantly greater 




Figure 3.18 Podoplanin mRNA is upregulated in human chronic liver disease:  
RNA was extracted from normal or chronically diseased ALD, PSC, PBC, AIH or NASH) 
human livers using a RNEasykit (Qiagen, UK) and cDNA was generated using a High 
capacity cDNA reverse transcription kit (ThermoFisher, UK) according to manufacturer’s 
instructions. Quantitative analysis of Podoplanin mRNA expression was performed using 
TaqmanFluorogenic5' nuclease assays using gene-specific 5' FAM labelled probes (Applied 
Biosystems) run on a ABI Prism 7900 sequencer with 18S;SRFS4used as internal control. 
Differential expression levels were calculated according to the 2-ΔΔCtmethod. Mann-whitey 
test confirmed that expression was significantly different in diseased groups compared to 
control livers *P < 0.05, **P < 0.01, ***P < 0.001. each dot indicates an individual patient 
sample and bar is median expression within the indicated cohort. 
 
 
We next sought to investigate whether the amount of podoplanin expressed by 
diseased liver tissue varied with type of disease studied. We found that the 
autoimmune cholangiopathies (PSC and PBC) and end stage liver disease arising 
from chronic alcohol exposure (ALD) had the highest expression of podoplanin, 
whilst the other disease types were not significantly elevated compared to non-
diseased tissue (fig 3.19). 


























Figure 3.19 Expression of podoplanin mRNA varies with disease type:  
qPCR was performed on mRNA extracted from explanted normal or diseased livers (PSC, 
AIH, DILI, ALD, PBC, NASH cirrhosis) as described in Figure X. ANOVA test confirmed that 
expression was significantly different in diseased groups compared to control livers *P < 
0.05, **P < 0.01, ***P < 0.001. Each dot indicates an individual patient sample and bar is 





Our histological analyses broadly suggested that whilst podoplanin expression was 
also elevated in acutely injured livers (eg paracetamol induced fulminant liver failure) 
this was (in contrast to chronically damaged livers) primarily upon hepatic 
macrophages. Figure 3.20 confirms that at least at the level of mRNA there is an 
increase in podoplanin expression in DILI. All of the values for the DILI livers were 
above the mean mRNA level seen in normal controls but the change was not 
significant with our small sample size. 





























Figure 3.20 Podoplanin is upregulated during acute fulminant liver failure due to 
paracetamol overdose:  
qPCR was performed on mRNA extracted from explanted normal or diseased livers (DILI) as 
described in Figure X. Mann-Whitney test confirmed that expression was significantly 
different in diseased groups compared to control livers. Each dot indicates an individual 



































3.5.2.  Hepatic podoplanin expression increases with severity of liver disease 
The MELD score is a commonly used clinical score to predict survival in patients with 
chronic liver disease. This score is used to assess urgency for transplantation and 
generally correlates with the severity of liver disease(184). As we noted elevated 
podoplanin expression within explanted livers with end stage liver disease, we next 
wished to see whether severity of liver disease correlated with podoplanin 
expression. Hence, I calculated the MELD scores of patients at time of 
transplantation and correlated it with the amount of hepatic podoplanin mRNA within 
the explanted liver sample. Figure 3.21 shows that although there was significant 
variability in values from the grouped cohorts of damaged liver samples, there was a 
correlation between podoplanin expression and MELD scores. The relationship was 




Figure 3.21 Patient MELD scores correlate hepatic podoplanin mRNA expression at 
time of transplantation:  
MELD scores corresponding to each diseased or normal liver were calculated. Podoplanin 
mRNA levels were measured by qPCR as described previously. Samples shown are pooled 
(PSC, AIH, DILI, ALD, PBC, NASH cirrhosis- state types) and each point represents an 




It is important to note however that an increase in podoplanin commensurate with 
MELD score was not always observed for every individual disease category. Notably 
figure 3.22 shows that in autoimmune liver disease we found that higher MELD 
scores were associated with lower podoplanin expression. 














Slope=significant deviation from 0, 
P<0.0001.
Equation: Y = 26445*X + 0
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Figure 3.22 In autoimmune liver disease higher MELD scores correspond with lower 
levels of podoplanin: 
MELD scores corresponding to each diseased or normal liver were calculated. Podoplanin 
mRNA levels were measured by qPCR as described previously. Samples shown are pooled 




3.5.3.  Venous thrombosis 
The data in fig 3.9 suggested that at least some of the increase in podoplanin 
expression seen in chronic liver disease occurred upon vascular endothelium 
(CD31+), see representative images in section 3.9). Previous studies in Birmingham 
have shown that perivascular expression of podoplanin in murine sepsis is 
associated with intravascular thrombosis(94). Portal vein thrombosis is a common 
and feared complication of cirrhosis, and so it is possible that this may be explained 
by vascular podoplanin expression in chronic disease. Thus I sought to determine 












Slope= No significant deviation from 0, 
P=0.1637
Equation: Y = -131856*X + 21.16
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whether there was a link between the occurrence of portal venous thrombosis and 
the amount of podoplanin expressed within livers in my cohort. Figure 3.23 shows 
that approximately 30% of our patients had evidence of portal venous thrombosis 
developments, and that more podoplanin mRNA expression was evident in these 
livers. However the data were highly variable between individuals. 
 
 
Figure 3.23 Evidence of portal venous thrombosis pre-transplantation is associated 
with greater podoplanin mRNA expression:  
Podoplanin mRNA was quantified by qPCR as described previously in explanted normal or 
diseased human livers. Presence of portal venous thrombosis prior to transplant was 
assessed by interrogation of the corresponding patient notes. Samples are divided into two 
groups based on whether a portal venous thrombosis was present or not and points 






























3.6.  Summary and discussion 
3.6.1.  Role of podoplanin in the liver 
Our data suggests that hepatic podoplanin levels are upregulated in both chronic and 
acute human liver disease. In a non-injured liver platelets do not interact with 
podoplanin, as most of the podoplanin is present within lymphatic vessels and we 
found very little expression upon leukocytes (fig 3.1), thus platelet activation via 
CLEC-2 is unlikely to be necessary to normal liver function. In acutely injured livers 
(explanted paracetamol overdose) we noted that podoplanin was upregulated upon 
portal and sinusoidal leukocytes (fig 3.4, 3.4). We confirmed that at least some of 
these cells were macrophages (fig 3.5). Although podoplanin expression on 
inflammatory macrophages has been previously noted(90), we provide the first 
demonstration of hepatic macrophages expressing the only known ligand for CLEC-2 
and thus potentially a role for CLEC-2 dependent platelet activation in acute liver 
injury. This is an important finding as the platelet interaction with macrophages has 
relevance in acute inflammation particularly in the context of the liver. For example, 
the Kupffer cell-platelet interaction aids pathogen clearance, platelets interact with 
Kupffer cells in the early period following ischaemia-reperfusion injury(117,185) and 
these interactions dictate injury severity in steatotic livers(186). Furthermore as 
platelets sequester to podoplanin expressing macrophages in drug induced acute 
liver injury it may be that this interaction has a role in the pathogenesis of DILI (we 
investigate this further in the next chapter). The role this axis has in thrombosis 
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during acute liver inflammation has also been described as podoplanin expression on 
inflammatory monocytes and Kupffer cells (in mice) within the liver during salmonella 
infection drives post-infection inflammatory thrombosis(94). 
3.6.2.  Vascular expression 
In chronic human liver disease we noted that most of the podoplanin upregulation 
was found localized to periportal areas of the liver. Here it appeared to be expressed 
on both inflammatory cells and on vessels. The lymphatic vessel expression is 
perhaps unsurprising as podoplanin has been used as a marker for lymphatic 
endothelium and thus lymphatic vessels(166) in cirrhotic and normal livers. Little is 
known about the lymphatic venous system in the liver, perturbation in lymphatic 
function is however thought to be contributory to the development of ascites(187) . 
Thus enhanced expression in the context of cirrhotic end stage diseased livers may 
reflect expansion of lymphangiogenesis in an attempt to improve lymphatic drainage. 
Certainly lymphatic expansion is observed in portal areas during cirrhosis, the role of 
such lymphangiogenesis is not clear(188); but this fits with lymphatic expansion as a 
compensatory mechanism designed to offset the increased lymphatic flow(188) that 
occurs in liver cirrhosis; alternatively the enhanced lymphatic vasculature may itself 
be contributing to the increased portal pressures, by physically compressing the 
portal blood outflow. 
We also noted that some of the vessels that expressed podoplanin (fig 3.9) did not 
morphologically resemble lymphatic vessels, the fact that these portal vessels were 
lined with CD31+ cells suggested that they contained vascular endothelium and were 
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probably portal venules (fig 3.9). We thus provide the first ex vivo demonstration of 
vascular endothelium anywhere in the body expressing podoplanin. However we also 
noted that there also appeared to be degree of sub endothelial stromal staining (fig 
3.13, 3.14), this fits with recent work that has revealed that podoplanin is expressed 
by stromal cells in injured murine livers(183), work to elucidate whether similar 
stromal progenitor cells express podoplanin in the injured human live is currently 
underway. As the endothelium that lines in the liver vasculature is fundamentally 
different to that found elsewhere(15), with there being multiple similarities between 
lymphatic endothelium and sinusoidal endothelium it is not inconceivable therefore 
that the response to liver damage an upregulation of podoplanin is observed. 
Furthermore subsequent in vitro experiments from our lab have confirmed that 
isolated liver endothelial cells express podoplanin(189). 
3.6.3.  Venous thrombosis 
The relevance of the expression of a platelet activating ligand within the vascular 
space is however less clear. Authors have shown that platelets come into contact 
with podoplanin at the point where lymph returns to the circulation, and this 
interaction causes thrombosis maintaining the integrity of the lympho-venular 
valve(92). An upregulation of vascular podoplanin in chronic liver disease may 
provide a mechanism for explaining the occurrence of portal venous thrombosis in 
cirrhotic patients. In support of this I showed that higher levels of podoplanin within 
cirrhotic livers is linked to greater occurrence of portal venous thrombosis. This data 
is not statistically significant based on the small numbers of samples and mixed 
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etiologies of liver disease analyzed. One of the key issues with extensive portal 
venous thrombosis is that it can render patients untransplantable. Thus we may have 
missed a key cohort of patients from our analysis, as patients with the most extensive 
portal venous thrombosis would never undergo transplantation and thus donate their 
explanted liver for our studies. Obtaining liver biopsies from patients with cirrhosis 
with or without portal venous thrombosis is a potential solution to this problem. 
Nonetheless given our current lack of understanding about how portal venous 
thrombosis occurs(190) and the its potentially devastating complications including 
worsening portal hypertension, liver failure (acute portal venous thrombosis) and the 
consequence of portal venous thrombosis on transplantability; podoplanin driven 
inflammatory venous thrombosis in the cirrhotic liver merits further analysis. A 
particularly exciting aspect of this work is the fact that blocking CLEC-2/podoplanin 
does not worsen bleeding risk(94), therefore in patients with oesophageo-gastric 
varices and portal venous thrombosis, therapy to block CLEC-2 driven platelet 
activation could block further propagation of the thrombus whilst theoretically not 
worsening the risk of a variceal bleed. 
3.6.4.  Regeneration 
We noted an upregulation of podoplanin amongst and around areas of ductular 
reaction in the cirrhosed livers we studied. This was more pronounced in alcoholic 
liver disease, PBC and PSC. These were also the diseases that the highest levels of 
podoplanin mRNA was observed (fig 3.19). The significance of the ductular reaction 
has not been comprehensively evaluated, but the prevailing concept appears to be 
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one of driving parenchymal regeneration early on in liver injury, and persistent 
activation being linked with increasing amounts of hepatocyte senescence in chronic 
fibrotic disease(191) . Podoplanin may have a role in driving these ductular reactions 
as it has recently been described as being present on a distinct subset of progenitor 
stromal cells within chronically damaged murine livers(183). Furthermore recent work 
reveals that platelet CLEC-2 is important in driving liver regeneration in murine 
models of hemi-hepatectomy(192). 
3.6.5.  Correlation with disease activity 
Although the overall score for all livers with chronic liver disease revealed that there 
was an overall positive correlation between MELD score and podoplanin expression 
we noted that this was not that case when we did a sub-group analysis with livers 
only from the autoimmune hepatitis group. These patients had a significantly high 
MELD score (thus were placed on the transplant list) and we noted that the 
podoplanin levels seemed to dip with higher MELDs (fig 3.21). This may be due to 
the fact that the patients with the autoimmune hepatitides were the only cohort of 
patients on immune modulating drugs (azathioprine and prednisolone), and the 
immunosuppressive medication may have had a role in suppressing hepatic 
podoplanin production. This is particularly the case with prednisolone which is known 
to suppress macrophage function(193), one of the key cells that we found to 
upregulate podoplanin. The fact that all the livers we analyzed were end stage 
cirrhotic livers makes drawing meaningful conclusions about how podoplanin levels 
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vary with severity of disease, particularly early on in the disease and what effect 
immunosuppressant medication may have difficult, further studies are warranted. 
Since podoplanin levels go up with severity of liver disease, it is interesting to 
speculate whether podoplanin has diagnostic utility as a biomarker of severity of 
fibrosis, or even as a predictor of tendency to develop portal venous thrombosis. Our 
work focused on intrahepatic podoplanin expression but researchers have also found 
soluble versions of this molecule detectable in human serum in the context of certain 
cancers(194) correlating this with the development of portal venous thrombosis, 
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4.  Platelet activation drives liver injury during carbon 
tetrachloride and paracetamol induced liver injury 
 
4.1.  Models of acute toxic liver damage 
Carbon tetrachloride (CCl4) induced hepatic necroinflammation represents a widely 
used and easily reproducible model of murine liver injury. This organic has been 
used as a grain fumigant, solvent for oils, in the manufacture of chlorofluorocarbons 
and as a dry-cleaning agent in the past. Owing however to its profound toxicity, its 
use became prohibited in the US in the 1970s(195,196) . 
To induce hepatic damage CCl4 is normally administered intraperitoneally dissolved 
in mineral oil(160) . Within the liver CCl4 is metabolized by the cytochrome P450 
isozymes of the endoplasmic reticulum (ER) system to trichloromethyl free radicals. 
These then react with molecular oxygen to form highly toxic trichloromethyl peroxy 
radicals(195). The specific isoform responsible for majority of CCl4 metabolism is 
CYP2E1; mice deficient in this enzyme are therefore resistant to the hepatotoxic 
effects of CCl4 (195) . After being produced these highly reactive radicals react with 
the polyunsaturated fatty acids(196) comprising the phospholipids present within cell 
and cell organelle membranes. The resultant effect on the permeability of the cell 
plasma membrane, ER membrane and mitochondrial membrane causes a marked 
dysregulation of cellular calcium homeostasis and eventually cell death(197) . CCl4 
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also causes hypomethylation of cellular components including RNA and 
phospholipids thereby resulting in impairment of protein synthesis and lipoprotein 
production respectively and this is thought to also be contributory to CCl4 mediated 
cellular injury(197). CCl4 bioactivation thus sets in place an essentially self-
propagating cycle of lipid peroxidation, which eventually results in massive amounts 
of necrotic hepatocyte death(198) . The need for bioactivation of CCl4 to generate its 
reactive metabolites dictates the histological pattern of injury induced by CCl4. The 
majority of liver injury is centrizonal as the zone 3 (centrizonal) hepatocytes have the 
most abundant CYP450 expression. 
Paracetamol overdose is also used to model acute hepatitis in rodent models. This 
has the added advantage of being pathophysiologically very similar to human 
paracetamol-induced liver damage, and has thus already yielded clinically relevant 
treatments such as N-acetylcysteine (NAC)(18) . The majority of paracetamol (almost 
90%) is metabolized in the liver by glucuronidation and sulfation and then excreted in 
the urine(199), this pathway results in safe metabolism and clearance of paracetamol 
and therefore no liver damage. The remaining 10% is metabolized within hepatocytes 
by isozymes of the cytochrome P450 system-mainly CYP2E1 (hence paralleling CCl4 
metabolism), to N-acetyl-p-benzoquinone imine (NAPQI)(200). Liver glutathione 
(GSH) reduces NAPQI into a harmless form, which is then excreted in the bile(199). 
In situations of excessive paracetamol consumption, the reductive capacity of GSH is 
overwhelmed and toxic NAPQI starts to build up. Excess NAPQI binds to the 
sulfhydryl groups within proteins resulting in the formation of toxic protein 
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adducts(18). The formation of these adducts within mitochondrial proteins is thought 
to be critical to APAP hepatotoxicity(201). Mitochondrial NAPQI-protein adducts 
disrupt mitochondrial electron transport triggering peroxynitrite formation within the 
mitochondria(18). The resultant oxidant stress results in the membrane permeability 
transition (MPT) pore opening and ultimately the collapse of mitochondrial membrane 
potential(18). As the mitochondria swell, collapse and eventually disintegrate they 
release inter-membrane proteins including endonuclease G and apoptosis inducing 
factor (AIF)(201). Both of these molecules translocate to nucleus causing rapid and 
extensive nuclear fragmentation(202). It is this combination of nuclear fragmentation 
and mitochondrial collapse that results in the massive pericentral hepatocellular 
necrosis that is characteristic of paracetamol overdose. 
4.2.  The sterile inflammatory response of toxic liver injury 
After both APAP and CCl4 induced liver damage a striking increase in the amount of 
infiltrating hepatic leukocytes indicating a pronounced inflammatory response is 
observed(160,203). The type of inflammation that both paracetamol and CCl4 elicit is 
known as sterile liver inflammation. Sterile inflammation (SI) occurs in the absence of 
pathogens in response to a wide variety of stimuli including toxic agents such as 
CCl4, acetaminophen (APAP) and thioacetamide (TAA) or other tissue stress 
inducing injuries such as ischaemia-reperfusion and crush injuries(47,204). Liver SI 
is a key component of human liver injuries including non-alcoholic steatohepatitis 
(NASH), alcoholic steatohepatitis and drug induced liver injury(47). The unifying 
molecular characteristic of SI is the expression of endogenous damage associated 
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motif patterns (DAMPs) on tissue damage(33), over 20 DAMPs have thus far been 
identified(47). DAMPs are molecules that are released from dying cells and serve as 
ligands for toll-like receptors (TLRs) on macrophages and other cell types. After 
APAP or CCl4 induced necrotic hepatocyte damage, Kupffer cells (KCs), dendritic 
cells and possibly circulating monocyte derived macrophages recognize DAMPs 
expressed by the damaged liver tissue(33). This recognition is via pattern 
recognizing receptors (PRRs) such as toll like receptors (TLRs) expressed on these 
cells and represents a crucial step, linking toxic necrotic cell death to immune system 
activation and recruitment; the beginning of the sterile inflammatory response(200). 
DAMP recognizing cells thus become activated and produce the cytokine milieu that 
is characteristic of acute liver injury. 
Liver resident macrophages are activated within 1-2 hours of an APAP overdose in 
mice(34). Initially numbers of these cells seems to go down probably due to a direct 
cytotoxic effect of CCl4, but then overall macrophage numbers within the liver actually 
increase due to CCL2 driven recruitment from the blood(33). On recognizing DAMPs 
expressed by necrotic hepatocytes, KCs and infiltrating macrophages start producing 
inflammatory cytokines including TNFα, IL-1β and IL6(33). It is clear that both TNFα 
and hepatic macrophages are important in dictating the outcome from toxic liver 
damage(205), but a comprehensive role for either is yet to be defined. Depleting 
Kupffer cells preferentially using gadolinium chloride or all populations that contribute 
to hepatic macrophages including monocyte derived macrophages and circulating 
monocytes using clodronate result in varying phenotypes after APAP challenge, with 
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the former ameliorating liver injury and the latter aggravating it(33). As already 
mentioned in the introduction, platelets influence the macrophage contribution to liver 
injury or sterile inflammation at multiple levels linked to monocyte recruitment from 
the blood(15) and phenotypic modulation(53). 
Another critical cell that helps dictate the outcome from acute liver damage is the 
neutrophil(48). Inflammation including both infective and sterile results in trafficking of 
neutrophils to the damaged areas within the liver(47). The central role of these 
granulocytic cells in combating fungal and bacterial infections is underlined by the 
profound susceptibility neutropaenic patients have to invasive infections(206) . 
Neutrophils accumulate within the liver vasculature in response to a number of 
cytokines produced by cells within the inflamed liver including but not exclusively 
TNF-a, IL-1b, platelet activating factor (PAF) and a number of CXC 
chemokines(207). Sequestration of neutrophils within the liver vasculature is not 
enough for the cells to function as effectors; extravasation to the hepatic parenchyma 
is a prerequisite(207). Once through the endothelium, danger signals guide 
granulocytic infiltration to the area of maximal liver damage via inflammasome 
activation as detailed above and a combination of CXCL chemokine gradients and 
adhesion (ICAM-1 and VCAM-1) molecule upregulation(208). Multiple models of 
human and rodent live injury demonstrate neutrophil accumulation within the liver 
parenchyma, unsurprisingly neutrophil cytotoxicity has thus been extensively studied 
in the context of liver damage and blocking hepatic neutrophil homing, sequestration 
and extravasation have all been identified as potential therapeutic strategies(206). 
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Recent evidence however suggests that neutrophils may not always be deleterious 
during liver injury and in fact have been shown to (as already mentioned in the 
introduction) have restorative roles particularly as part of the sterile inflammatory 
response(50). 
An increasing body of recent literature recognizes that platelets play a central but 
paradoxical role in liver injury, being able to both drive damage and aid 
resolution(53). Platelets interact with the key protagonists of the sterile inflammatory 
response including neutrophils and macrophages(52) and can enhance hepatic 
leucocyte recruitment into the liver across the sinusoidal endothelium(15). However, 
little is known about the molecular basis of platelet activation during acute liver failure 
and specifically whether manipulating platelet function could influence the sterile 
inflammatory response to toxic liver injury. As already discussed platelet activation 
occurs through multiple pathways including ligation of platelet-expressed CLEC-2 by 
its ligand podoplanin(70) . Because inflammatory macrophages upregulate 
podoplanin(90) and have an important role in driving the sterile inflammatory 
response to toxic liver injury(33), we wanted to investigate whether CLEC-2 driven 
platelet activation by inflammatory macrophages had a role in acute toxic liver injury. 
The outcome from toxic hepatic insults such as CCl4 intoxication is dictated by the SI 
response, which may contribute to and worsen the liver damage, or be reparative 
and drive resolution(47). Manipulating the sterile inflammatory response to a toxic 
liver insult such as paracetamol overdose induced liver injury in humans may allow 
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for the development of treatments in human drug induced acute liver failure (ALF); 
platelets may provide exactly such as an avenue. 
4.3.  Aims for this chapter 
The focus of this chapter is to elucidate how platelets may interact with the cells of 
the innate immune system that are of key importance in sterile inflammation, and to 
investigate whether blocking platelet activation may influence recruitment of these 
effector cells to the damaged liver. Importantly I also wanted to, ascertain whether 
this may influence the outcome from a toxic liver injury. My ultimate goal was to 
replicate a clinically relevant problem, such a paracetamol-induced acute liver failure 
and investigate the therapeutic potential of blocking platelet activation in such a 
context . 
Thus the specific aims for this chapter were: 
1) To assess the nature of the sterile inflammatory response and amount of liver 
damage intraperitoneally administered CCl4 or APAP elicit in C57Bl6 wild type mice. 
2) To abrogate CLEC-2 mediated platelet activation during CCl4 and APAP -induced 
liver damage, and assess whether platelet activation influences the outcome from 
these injuries. 
3) To ascertain how platelet function influences the nature of the sterile inflammatory 
response after toxic liver injury and whether this abrogates or worsens liver damage. 
 
 137 
4.4.  Administration of intraperitoneal CCl4 or paracetamol results in 
centrizonal hepatic necroinflammation 
Wild type C57Bl6 Mice were injected with a single dose of intraperitoneal CCl4 as 
described above, and then sacrificed at serial time points. We detected liver damage 
as measured by histological necrosis and mononuclear cell infiltration as early as 24 
hours after a single dose of CCl4 (figure 4.1). This was accompanied by raised serum 
transaminases (fig 4.1), which continued to increase until 48 hours after 
administration, but started to reduce thereafter. The pattern of damage observed was 
dominantly centrizonal, or around the central vein (panel A, fig 4.1). Importantly mice 
administered the mineral oil carrier alone did not demonstrate injury (panel B, fig 4.1) 
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Figure 4.1 Murine livers develop centrizonal necrosis after IP CCl4 injection:  
WT mice were injected with CCl4 (dose) or mineral oil alone as indicated, and sacrificed after 
24 hours. The livers were removed and paraffin embedded and representative images from 
stained with H/E are presented above. A) Original magnification 10x, n>10 animals per 
group. Centrizonal (around the central vein) necrosis is highlighted with arrows, portal vein-









The peak serum ALT values at 48 hours after CCl4 injection, this correlates with the 
amount of hepatocellular necrosis observed histologically (figure 4.2). After 48 hours, 
resolution of injury began and this correlated with histological improvement of the 
necrotic injury, reduction in the visible amount of infiltrating mononuclear cells 
(arrows, fig 4.2) and reduction in serum ALT(fig 4.2). 
 
Figure 4.2 Hepatocellular injury peaks at 48 hours post intraperitoneal CCl4 injection: 
WT mice were injected with CCl4 and sacrificed at 24, 48 or 72 hours. Representative 
images from H/E stained sections are shown for each timepoint (10x original magnification, 
A). Serum was harvested via cardiac puncture for ALT analysis (B) and each dot represents 
one animal. C) same data as B, X-axis changed to log10 to illustrate the difference between 
serum ALT levels at 0 hrs. and 72 hrs. Each dot is an individual mouse, median shown. 






































IP administration of paracetamol elicited more extensive liver damage and this 
occurred at earlier time points compared to CCl4 (fig 4.3). Serum evidence of hepatic 
necroinflammation as gauged by a rise in ALT was detected as early as 6 hours 
(panel A, B fig 4.3) after the paracetamol was administered and this correlated with 
clinical parameters, including the mice exhibiting an antalgic gait, reduced grooming 
and reduced feeding. This clinical deterioration was however transient and mice 
began to show signs of clinical improvement at 24 hours. In a similar pattern to CCl4, 
this sub-lethal dose of paracetamol resulted in a peak of necrosis as indicated by H/E 
staining at 24 hours and then resolution of injury thereafter (fig 4.3). 
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Figure 4.3 Hepatocellular injury peaks at 24 hours post intraperitoneal APAP injection:  
WT mice were injected with APAP and sacrificed at 6, 24 or 48 hours. Serum was harvested 
via cardiac puncture for ALT analysis and representative sections stained with H/E are 
presented above. A) 10x magnification representative pictures for each time point are shown. 
H/E stain, paraffin section. B) Serum ALT values from WT mice taken at each point are 







































4.5.  Podoplanin is upregulated in murine livers after toxic liver 
injury 
We had already established that in acute and chronic human disease podoplanin 
expression is upregulated and that platelets sequester to this podoplanin thus 
providing a potential mechanism for platelet activation via CLEC-2 in liver disease 
(Chapter 3). We next sought to determine if this also occurred in murine liver injury. 
We found that in uninjured or non-inflamed livers, podoplanin expression in mouse 
livers was similar to human liver disease i.e. fairly limited. In non-injured wild type 
murine livers podoplanin expression was limited to small periportal vessels that were 
morphologically and anatomically consistent with lymphatic vessels(166)(figure 4.4). 
 
Figure 4.4 Podoplanin expression within uninjured murine liver is restricted to 
lymphatic vessels: 
Representative images from uninjured WT mice were stained with podoplanin antibody and visualized 
using DAB stain (brown). Representative samples shown at 20x original magnification. Arrow 
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highlights lymphatic vessel, IMC stain was negative (right). Samples are representative of at least 4 
livers 
After both APAP and CCl4 induced hepatic injury, we noted an increase in the 
amount of podoplanin expressed within murine livers (figure 4.5). This upregulation 
was not seen in control mice that were treated with mineral oil or PBS (figure 4.5). 
Microscopic analysis suggested that podoplanin was upregulated on a sub-
population of mononuclear cells within the hepatic infiltrate and also upon vessels 
(figure 4.5). Further immunohistochemical analyses confirmed that podoplanin 
expression co-localized with the F4/80 expressing cells (fig 4.5, blue arrows). Such 
upregulation of podoplanin was not observed in uninjured control mice. 
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Figure 4.5 Podoplanin is upregulated on hepatic macrophages after hepatic injury in 
mice:  
Representative images from acutely injured murine livers taken at time point of peak hepatic injury i.e. 
24 hours after APAP injection or 48 hours after CCl4 injection are shown A) WT Murine liver sections 
stained with podoplanin DAB, and at 20X original magnification demonstrating podoplanin 
upregulation (brown, arrows) on cells and vessels (IMC was negative). B) Higher magnification 40x 
image from a representative APAP sample demonstrating staining of cells within the hepatic 
inflammatory infiltrate (brown, arrows) C) Confocal microscopy (40x original magnification) 
demonstrating colocalisation of macrophages (F4/80-green) and podoplanin (blue). Macrophages co-
expressing podoplanin are sea-blue (arrows). Isotype stains negative (not shown). Images 































To confirm that it was the macrophages that specifically upregulated podoplanin 
during hepatic injury we used Blomhoff’s method of selective adherence (164) to 
isolate a pure population of hepatic macrophages from non-injured wild type livers 
(figure 4.6). Macrophages could be distinguished amongst cellular debris by F4/80 
expression (figure 4.6, panel A, B).These cells were confirmed as being 
macrophages by F4/80 expression (figure 4.6). Paralleling our in vivo findings, very 
little basal expression of podoplanin was found on these cells in the unstimulated 
state. However, on stimulating these isolated macrophages with lipopolysaccharide 
(LPS) (100ng/ml in DMEM) we observed a change in morphology of the 





Figure 4.6 Isolated macrophages upregulate podoplanin expression in vitro  on 
stimulation with lipopolysaccharide:  
Macrophages were isolated from WT mouse livers and cultured in DMEM alone or DMEM 
containing 100ng/ml LPS for 6 hours. Confocal microscopy images showing F4/80+ cells 
(red), and podoplanin (green) on isolated macrophages under basal (A) or LPS-stimulated 



















4.6.  Platelet and macrophage distribution during acute liver damage 
After noting enhanced podoplanin expression on macrophages within the injured liver 
we next sought to define the distribution and numbers of hepatic macrophages after 
liver injury. Histochemical analysis, in WT mice suggested that the number of 
macrophages appeared to increase after liver injury and that these cells had a 
predominantly sinusoidal distribution(fig 4.7). 
 
Figure 4.7 Macrophages are distributed in a sinusoidal distribution after toxic liver 
injury:  
Representative images from acutely injured murine livers taken at time point of peak hepatic injury i.e. 
24 hours after APAP injection or 48 hours after CCl4 injection are shown. WT Murine liver sections 
stained with F4/80 DAB, and at 20X original magnification demonstrating podoplanin upregulation 












We next investigated whether platelets sequestered to the injured liver. Figure 4.8 
reveals that after both APAP and CCl4 injury CD41+ platelets accumulated within the 
hepatic sinusoids and within the hepatic inflammatory cell infiltrate. Higher 
magnification pictures (fig 4.8) revealed that platelets actually sequestered to 
mononuclear cells rather than being localized amongst the liver parenchymal cells or 
upon sinusoidal endothelium. We next assessed whether these inflammatory cells 
were macrophages. Confocal microscopy confirmed that platelets (CD41+) 
colocalised with podoplanin expressing macrophages (F4/80+) during acute toxic liver 
injury (fig 4.8). 
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Figure 4.8 Platelets are found sequestered within the acutely injured liver:  
WT mice were injected with CCl4 and sacrificed at 48 hours. Liver paraffin sections stained with a 
platelet (CD41) DAB stain (brown, arrows), with a haematoxylin nuclear counterstain. Top picture at 
20x magnification demonstrates platelet sequestration within hepatic sinusoids. Higher magnification 
(40x) reveals that platelet sequestration is also to mononuclear cells distinct to hepatocytes or 




















We have already established that macrophages upregulate podoplanin during acute 
liver injury (fig 4.5, 4.6). As platelets appeared to sequester to mononuclear 
inflammatory cells within the damaged liver; we next assessed whether these 
inflammatory cells were macrophages. Confocal microscopy confirmed that platelets 
(CD41+) sequester to podoplanin expressing macrophages (F4/80) during acute toxic 
liver injury (fig 4.9-arrows) 
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Figure 4.9 Platelets sequester to podoplanin expressing macrophages after acute liver 
injury:  
APAP injured mouse liver, frozen section(taken at peak time of injury-24 hours after injection) 
demonstrating platelet (CD41-yellow) sequestration to podoplanin (green) expressing 







4.7.  Mice with CLEC-2 deficient platelets exhibit enhanced healing 
after CCl4 and paracetamol injury 
After establishing the nature and time course of the hepatic necroinflammatory 
response to both IP CCl4 and APAP in WT animals, and critically that platelets 
sequestered to podoplanin expressing macrophages in the injured liver areas in both 
models, we next sought to investigate whether CLEC-2 dependent platelet activation 
had a role to play in driving this injury. We thus used mice that bore a conditional 
deletion of the CLEC1b gene in cells expressing PF4 (PF4CreCLEC1bfl/fl) i.e. the 
megakaryocytic lineage in our CCl4 and paracetamol-induced injury models. At the 
earliest time points studied, after both APAP (6 hours) and CCl4 (24 hours) no 
difference in liver damage as gauged by serum ALT rise and liver histology was 





Figure 4.10 Injury at early time points is comparable between WT and CLEC-2 deficient 
mice after either CCl4 or APAP induced liver injury:  
WT or CLEC-2 deficient mice were injected with CCl4 and sacrificed at 24 hours or APAP 
and sacrificed at 6 hrs. Serum was harvested and sent for ALT analysis, livers were 
removed, embedded in paraffin and sections prepared. Serum ALT from both groups is 
presented in the top graphs (CCl4-left, APAP-right). Each dot is an individual mouse, median 
shown. H/E stained paraffin sections are shown below. H/E stain 10x or 20x. (Mann-Whitney 
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However when we compared WT murine livers with livers from CLEC-2 -deficient 
mice 48 and 72 hours after IP CCl4 administration we noted far less hepatic injury in 
the livers from the PF4CreCLEC1bfl/fl mice compared to WT (figure 4.11). The CLEC-
2 deficient mice had much smaller areas of hepatic necrosis and lower serum ALT 




Figure 4.11 CLEC-2 deficient animals develop less hepatic injury after CCl4 injection:  
WT or CLEC-2 deficient mice were injected with CCl4 and sacrificed at 48 or 72 hours. 
Serum ALT level (top of figure) and hepatic necrosis observed (bottom of figure. H and E 
stain, paraffin sections, 10x magnification). Each dot represents an individual mouse, median 
shown. (Mann Whitney test to gauge significance*P < 0.05, **P < 0.01, ***P < 0.001). 
 
 









































This phenotype was reproduced when we used paracetamol injury. When we 
analyzed the CLEC-2-deficient mice at 24 and 48 hours after treatment, we noted far 
less damage in the PF4CreCLEC1bfl/fl mice when compared to age and litter 
matched controls (figure 4.12). Thus a similar pattern of liver injury and healing was 
noted after both APAP and CCl4 injection, with the CLEC-2 deficient animals 
exhibiting enhanced healing after both toxic insults (figures 4.11). The magnitude and 
temporal pattern of liver damage was however different when comparing the two 
injury models, as liver injury occurred sooner after APAP injection and the severity of 
injury (as gauged by ALT) was greater in both WT and PF4CreCLEC1bfl/fl mice after 
APAP compared to CCl4. Another notable difference was that no observable clinical 
deterioration in the physical health of the mice (both WT and PF4CreCLEC1bfl/fl mice) 
aside from a mild and transient antalgic gait was noted after CCl4 administration. 
Mice treated with IP APAP (both WT and PF4CreCLEC1bfl/fl) in contrast exhibited 
more significant behavioral signs manifest as reduced feeding, reduced grooming, 
the development of a greasy coat and an antalgic gait as soon as 4 hours after the 
injection. This observed clinical deterioration was transient with the mice improving 
spontaneously by 24 hours. 
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Figure 4.12 CLEC-2 deficient mice exhibit enhanced recovery after APAP injection:  
WT or CLEC-2 deficient mice were injected with APAP and sacrificed at 24 or 48 hours. Serum ALT 
level (top of figure) and representative histology (bottom of figure. H and E stain, paraffin sections, 10x 
magnification). Each dot represents one animal. Median shown. (Mann Whitney test to gauge 
significance*P < 0.05, **P < 0.01, ***P < 0.001). 













































As macrophages were a source of podoplanin in the injured liver and thus were 
potentially providing an activation stimulus for CLEC-2 in the injured liver, we next 
examined livers from both WT and CLEC-2 deficient (PF4CreCLEC1bfl/fl) mice to see 
if there was a difference in pattern of macrophage distribution after injury, which 
could help potentially explain the enhanced liver healing observed in the CLEC-2 
deficient mice. 
We noted that after a toxic injury there were an overall greater number of 
macrophages in both WT and CLEC-2 deficient animals compared to uninjured 
controls (fig 4.13) (on initial histological analysis alone). In the WT mice the 
macrophages were present primarily within the sinusoids (Fig 4.13), in the CLEC-2 
deficient mice however a large number of greater macrophages were (in addition to 
the sinusoids) present around the central vein (centrizonal distribution-this is where 
both APAP and CCl4 caused maximum necrotic damage, fig 4.13). 
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Figure 4.13 After toxic injury macrophages sequester to the injured area in CLEC-2 
deficient mice:  
WT or CLEC-2 deficient mice were injected with CCl4 and sacrificed at 48 hours. Representative 
paraffin sections stained with a macrophage (F4/80) DAB stain (arrows), and visualized at 20X 
magnification with a haematoxylin counterstain. IMC staining was negative. 
 
 
Next, when we studied platelet sequestration within the same injured livers we noted 
that there was remarkably more intrahepatic platelet sequestration within the livers of 














injury (figure 4.14). The CLEC-2 deficient animals had greater platelet sequestration 
(arrows) along the hepatic sinusoids and also within the centrizonal inflammatory 
infiltrate (fig 4.14). This spatially correlated with the macrophage (F4/80) distribution 
in the CLEC-2 deficient mice at the same time points. 
 
Figure 4.14 After toxic injury larger amounts of platelets sequester to the injured liver 
in CLEC-2 deficient mice compared to wild type:  
WT or CLEC-2 deficient mice were injected with CCl4 and sacrificed at 48 hours. Liver 
paraffin sections stained with a platelet (CD41) DAB stain (arrows), and visualized at 20X 
















This suggested that platelets could associate with greater avidity to podoplaninhi 
macrophages if they were CLEC-2 deficient. To confirm this we again isolated liver 
macrophages (as described in chapter 2) and after stimulating them with LPS co-
cultured the macrophages with either WT or CLEC-2 deficient platelets(isolated from 
WT or PF4CreCLEC1bfl/fl mice respectively). More CLEC-2 deficient platelets 
attached to LPS stimulated hepatic macrophages than WT platelets (figure 4.15). 
However, it was not clear from our experiments whether the macrophages were 
actively phagocytosing platelets or the platelets were merely binding to the surface of 
the macrophages (fig 4.15). 
 
Figure 4.15 CLEC-2 deficient platelets sequester to wild type macrophages in greater 
numbers than wild type platelets:  
Macrophages isolated from a single WT mouse liver were divided and plated in a 6 well 
plate. DMEM containing LPS was added to all the wells. To these macrophages were added 
WT or CLEC-2 deficient platelets, after a 1 hour incubation the wells were washed with 
sterile PBS and cells fixed. Images representative of confocal microscopic analysis of 6 wells 
are shown. Platelets CD41+ are in purple, nuclear stain DAPI is blue and the macrophage 






















After we had established that mice with CLEC-2 deficient platelets exhibited 
enhanced liver healing after toxic insults and that both macrophages and platelets in 
CLEC-2 deficient mice sequestered to the injured liver (specifically to areas of 
centrizonal necrosis) with greater avidity than in WT mice we next sought to 
investigate the functional consequences of this enhanced sequestration and 
interaction. 
Hepatic macrophages (specifically Kupffer cells) are known to be key cells in 
monitoring the liver environment for signs of damage and upon sensing damage 
(DAMP expression) (33) initiate the sterile inflammatory response characterized by 
further immune cell recruitment (47). This immune response can then, depending 
upon context and nature of injury heal the liver or worsen damage(204). We thus 
wondered whether there was indeed an enhanced macrophage presence in the livers 
of CLEC-2 deficient mice (as per our initial histological investigations) and whether 
the macrophage interaction with CLEC-2 deficient platelets influenced the sterile 
inflammatory response to drive enhanced liver recovery in the PF4CreCLEC1bfl/fl 
mice.  
Thus, we next assessed the damaged livers to establish the kinetics of immune cell 
particularly macrophage recruitment to see whether this was different between WT 
and CLEC-2 deficient animals and critically whether this correlated with the 
enhanced healing observed in the CLEC-2 deficient mice. 
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4.8.  Kinetics of immune cell recruitment after toxic liver injury 
4.8.1.  CD45+ recruitment 
Our data demonstrates that both the maximum amount of liver damage and 
leukocyte sequestration occurred in centrizonal areas of the liver after a single dose 
of both APAP and CCl4, at 48 hrs. in the case of CCl4 and 24 hrs. in the case of 
APAP. This pattern was seen in both WT and CLEC-2 deficient animals (fig 4.16). 
Initial histological analysis suggested there may be greater amounts of inflammatory 
leukocytes present within the livers of CLEC-2 deficient mice after injury (see arrows 




Figure 4.16 Wild type and CLEC-2 deficient animals both develop centrizonal damage 
and leukocyte sequestration after toxic liver damage: 
WT or CLEC-2 deficient mice were injected with a single dose of IP CCl4 or IP APAP. Mice were 
sacrificed at point of peak injury (i.e. 48 hrs. after IP CCl4 or 24 hours after IP APAP). Centrizonal 

























To quantify and phenotype the inflammatory infiltrate we digested murine livers as 
detailed above (chapter 2) and then used flow cytometric analysis to quantify the 
numbers of infiltrating leukocytes per gram of liver tissue. We used CD45 as a pan 
leukocyte marker (see gating strategy in fig 4.18) and found that in WT mice after a 
toxic liver injury such as CCl4, the numbers of infiltrating CD45+ cells increased (Fig 
4.17, top right panel), peaking at time of maximum injury indicated by serum ALT 
quantitation (48 hours, fig 4.17 bottom panel). 
 
Figure 4.17 Liver infiltrating CD45+ leukocytes increase and peak at time point of 
maximal necrotic damage after toxic liver injury:  
WT mice were injected with a single dose of IP CCl4. Mice were sacrificed at 24, 48 or 72 hours after 
injection. Serum was analyzed for ALT level and the liver was digested to isolate leukocytes, which 
are expressed as numbers of CD45+ cells per gram of liver. Top graphs demonstrate the same data 
as a scatter plot (left) or connected mean (right). Graph below shows ALT at the time points after 
CCl4administration. Each dot represents an individual mouse, median shown.  
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When I compared CD45+ immune cell number in injured WT and CLEC-2 deficient 
mice (PF4CreCLEC1bfl/fl) I noted that despite initial histochemical analyses 
suggesting greater leukocyte infiltration within the livers of CLEC-2 deficient animals, 
absolute numbers of liver infiltrating CD45+ cells were not significantly different. 
There were only marginally greater numbers of CD45+ cells in CLEC-2 deficient mice 
at 24 hours in the IP CCl4 group, and this difference was not statistically significant. 
At all other time points (particularly at points of maximum histological and 
biochemical damage, i.e. 48 hrs. after IP CCl4 and 24 hours after IP APAP) there was 
no difference in amount of leukocytes per gram of liver tissue when comparing the 
CLEC-2 deficient to WT mice, with either injury (fig 4.18). 
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Figure 4.18 Numbers of liver infiltrating CD45+ leukocytes are similar at most 
timepoints after toxic liver injury:  
A) WT or CLEC-2 deficient mice ( mice were injected with a single dose of IP CCl4 or IP APAP. Mice 
were sacrificed at 24, 48 or 72 hours after injection. The liver was digested to isolate leukocytes, which 
were expressed as numbers of cells per gram of liver tissue. B) CD45+ cells were gated as shown in 
the strategy . The figure on the left is a side scatter vs forward scatter plot, with the leukocyte 
population being gated out. The image in the right, gates out the dead cells and CD45- cells. The plot 
is a live dead stain (APC-Cy7) Vs CD45(PercP-Cy5.5), the gated population is thus live (APC-cy7-) 
and CD45+. At no point was a statistically significant difference seen when comparing WT and CLEC-
2 deficient mice undergoing a toxic insult. (Each dot represents an individual mouse, median shown.  













































































We next immunophenotyped the CD45+ positive cells into lymphocytes and myeloid 
cells as detailed below. 
4.8.2.  Lymphocyte recruitment 
To identify the lymphocyte compartment from the infiltrating CD45+ cells, we first 
gated the CD3+ and CD3- populations and then subsequently applied a gating 
strategy to define CD4+ and CD8+ T cells (see strategy in Fig 4.19). In both WT and 
CLEC-2 deficient animals an increase in the number of lymphocytes was observed 
post injury. We noted that at 48 hours after CCl4 injection statistically greater 
amounts of CD4 and CD8 T cells were seen within the CLEC-2 deficient mice and at 
24 hrs. after APAP injection a statistically greater amount of CD4 T cells was 
observed within CLEC-2 deficient murine livers (Fig 4.20). At the remaining time 
points the numbers were comparable between CLEC-2 deficient and WT mice. 
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Figure 4.19 Lymphocyte gating strategy:  
Mice were injected with a single dose of IP CCl4 or IP APAP. Mice were sacrificed at 24, 48 
or 72 hours after injection. The liver was digested to isolate leukocytes. After the live CD45+ 
population was gated out (top right), gates were applied to separate out the CD3- population 
(bottom right figure). The CD3+ population was then further gated into CD8 T-cells (thus 
CD45+CD3+CD8+CD4-), CD4 T-cells (CD45+CD3+CD8-CD4+) and CD3 T-cells 































Figure 4.20 CD4 and CD8 lymphocytes are present in greater amounts within the livers 
of CLEC-2 deficient mice after toxic liver injury:  
WT or CLEC-2 deficient mice were injected with a single dose of IP CCl4 or IP APAP. Mice 
were sacrificed at 24, 48 or 72 hours after injection. The liver was digested to isolate 
leukocytes. CD4+, CD8+ and CD3+ leukocytes were analyzed using previously described flow 
cytometric methods  and gated using the previously defined strategy and expressed as 
number of cells per gram of liver tissue. Absolute CD4+, CD8+ and CD3+ numbers are shown 
for individual animals at each time point after either CCl4 or APAP was administered. Each 
dot represents an individual animal. The bar represents median values of each group and 




































































































































































































































































4.8.3.  Myeloid cell recruitment 
We next undertook further phenotyping of the hepatic infiltrate after liver injury to 
specifically see if there was a difference between WT and CLEC-2 deficient animals 
when quantifying absolute numbers of macrophages and neutrophils (see gating 
strategy in Fig 4.21). Despite histological evidence suggesting enhanced platelet-
macrophage cell interaction in CLEC-2 deficient animals, and greater macrophage 
accumulation within the livers of CLEC-2 deficient mice, cytometric analysis showed 
that absolute numbers of macrophages (CD3-CD11b+F4/80+) were similar between 
WT and CLEC-2 deficient animals at all time points studied (Fig 4.22) after either 




Figure 4.21 Myeloid cell gating strategy:  
Mice were injected with a single dose of IP CCl4 or IP APAP. Mice were sacrificed at 24, 48 or 72 
hours after injection. The liver was digested to isolate leukocytes. After the live CD45+ population was 
gated out (top right), gates were applied to separate out the CD3+ population (bottom right figure). The 
CD3_ population was then further gated into macrophages (CD45+CD3-CD11b+F4/80+) (bottom left) 
and neutrophils (CD45+CD3-CD11b+GR1hi) (figure in the middle, left hand side). numbers are shown 




































Figure 4.22 Hepatic macrophage numbers are similar in WT and CLEC-2 -deficient 
mice after a toxic liver injury:  
WT or CLEC-2 -deficient mice were injected with a single dose of IP CCl4 or IP APAP. Mice 
were sacrificed at 24, 48 or 72 hours after injection. The liver was digested to isolate 
leukocytes. Leukocytes were analyzed using flow cytometric methods. Macrophages were 
gated using the previously defined strategy and expressed as number of cells per gram of 
liver tissue. Absolute macrophage numbers are compared in WT and CLEC-2 deficient mice 
at each time point after either CCl4 or APAP was administered. Each dot represents an 
individual mouse. The bar represents median values of each group and Mann Whitney test 























































































However when we examined neutrophil infiltration (Cd3-Cd11b+Gr1hi), we noted that 
in response to a toxic injury (both APAP and CCl4) CLEC-2 deficient mice exhibited 
significantly greater numbers of infiltrating neutrophils per gram of liver tissue 
compared to control WT animals (fig 4.23) at most time points studied (the 




Figure 4.23 CLEC-2 deficient mice exhibit enhanced hepatic neutrophil numbers at the 
peak point of liver injury after toxin administration:  
WT or CLEC-2 deficient mice were injected with a single dose of IP CCl4 or IP APAP. Mice 
were sacrificed at 24, 48 or 72 hours after injection. The liver was digested to isolate 
leukocytes. Leukocytes were analyzed using flow cytometric methods. Neutrophils gated 
using the previously defined strategy and expressed as number of cells per gram of liver 
tissue. Absolute neutrophil numbers are compared in WT and CLEC-2 deficient mice at each 
time point after either CCl4 or APAP was administered. Each dot represents an individual 
mouse. The bar represents median values of each group and Mann Whitney test used to 





























































































4.9.  Podoplanin blockade recapitulates the effects seen in CLEC-2 
deficient mice 
After having established that the cognate ligand for CLEC-2, podoplanin was 
upregulated within the livers of mice undergoing a toxic acute liver injury and that 
mice with CLEC-2 deficient platelets exhibited enhanced healing after toxic liver 
injury, we next sought to establish whether it was indeed podoplanin upregulation 
within injured livers that provided the signal for platelet activation, thus worsening 
injury after a toxic hepatic insult. Therefore we next interrogated the role of this 
pathway from the other side by removing podoplanin and assessed whether 
removing this platelet activation stimulus would result in reduced injury after APAP or 
CCl4 mediated liver injury. 
The most pronounced difference in terms of hepatic damage was noted at 48hrs after 
CCl4 administration and 24 hrs. after APAP administration when comparing CLEC-2 
deficient mice to WT mice. At these time points whilst the WT mice continued to 
develop worsening liver damage with a rising serum ALT and increasing hepatic 
necrosis, the CLEC-2 deficient mice had much lower serum level of ALT (fig 4.24, 
blue boxes) and exhibited restoration of the hepatic architecture as well. For our 




Figure 4.24 Time line for injury after APAP and CCl4 injection:  
WT and CLEC-2 deficient mice were injected with CCl4 and sacrificed at 24, 48 or 72 hours; or WT 
and CLEC-2 deficient mice were injected with APAP and sacrificed either 6, 24 or 48 hours. Mice were 
sacrificed using cardiac puncture and serum harvested for ALT analysis. Time points of peak injury in 
WT mice are highlighted. (n=5-11). S.E.M shown and Mann Whitney test used *P < 0.05, **P < 0.01, 
***P < 0.001. 
4.9.1.  Genetic podoplanin deletion 
To remove podoplanin we used a genetic mutant mouse with a conditional deletion 
for podoplanin (Vav1-iCre+pdpnfl/fl) (209). The mice were subjected to either a single 
dose of IP CCl4 or APAP as described above, and sacrificed at points of maximal 







































liver injury as determined in our previous experiments, this was [24 hours in the case 
of APAP and 48 hours in the case of CCl4 (fig 4.25)] 
4.9.1.1.  CCl4 
After a single injection of IP CCl4, podoplanin deficient mice (Vav1-iCre+pdpnfl/fl) or 
WT (cre negative) control animals were sacrificed at 48 hours. The podoplanin mice 
had less injury as gauged by reduced serum ALT levels and histological analysis 
compared to their cre-negative counterparts. 
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Figure 4.25 Podoplanin deficient (Vav1-iCre+pdpnfl/fl) mice exhibit less injury after IP 
CCl4 injection:  
Podoplanin deficient mice or WT mice were injected with IP CCl4 and sacrificed at 48 hours. Serum 
ALT level (top graph) comparing WT and podoplanin deficient mice is shown. Images below are 
paraffin sections and are representative of at least 5 mice (10x, H/E stain). Each dot represents an 
individual mouse. The bars represent median values of each group. 
 
 


















Analysis of the hepatic inflammatory infiltrate again revealed that although overall 
numbers of infiltrating cells were similar between the two groups (this extended to 
most subtypes-all data not shown); there again appeared to be a tendency to greater 
neutrophil accumulation after CCl4 was administered (fig 4.26). 
 
Figure 4.26 Podoplanin deficient mice exhibit enhanced neutrophil infiltration after IP 
CCl4 administration:  
Podoplanin deficient mice (Vav1-iCre+pdpnfl/fl) or WT mice were injected with a single dose of IP CCl4. 
Mice were sacrificed at 48 after injection. The liver was digested to isolate leukocytes, these were 
analyzed using flow cytometric techniques  and then were expressed as numbers of cells per gram of 
liver tissue. The bars represent median values of each group. 
 















































4.9.1.2.  APAP 
We next used podoplanin deficient mice (Vav1-iCre+pdpnfl/fl) in APAP models of liver 
damage. Mice were taken at 24 hours after IP APAP injection. We found that the 
podoplanin deficient mice again had less injury than their cre negative counterparts, 
and again this correlated with enhanced neutrophil recruitment to the injured liver. 
The remainder of leukocyte recruitment studied was similar between the two groups 
(CD45+ shown in fig 4.27, remaining subtypes not shown) 
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Figure 4.27 Podoplanin deficient mice (Vav1-iCre+pdpnfl/fl) exhibit reduced injury and 
enhanced neutrophil infiltration after IP APAP administration:  
Podoplanin deficient mice (Vav1-iCre+pdpnfl/fl) or WT mice were injected with a single dose of IP 
APAP. Mice were sacrificed at 24 hrs. after injection. The liver was digested to isolate leukocytes, 
which were expressed as numbers of cells per gram of liver tissue and serum ALT was measured in 
extracted blood. A) serum ALT is shown, B and C) neutrophils and CD45+ leukocytes per gram of liver 
tissue are shown. D) representative histology from 5 animals per group is shown (H/E, 10x, Paraffin). 
Each dot in the scatter plots represents a single mouse. 
 


































































4.9.2.  Use of function blocking antibody 
Our ultimate goal was to see if we could therapeutically treat toxic liver injury and 
thus we next used a specific podoplanin function-blocking antibody to see whether 
we could enhance liver healing after toxic liver injury, in a manner similar to what we 
observed in the genetic models of CLEC-2 or podoplanin deficiency. We thus pre-
treated wild type mice with a function blocking antibody, prior to injecting them with 
the injurious stimulus (i.e. APAP or CCl4, see treatment schedule in fig 4.28). We 
found that mice that had been pretreated with the anti-podoplanin function blocking 
antibody exhibited reduced hepatic injury after both APAP and CCl4 at peak point(s) 
of liver injury (i.e. 48 hrs. after CCl4 and 24 hrs. after APAP). 
 
Figure 4.28 Timeline of podoplanin antibody treatment:  
WT mice were pretreated with a podoplanin function blocking antibody (or the corresponding isotype 
matched control). The mice were then administered either IP CCl4 or IP APAP 24 hours later. The 
mice that had been administered CCl4 were taken 48 hours after the toxin was administered; mice that 
had been given APAP were culled at 24 hours after toxin administration. 
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Figure 4.29 Treating mice with a podoplanin antibody reduces injury after both CCl4 
and APAP mediated injury:  
Mice were treated with a podoplanin function blocking (5 μg /gm) or isotype matched control AB and 
then treated with either APAP or CCl4. Blood was harvested via cardiac puncture and serum ALT 
measured at time points shown. The graphs at the top compare serum ALT after APAP and CCl4 
injection in podoplanin AB treated and control AB groups. Representative histology from 4 mice in 
each group is shown at the bottom (H/E, 10x, Paraffin). Each dot in the scatter plots represents a 
single mouse, the bars represents median values of each group and the Mann Whitney test was used 








































We next analyzed the livers from these mice for absolute leukocyte numbers, and 
found that again there was a greater amount of neutrophils within the livers of the 
mice that had been given the podoplanin blocking antibody compared to the isotype 
treated controls (IMC fig 4.30). Total number of leukocytes (CD45+) and remaining 
subtypes (data not shown) were similar in both AB and IMC groups (in both APAP 
and CCl4 arms). 
 
 
Figure 4.30 Mice treated with a podoplanin antibody exhibit enhanced neutrophil 
infiltration after IP CCl4 or IP APAP administration:  
Mice were treated with a podoplanin function blocking or isotype matched control AB and then injected 
with a single dose of IP CCl4 or APAP. Mice were sacrificed at time points shown. The liver was 
digested to isolate leukocytes, which were expressed as numbers of cells per gram of liver tissue. 
Each dot in the scatter plots represents a single mouse, the bars represents median values of each 
































































































4.10.  The effect of neutrophil depletion on liver injury 
The cell type that was consistently the most numerous within the livers of mice that 
had either a CLEC-2 deficiency or podoplanin blockade (both genetic and AB 
mediated) after an acute toxic liver insult was the neutrophil. In our models’ 
neutrophil infiltration (assessed cytometrically) clearly correlated temporally with a 
reduction in liver injury (blue box, fig 4.31). Furthermore, histochemical analyses 
(using a neutrophil elastase antibody) confirmed that neutrophils were present within 
areas of resolving injury in the CLEC-2 deficient and podoplanin blocked mice, and in 
greater numbers than their WT counterparts (fig 4.32).  
 
 
Figure 4.31 Hepatic neutrophil infiltration peaks at time of maximal reduction of ALT in 
CLEC-2 deficient mice:  
CLEC-2 deficient mice were injected with CCl4 and sacrifice at either 24, 48 or 72 hours. Blood was 
harvested via cardiac puncture and serum ALT measured at time points shown. The liver was 
collected and digested. Neutrophils (CD11b+Gr1+) were isolated using a gradient centrifugation 
method, stained and expressed as cells per gram of liver tissue. Highlighted area (at 48 hours’ post 
CCl4 dose) reveals time point of peak neutrophil infiltration and maximum reduction in serum ALT. 
 

























Figure 4.32 After toxic liver injury more neutrophils sequester to damaged areas 
within the livers of CLEC-2 deficient mice than WT mice:  
WT or CLEC-2 deficient mice were injected with CCl4 and sacrificed at 48 hours. Liver 
paraffin sections stained with a neutrophil elastase primary AB with DAB (brown) secondary 
stain (arrows), and visualized at 20X (top images) or 10X magnification (bottom images) with 
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After confirming the temporal and spatial relationship between neutrophil infiltration 
and liver healing we next sought to functionally confirm that to was indeed this 
enhanced neutrophil infiltration that was driving liver healing in the CLEC-2 deficient 
mice. We thus pre-treated CLEC-2 deficient mice with either a neutrophil depleting 
antibody or control AB, prior to administering CCl4 (see timeline in fig 4.33). We found 
that CLEC-2 deficient mice that had been administered a selective neutrophil 
depleting antibody (anti-Ly6G) prior to CCl4 treatment had lower levels of peripheral 
circulating neutrophils and had reduced hepatic neutrophil infiltration (fig 4.33). The 
lower hepatic neutrophil infiltration in the antibody treated group correlated with 
worse injury as gauged by serum ALT levels compared to the CLEC-2 deficient mice 
that had the control AB prior to CCl4 administration. (Fig 4.33). 
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Figure 4.33 Neutrophil depletion in CLEC-2 deficient mice removes the protective 
effect of CLEC-2 deficiency in mice undergoing a toxic liver injury:  
CLEC-2 deficient mice were pre-treated with either saline or a neutrophil depleting antibody. 
All mice were then administered IP CCl4 and sacrificed at 48 hours (top left image).The liver 
was collected and digested. Neutrophils (CD11b+Gr1+) were isolated using a gradient 
centrifugation method, stained and expressed as cells per gram of liver tissue, blood was 
harvested via cardiac puncture and serum ALT and circulating neutrophil count determined 
using a coulter counter. A) Circulating neutrophil count is shown B) infiltrating neutrophils per 
gram of liver tissue are shown C) serum ALT. Each dot in the scatter plots represents a 
single mouse, the bars represents median values of each group and the Mann Whitney test 
was used to gauge significance *P < 0.05, **P < 0.01, ***P < 0.001. 
 
 

































































4.11.  Macrophage derived TNF-a recruits’ neutrophils to the injured 
liver 
Macrophages or specifically hepatic Kupffer cells have an important role in 
paracetamol induced acute liver injury and macrophage depletion has a deleterious 
effect on the liver after APAP(39,210) overdose. Our data confirmed that hepatic 
macrophages upregulate podoplanin after toxic liver injury, thus providing a ligand for 
platelet activation via CLEC-2; additionally we noted that platelets sequester to 
podoplanin expressing macrophages, and that blocking the CLEC-2-podoplanin axis 
enhanced this interaction and also increased hepatic platelet sequestration. We have 
also established that removing either CLEC-2 from platelets or podoplanin 
(genetically or blocking using an antibody) resulted in enhanced healing from toxic 
liver injury by enhancing neutrophil recruitment to the injured liver. Our experiments 
thus far had not however established exactly how removing CLEC-2 from platelets or 
blocking/removing podoplanin on macrophages enhanced neutrophil recruitment to 
the injured liver or indeed whether the two were linked. 
TNF 𝛼 is a cytokine with established roles in liver regeneration (211) and importantly 
is known to be crucial for CD11b+GR1+ cell recruitment (212–214). We thus analyzed 
murine serum after liver injury to compare serum TNF 𝛼 levels between WT and 
CLEC-2 deficient mice. At the point of peak damage we noted that there was very 
little TNF 𝛼 in murine serum (fig 4.34), however we argued that if the peak point of 
injury resolution in the CLEC-2 deficient animals (i.e. 48 hr. after CCl4 administration) 
corresponded to peak neutrophil infiltration, the stimulus for this recruitment must 
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precede hepatic neutrophil infiltration. We thus examined sera from mice at an earlier 
timepoint (24 hrs. after CCl4 administration) and found that the CLEC-2 deficient mice 
had significantly higher levels of serum TNF- 𝛼 after toxic liver injury compared to 
their WT counterparts (fig 4.34). 
 
 
Figure 4.34 CLEC-2 deficient mice have greater amounts of serum TNF-	𝜶 at early 
points after toxic liver injury:  
WT or CLEC-2 deficient mice injected with IP CCl4 and sacrificed at either 24 or 48 hour. The serum 
extracted was analyzed using a sandwich ELISA technique. Each dot in the scatter plots represents a 
single mouse, the bars represents median values of each group and the Mann Whitney test was used 












































4.11.1.  Macrophage TNFa production is enhanced when cells are incubated with 
CLEC-2 deficient platelets 
There are multiple sources of TNFa in the liver, with macrophages (specifically 
Kupffer cells) being a particularly potent source during liver injury(205); as abrogating 
the CLEC-2/ podoplanin axis seemed to enhance systemic TNFa levels, we next 
sought to establish whether the source of this enhanced TNFa was the altered 
macrophage-platelet interaction. We thus isolated macrophages from WT murine 
livers and cultured them in six well plates as before. To mimic inflammatory 
conditions we treated the isolated macrophage population with 100ng/ml of 
lipopolysaccharide (LPS). We then measured the amount of TNFa within the 
macrophage secretome via ELISA. We found as before that compared to 
macrophages treated with control media alone, macrophages co-cultured with LPS 






Figure 4.35 Hepatic macrophages produce TNF-	𝜶 after stimulation with LPS:  
Non-injured WT mice were sacrificed, their livers were removed and hepatic macrophages 
isolated. After being stimulated with LPS (or control DMEM alone, the macrophage 
secretome was collected and analyzed for TNFa levels via a sandwich ELISA. Each dot in 
the scatter plots represents different wells but macrophages are from a single mouse, the 
bars represents median values of each group and the Mann Whitney test was used to gauge 


























We next stimulated hepatic macrophages with LPS and co-cultured these with either 
WT or CLEC-2 deficient platelets and found that the presence of WT platelets 
suppressed TNFa production by macrophages in response to LPS, but CLEC-2 





Figure 4.36 CLEC-2 deficient platelets enhance hepatic macrophage TNF-	𝜶 production 
after stimulation with LPS:  
Non-injured WT mice were sacrificed, their livers were removed and hepatic macrophages 
isolated. After being stimulated with LPS, the macrophages were co-incubated with either 
WT or CLEC-2 deficient platelets. The macrophage secretome was collected and analyzed 
for TNF-a levels via a sandwich ELISA. Each dot in the scatter plots represents 
macrophages from a single mouse, the bars represents median values of each group and 
the Mann Whitney test was used to gauge significance. 
 
 





















We then used CLEC-2 deficient platelets or podoplanin deficient macrophages and 
cultured them in LPS containing media. Our results demonstrate that removing 
CLEC-2 or podoplanin resulted in enhanced TNFa production by macrophages (fig 
4.37), compared to CLEC-2 expressing platelet (WT) incubation with podoplanin 





Figure 4.37 Podoplanin deficient macrophages produce more TNF-	𝜶 production after 
stimulation with LPS:  
Non-injured WT mice and podoplanin deficient (Vav1-iCre+pdpnfl/fl)mice were sacrificed, their livers 
were removed and hepatic macrophages isolated. After being stimulated with LPS, the macrophages 
were co-incubated with either WT or CLEC-2 deficient platelets. The macrophage secretome was 
collected and analyzed for TNF-a levels via a sandwich ELISA. Each dot in the scatter plots 


























4.11.2.  Etanercept pre-treatment abrogates neutrophil recruitment in CLEC-2 
deficient mice 
We next aimed to confirm whether the enhanced TNF-a production in CLEC-2 
deficient mice provided the cue for increased neutrophil recruitment and thus 
enhanced liver healing. We pretreated CLEC-2 deficient mice with a TNF-a blocking 
antibody (etanercept) or PBS (as a control), prior to induction of toxic liver injury (see 
treatment schedule in Fig 4.38). We found that pre-treatment of CLEC-2 deficient 
mice with etanercept reduced hepatic neutrophil accumulation and restored liver 
injury to WT levels (fig 4.38). 
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Figure 4.38 Abrogating TNF-	𝜶 function by pretreating CLEC-2 deficient mice with 
etanercept removes the protective effect of CLEC-2 deficiency:  
CLEC-2 deficient mice were pre-treated with either etanercept (10mg/Kg) or PBS as indicated in the 
timeline. All mice were then administered IP CCl4 and sacrificed at 48 hours (top image). Pretreating 
CLEC-2 deficient mice with etanercept reduced hepatic neutrophil infiltration and restored hepatic 
injury to WT levels (middle and bottom graphs respectively) Each dot in the scatter plots represents a 
single mouse, the bars represents median values of each group and the Mann Whitney test was used 
to gauge significance *P < 0.05, **P < 0.01, ***P < 0.001. 







































4.12.  Hepatic CYP2E1 expression is unaffected by CLEC-2 or 
podoplanin deficiency 
Since both APAP and CCl4 are metabolized by enzymes of the cytochrome P450 
system, specifically CYP2E1 we next sought to investigate whether expression of this 
enzyme was altered in the CLEC-2 or podoplanin deficient mice. This would result in 
less hepatotoxic metabolites being produced and provide an alternative explanation 
for our findings. As expected we found that there was no significant difference in 
induction extent or localization when we examine CYP2E1 expression between WT 




Figure 4.39 Hepatic CYP2E1 expression is unaffected by CLEC-2 or podoplanin 
deficiency:  
Uninjured and injured (with APAP or CCl4) WT or CLEC-2 deficient mice were sacrificed at peak point 
of liver injury (48hrs-CCl4, 24hrs-APAP), or the corresponding time point for the uninjured control 
group. Mouse liver tissue was collected and paraffin embedded. The sections were then stained with a 
CYP2E1 antibody (or isotype matched control) and staining was visualized using DAB substrate 
































Mouse genetic variant ( +/- 
AB pre-treatment) 
Paracetamol induced 
peak liver injury (24 
hours) 
Carbon tetrachloride 
induced peak liver 
injury (48 hours) 
WT ALT high 
CD11bGR1 low 
ALT high 
         CD11bGR1 low 
PF4creCLEC1bfl/fl ALT low 
CD11bGR1 high 
ALT low 
       CD11bGR1 high 
Vav-1crePDPNfl/fl ALT low 
CD11bGR1 high 
ALT low 
       CD11bGR1 high 





       CD11bGR1 high 
Etanercept (antiTNF AB) 
given to PF4creCLEC1bfl/fl  
Data not available  ALT high 
       CD11bGR1 low 
Anti-ly6G AB (neutrophil 
depleting) given to 
PF4creCLEC1bfl/fl mice 
Data no available ALT high 
       CD11bGR1 low 
Table 4.1 The effect of genetic disruption and antibody treatment on toxic liver 
injury 
Summary of the effect(s) genetic mutant mice or blocking antibodies have on the 
development of toxic liver injury as gauged by serum ALT and intrahepatic neutrophil 




4.13.  Discussion 
Platelets have important roles in several pathophysiological processes relevant to 
liver disease (53); however as they often mediate seemingly opposing processes(53) 
their overall contribution to liver pathology is unclear and is likely to be disease and 
context dependent(37). We report a completely novel mechanism through which 
platelets accelerate recovery from acute liver injury in response to APAP and CCl4 
toxicity. After acute toxic injury to the liver (due to either APAP or CCl4) podoplanin is 
upregulated (in both humans and mice) on hepatic macrophages. These 
macrophages are likely to be derived from a combination of haematogenous and liver 
resident or Kupffer cells. We confirm that under resting or non-inflammatory 
conditions there is minimal podoplanin expression by these cells and thus little or no 
ligand available for CLEC-2 dependent platelet activation. On stimulation (i.e. during 
acute liver damage), the number of macrophages expressing podoplanin increases 
within the liver and this macrophage expressed podoplanin then activates platelets 
via CLEC-2. We demonstrate that abrogating CLEC-2-dependent platelet activation 
from macrophage expressed podoplanin enhances liver healing after toxic injury by 
increasing hepatic neutrophil infiltration. This clearly has therapeutic potential in 
human APAP induced acute liver failure where current therapies have limited efficacy 
and a challenging window for best benefit. One of the concerns that has been raised 
in the past when considering anti-platelet therapy in liver disease, is the risk of 
blocking platelet function in clinical situations where a bleeding diathesis may be 
present. As CLEC-2 mediated platelet activation is independent of major haemostatic 
 202 
pathways, and studies confirm that the bleeding risk CLEC-2 blockade confers is 
minimal(215), this pathway becomes particularly attractive for therapeutic 
intervention. 
4.13.1.  Experimental design 
In order to establish the pattern of toxic injury and gauge the sterile inflammatory 
response in mice I began my experiments with the CCl4 model. Although arguably 
not of direct relevance to human liver disease this compound elicits fatty 
degeneration, fibrosis, hepatocellular death, and carcinogenicity(160) within the liver, 
these are liver pathological processes with correlates with human liver disease and 
thus CCl4 induces a pattern of liver inflammation not dissimilar to human liver 
diseases including steatohepatitis and drug induced liver injury(216). Another 
attractive feature of CCl4 is the solubility of this compound in oil and thus ease of use, 
lower and more predictable toxicity (compared to APAP) to mice, and finally the 
reproducibility of the model. I thus used CCl4 to set up all the initial acute toxic liver 
injury experiments, and then moved on to paracetamol induced liver damage. 
Paracetamol due to its lower solubility, and arguably higher and more acute toxicity 
required greater care in setup and more intensive monitoring after injection. This 
limited the numbers of animals I was allowed to place on protocol and as a result 
certain experiments had smaller number of mice than would be required to 
adequately power studies. 
Human paracetamol overdose is mechanistically very similar to what is observed in 
rodent models. Exposure of primary human hepatocytes to high levels of 
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paracetamol generates excessive amounts of NAPQI which depletes GSH, drives 
mitochondrial protein adduct formation and cell death(202) . It should be noted that 
minor differences between humans and mice have been reported when studying 
paracetamol induced liver damage including slower but larger amounts of protein 
adduct formation(202) . However, allowing for these minor differences murine models 
still provide a very valuable resource for studying acute toxic liver damage. 
The podoplanin deficient mice (Vav1-iCre+pdpnfl/fl) were difficult to breed, and thus 
we only had limited numbers of mice available. Therefore we focused on time points 
of maximal injury noted from CLEC-2 deficient and WT animals’ experiments (fig 
4.24). Although we show that in the CLEC-2 deficient mice the initial liver injury after 
APAP and CCl4 is comparable between CLEC-2 and WT mice and that there is then 
enhanced recovery in the CLEC-2 deficient mice, we do not actually show this in the 
podoplanin deficient or podoplanin antibody injected mice, merely that there is less 
liver injury compared to WT mice at peak points of liver damage. To demonstrate that 
the same mechanism was at work in the podoplanin deficient mice, a similar set of 
experiments comprehensively gauging injury (and healing) at each of the time points 
after injection would be necessary. 
Although we used the same process for isolating macrophages from liver digests as 
we did for flow cytometric analysis; and we thus confirm that WT mice had little inter-
animal variability in terms of number of macrophages, we did not actually count the 
number of macrophages per well in the vitro studies. To minimize variability I used 
the one mouse liver and uniformly suspended macrophages prior to plating out in the 
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6 well plates. To improve accuracy of our experiments, the in vitro arm should be 
repeated with a standardized amount of macrophages per well. This would permit a 
more accurate way of expressing this data as the amount TNFa produced per a 
standardized number of cells. 
4.13.2.  TNFa and macrophages in acute liver injury 
Our data reveals that enhanced liver recovery correlates with increased TNFa levels. 
Activation of macrophages and the role of TNFa in mediating hepatic regeneration 
fits with accepted paradigms of liver healing(217–219) . Abrogating TNFa function 
negatively influences both liver regeneration and outcomes after acute hepatic 
inflammation in both mice and humans; the failure of anti-TNFa therapy to result in 
clinical improvement in patients with severe alcoholic hepatitis being particularly 
notable(11,220). Platelet interaction with macrophages and monocytes has been 
investigated in ischaemia-reperfusion models(117,186,221) in mice, and the ability of 
platelets to modulate both monocyte and macrophage function, cytokine profile and 
even final phenotype have previously been described(139,140); the specific 
molecular pathways that platelets may use to do this are however less clear. Our 
investigations suggest that platelets sequester to podoplanin expressing 
macrophages in the acutely injured liver. To elucidate the role of the CLEC-
2/podoplanin pathway in this interaction we isolated hepatic macrophages and used 
LPS to stimulate expression of podoplanin. We found that LPS stimulated podoplanin 
expressing macrophages that were co-incubated with CLEC-2 deficient platelets 
produced larger amounts of TNFa than macrophages co-cultured with WT platelets. 
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Thus it seems likely that CLEC-2 operates after liver injury to dampen TNFa 
production. Our in vivo investigations substantiate this by revealing that higher serum 
TNFa levels are found after toxic liver injury in CLEC-2 deficient mice compared to 
WT mice. Our models demonstrate that the result of enhanced TNFa production after 
a toxic insult is enhanced hepatic neutrophil infiltration, which then correlates with 
accelerated liver recovery. Thus CLEC-2 deficiency enhances the TNFa driven 
inflammatory response. As inflammation is a pleiotropic process that can both heal 
and worsen organ damage, the physiological role of CLEC-2 in certain situations may 
actually be protective. However, during toxic liver damage; specifically, APAP and 
CCl4 induced liver damage, CLEC-2 mediated platelet activation blocked the 
development of reparative inflammation which then worsened liver damage. The 
observation that platelets can promote cytokine release from macrophages is not 
novel(142) but to our knowledge ours is the first molecular definition of a pathway 
that links platelet activation with suppression of cytokine responses and liver repair. 
Ishida et al suggest that TNFα accentuates liver damage during APAP injury(222) 
and Sato et al report reduced hepatic injury in models of CCl4 hepatitis using TNFa 
neutralizing antibodies(205). In contrast to these findings others have noted a 
reduction in liver healing or hepatocyte proliferation (and thus greater injury) in TNF 
receptor deficient mice (TNFR1-/-)(223,224). Our data suggests that TNFa in the 
context of acute toxic liver injury actually aids liver recovery, but we only have data 
from the CCl4 model. Thus it would be necessary to repeat these experiments and 
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establish the TNFa levels in WT or mice with CLEC-2 abrogation after APAP 
treatment. 
4.13.3.  Neutrophil driven liver repair 
It seems paradoxical that enhancing liver inflammation (specifically increasing 
hepatic neutrophil infiltration) by blocking the CLEC-2/Podoplanin axis actually aids 
liver healing, but several studies, including ours confirm the role of restorative 
neutrophil driven inflammation(216), particularly in the context of sterile injury(50). 
Neutrophil dysfunction is part of the immune paresis that contributes to poor 
outcomes after liver inflammation(225); artificially enhancing neutrophil levels using 
granulocyte-colony stimulating factor (G-CSF) has been shown to improve liver 
recovery in patients with alcoholic hepatitis(226) and importantly neutrophil activation 
is critical to injury resolution after APAP overdose (44). TNF-a has well established 
roles in coordinating neutrophil flux, it thus seems plausible that the enhanced TNF-a 
production that blocking CLEC-2 mediated platelet activation resulted in drives 
enhanced neutrophil recruitment to the injured liver which in turn enhanced liver 
recovery.  The molecular and cellular cues that 'switch-on' such neutrophil mediated 
reparative inflammation are yet to be deciphered. We provide the first evidence that 
during acute liver injury platelets block the development of such neutrophil mediated 
'healing' inflammation; by abolishing CLEC-2 dependent platelet activation we 
manipulate the inflammatory response after a toxic insult to specifically increase 
hepatic neutrophil infiltration and enhance liver recovery. We thus provide the first 
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demonstration to our knowledge of artificially increasing reparative neutrophil 
recruitment to the acutely damaged liver. 
4.13.4.  Developmental and egress abnormalities in CLEC-2/Podoplanin deficient 
mice 
An important point to note is that both CLEC-2 and podoplanin have important roles 
during lymphatic development, specifically in maintaining blood and lymphatic 
separation during embryogenesis(170,227), and that CLEC-2 positive dendritic cells 
use lymphatic- expressed podoplanin to exit the lymph nodes(182). The 
PF4CreCLEC1bfl/fl and Vav1-iCre+pdpnfl/fl mice, may have thus had subclinical 
lymphatic defects which could contribute to neutrophil recruitment or egress in a 
manner similar to that described for dendritic cells. However, our observations of 
enhanced neutrophil inflammation and thus repair, when we conducted experiments 
using a function-blocking podoplanin antibody in adult wild type mice with normal 
lymphatic development suggested that altered recruitment or retention dynamics 





Figure 4.40 Blocking the CLEC-2 mediated platelet activation enhances TNF-a 
production to increase neutrophil recruitment and healing in the injured liver 
a)Upon liver injury Kupffer cells express increasing amounts of podoplanin, which 
then activates platelets via CLEC-2. This interaction dampens the production of 
Kupffer cell produced TNF-a and results in reduced hepatic neutrophil recruitment 
and blunted liver recovery. b) Blocking the CLEC-2/podoplanin axis using either mice 
with targeted deletions for CLEC-2 or podoplanin or using a podoplanin function 
blocking antibody increases Kupffer cell production of TNF-a. This enhanced TNF-a 








5.  The role of platelet CLEC-2 in chronic murine liver injury 
 
Fibrosis is a consequence of chronic activation of the wound healing mechanism 
within the liver. Iterative bouts of inflammatory activity due to variety of aetiologies 
including alcoholic and non-alcoholic liver disease, viral hepatitis, auto immune liver 
disease result in over activation of this reparative pathway eventually causing 
activation of the hepatic stellate cells(HSCs), which are widely regarded as the key 
effector cells driving liver fibrosis(228). HSC activation can be divided into two 
stages: initiation and perpetuation. Initiation, also referred to as the pre inflammatory 
stage represents the early changes to gene expression and phenotype that occur 
within HSCs in response to the products of acute hepatic injury including cytokines 
from KCs, apoptotic bodies(229) and DAMPs(230). This stage in effect primes the 
HSCs for the next stage, B) Perpetuation-here the HSCs undergo complex 
behavioural changes including chemotaxis, contractility and proliferation(229). 
Activated HSCs acquire a myofbroblast like phenotype thus assuming fibrogenic 
functions and depositing large amounts of extra-cellular matrix (ECM) within the liver. 
Fibrosis at these early stages remains reversible; removal of the injurious stimuli 
results in HSC senescence or apoptosis and thus fibrosis reversal (228). Continued 
activation of this pathway however results in the parenchymal architecture of the liver 
being progressively replaced by fibrous tissue, the hepatic response to this is the 
development of regenerative nodules and thus starts cirrhosis which essentially 
marks the of irreversible end stage liver disease(3). 
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A critical cell in the control of fibrosis through its ability to modulate HSC plasticity is 
the macrophage(13). Macrophages contain the potently fibrogenic cytokines TGF-b 
and PDGF, and macrophage conditioned media has been shown to promote HSC 
activation in vitro through the actions of these cytokines (137). Macrophages can also 
negatively regulate the development of hepatic fibrosis by promoting HSC apoptosis 
through MMP-9 and TNFa -related apoptosis-inducing ligand (TRAIL) (137) and also 
dictating extra cellular matrix or scar remodeling during liver fibrosis (by secreting 
MMP-9 and MMP-13)(231). Depleting macrophages at the time of onset of liver injury 
or fibrosis blocks the development of fibrosis, however at later time points blocks 
their ability to aid scar resolution(137). Ramachandran et al have described the 
principal MMP expressing population of restorative macrophages as the CD11Bhi 
F4/80intLy-6Clo(45), and demonstrated that depleting this specific population caused 
a failure in scar remodeling(45). Hepatic macrophages thus both promote and 
abrogate experimental fibrosis through their downstream actions(40). As our data in 
the acute models has suggested that platelet activation via macrophage expressed 
podoplanin is important in the pathogenesis of acute liver damage due to a toxic 
agent, we sought to explore the relevance of this pathway in chronic liver disease. 
Although there are numerous advantages to using animal models to better 
understand human fibrosis including limiting variables and strategic timing of 
sampling during fibrosis and resolution phases(232) there are notable limitations. 
Particularly relevant is the profound aversion rodents have for alcohol, as well as the 
tenacity their livers have to withstand alcohol induced fibrosis. Differing patterns in 
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development of fibrosis in mice and humans for example periportal vs pericentral and 
the lack of murine models to adequately mimic all the different types of human liver 
disease suggest that caution must be exercised when translating animal data to the 
human setting(232). 
Various animal models of fibrosis are available for experimental use, each with its 
own advantages and limitations(233). Thus the animal models we used to study 
hepatic fibrosis are introduced below. 
5.1.  Carbon tetrachloride induced chronic liver injury 
Acute CCl4 mediated injury is characterized by a transient liver injury and immune 
cell recruitment allowing a return to hepatic haemostasis. Our experience using 
carbon tetrachloride to induce hepatic necrosis and then liver healing inflammation 
after a single injection has been described above (chapter 4). However repetitive 
CCl4 injection results in iterative bouts of hepatic damage and over activation of 
wound healing pathways, which then drive liver fibrosis. Repetitive CCl4 
administration in mice represents a highly tractable and thus reproducible model of 
liver fibrosis model. The CCl4 induced liver fibrosis model has the additional benefit of 
having a resolution phase after cessation of CCl4 administration, which allows for not 
only study of development of liver fibrosis but resolution from liver fibrosis as well 
(232). 
The development of liver fibrosis due to CCl4 can roughly be divided into three 
phases. The initial phase involves acute toxic injury and a dominantly myeloid cell 
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driven innate immune response that initially worsens liver damage and then drives a 
strong regenerative response characterized by hepatocellular (both parenchymal and 
non-parenchymal) regeneration. The second phase is where the deposition of fibrous 
tissue is observed, this occurs as early as 3 weeks after bi-weekly IP CCl4 injections 
(234). Fibrosis initially appears in pericentral (around the central vein) areas, and 
then progresses to bridging fibrosis at around 4-6 weeks of treatment(234) followed 
by nodular regeneration and eventually hepatocellular cancer (235). A notable 
advantage of the chronic CCl4 model in mice is the distinct resolution phase one 
observes once the toxic stimulus is withdrawn, thus several weeks after cessation of 
CCl4, complete regression of fibrosis is observed (234). Such regression or reversal 
of fibrosis is a component of many human liver diseases including autoimmune 
hepatitis, biliary obstruction, iron overload, NASH, and viral hepatitis B and C (236–
239). 
5.2.  Methionine-choline deficient diet 
NAFLD or non-alcoholic liver disease represents one of the most rapidly rising 
causes of liver disease in the world and is certainly the commonest cause of 
abnormal liver enzymes in the United Kingdom(1) . The methionine choline deficient 
diet is a commonly used model in mice to mimic the development of initially a 
steatotic liver followed by inflammation or oxidation and thus eventually liver 
fibrosis(2); this two hit (inflammation within steatotic areas which precedes the 
development of liver fibrosis) mechanism parallels human NAFLD. Day et al 
proposed that liver damage in human NAFLD has two distinct driving phases(240). 
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The first hit is due to a combination of impaired mitochondrial beta oxidation, 
impaired VLDL synthesis and hepatocyte triglyceride accumulation(234). The second 
hit is probably due to mitochondrial dysfunction leading to enhanced intrahepatic 
oxidative stress, which then results in the oxidation of accumulated hepatic fat thus 
driving a powerful necroinflammatory response(241). The associated chronic 
inflammatory response is driven and maintained by multiple cytokines including 
TNF𝛼, IL-1 and IL-6, which then results in Kupffer cell driven HSC activation and liver 
fibrosis (241). - 
The MCD diet is a commonly used diet to model NASH/NAFLD in rodents. This diet 
is high in sucrose and fat but lacks methionine and choline which are important for 
the synthesis of very low density lipoproteins (VLDLs) by the liver and critical in the 
mitochondrial beta oxidation pathway(235). Thus this diet limits substrate availability 
for phosphatidylcholine synthesis resulting in the inability of the liver to assemble 
VLDLs and reduces hepatic triglyceride secretion (242). Mice fed this diet can 
develop hepatic inflammation as soon as three days after starting the diet, this is 
followed by pericentral steatosis at around 2 weeks. The timing however of the initial 
necroinflammatory response is highly variable, and it can take up to 3 weeks. At 
around 3-4 weeks a pronounced necroinflammatory injury is noted, and this is then 
followed by progressive fibrosis(241). The MCD diet therefore induces a similar two 
hit pattern of steatosis followed by inflammatory damage as seen in human NAFLD. 
Additionally, enhanced levels of ROS driven oxidative stress with concomitant 
activation of TNFa signaling seen with this diet have established the MCD diet as 
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one of the best models for studying non-alcoholic steatohepatitis (234). The major 
disadvantage of this model is the lack of classical metabolic phenotype that often 
precedes human fatty liver disease(234). Mice on this diet for instance actually lose 
weight, have reduced serum cholesterol and triglyceride levels and critically display 
no insulin resistance(161). 
5.3.  Aims 
We have already established from our studies in chronically damaged and thus 
fibrotic human livers that a significant upregulation of podoplanin occurs (chapter 3). 
Investigating CLEC-2-dependent platelet activation and how it may influence 
macrophage behaviour in the context of hepatic fibrosis has particular relevance 
when one considers the central role these cells play in modulating HSC behaviour 
and the fact that our data clearly demonstrates that upon liver injury hepatic 
macrophages upregulate podoplanin (section 4.5). Thus we wanted to investigate 
whether the podoplanin-CLEC-2 axis had a role in the development of hepatic 
fibrosis. Our aims for this section were as follows: 
1) To establish the pattern of podoplanin expression the chronically injured mouse 
liver 
2) To examine whether blocking CLEC-2 dependent platelet activation influenced the 
development of liver fibrosis in murine models of fibrosis. 
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5.4.  Use of the chronic carbon tetrachloride model 
The data from acute murine injury models revealed that mice deficient in CLEC-2 or 
podoplanin exhibited enhanced healing from acute liver injury. Platelet activation due 
to this axis in the acute setting thus served to perpetuate or worsen liver injury. 
Furthermore our human data reveals that there was a clear correlation between 
severity of liver disease as gauged by MELD score (section 3.5.2) and podoplanin 
expression in humans. We wished to study the role this axis may have in the 
development of fibrosis and thus used the PF4CreCLEC1bfl/fl mouse which has 
platelets selectively deficient in CLEC-2 and administered bi-weekly CCl4 injections 
for 8 weeks to induce liver fibrosis.  
5.4.1.  CLEC-2 deficient and wild type exhibit centrizonal fibrosis after chronic 
CCl4 exposure 
Both WT and CLEC-2 deficient mice exhibited fibrosis after 7 weeks of intraperitoneal 
carbon tetrachloride injections. All mice exhibited peri-venular fibrosis with extension 
to periportal areas (see representative images in fig 5.1). To minimize the acute 
necro-inflammatory damage a single dose of CCl4 results in, we only sacrificed the 
mice 96 hours after the last dose of IP CCl4 (fig 5.1-time line). 
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Figure 5.1 Mice exhibit centrizonal fibrosis after chronic CCl4 administration:  
WT or CLEC-2 deficient mice were injected twice weekly with CCl4 injections. Mice were sacrificed at 
the end of 7 weeks (after a total of 14 injections). The livers were harvested, paraffin embedded and 
sections stained using picrosirius red. Representative images from at least 5 mice in each group at 







Initial histological analyses using picrosirius red stain seemed to suggest that the 
CLEC-2 deficient mice exhibited greater amounts of fibrosis than the wild type mice 
(see representative images in figure 5.2). The fibrosis pattern was however similar in 
both groups of mice i.e. peri-venular (around central vein) with secondary extension 




Figure 5.2 CLEC-2 deficient mice exhibit greater fibrosis after chronic CCl4 
administration:  
WT or CLEC-2 deficient mice were injected twice weekly with CCl4 injections. Mice were 
sacrificed at the end of 7 weeks (after a total of 14 injections). The livers were harvested, 
paraffin embedded and sections stained using picrosirius red. Representative images from at 






To definitively quantify the level of hepatic fibrosis seen, we next undertook a 
hydroxyproline assay (fig 5.3). This revealed that although the CLEC-2 deficient mice 
had a slightly higher median (261.85 vs 241.7𝜇g/gm of liver) hydroxyproline content, 
this was not statistically relevant when compared to WT mice. Reassuringly both WT 
and CLEC-2 deficient mice that had been administered CCl4 had a significantly 
higher content of hepatic hydroxyproline compared to WT control animals that had 
been administered just mineral oil. 
 
 
Figure 5.3 CLEC-2 deficient and WT mice have equivalent levels of fibrosis after 
chronic CCl4 administration:  
WT or CLEC-2 deficient mice were injected bi weekly with CCl4 injections or mineral oil. Mice were 
sacrificed at the end of 7 weeks (after a total of 14 injections). The livers were harvested, 
homogenized and treated with trichloroacetic acid to enable protein precipitation. The hydroxyproline 
concentration of the protein precipitant was then determined by colorimetric analysis using 4-
(Dimethylamino)benzaldehyde (DMAB). Groups incorporated between 3 and 10 mice, data from 
individual mice are shown by a single point and median values are indicated by horizontal bar. Data 
are amount of hydroxy proline per gram of liver tissue, and test Mann-Whitney indicated significant 
differences between groups as indicated (*P < 0.05, **P < 0.01, ***P < 0.001). 


























5.4.2.  CLEC-2 deficient mice exhibit periportal podoplanin expression after 
induction of liver fibrosis 
We next examined hepatic podoplanin expression after chronic CCl4 administration. 
Similar to acute CCl4 or APAP injury, podoplanin expression was again restricted to 




Figure 5.4 WT and CLEC-2 deficient mice express podoplanin in portal areas after 
chronic CCl4 administration:  
WT or CLEC-2 deficient mice were injected with twice weekly CCl4 injections or mineral oil 
alone. Mice were sacrificed at the end of 7 weeks (after a total of 14 injections). The livers 
were harvested and paraffin embedded. Podoplanin was visualized using indirect 
immunohistochemical staining with DAB substrate(brown) on paraffin-embedded murine liver 







Analysis of portal areas showed that a large amount of portal podoplanin-expressing 
cells and vessels were interspersed amongst the fibrotic portal tracts (fig 5.5) when 
fibrosis was severe enough to include these areas. These cells had a morphological 
appearance suggesting they were macrophages and the vessels were 
morphologically consistent with both expanded lymphatics and portal venules. 
Podoplanin expression seemed greater on cells of the inflammatory infiltrate 
(macrophages) in the CLEC-2 deficient mice whilst podoplanin expression in WT 





Figure 5.5 Podoplanin expression increases in fibrotic portal tracts:  
WT or CLEC-2 deficient mice were injected with twice weekly CCl4 injections or mineral oil alone. 
Mice were sacrificed at the end of 7 weeks (after a total of 14 injections). The livers were harvested 
and paraffin embedded. Podoplanin was visualized using indirect immunohistochemical staining with 
DAB substrate(brown) on paraffin-embedded murine liver sections or the sections were stained for 
collagen (pink, arrows) using a Van giesen stain. Representative images of portal tracts are shown at 


















To see whether it was the development of fibrosis that resulted in a ‘local' 
upregulation of podoplanin we also examined centrizonal areas within murine livers 
where maximal fibrosis was seen in CCl4 mediated models of fibrosis. Importantly 
although we noted fibrosis here, podoplanin expression was not seen in 
centrizonal/peri-venular areas (fig 5.6). 
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Figure 5.6 Podoplanin expression does not increase in centrizonal areas after chronic 
CCl4 intoxication:  
WT or CLEC-2 deficient mice were injected with twice weekly CCl4 injections or mineral oil alone. Mice 
were sacrificed at the end of 7 weeks (after a total of 14 injections). The livers were harvested and 
paraffin embedded. Podoplanin was visualized using indirect immunohistochemical staining with DAB 
substrate(brown) on paraffin-embedded murine liver sections or the sections were stained for collagen 
(pink, arrows) using a Van giesen stain. Representative images from both WT and CLEC-2 deficient 
mice are shown at 10X magnification (IMC was negative-not shown). Slides are from sequential 
















5.4.3.  CLEC-2 deficient mice have altered hepatic inflammation and injury after 
chronic CCl4 administration 
We next analyzed the level of injury within the livers of mice after chronic CCl4 
administration and found that similar to our acute experiments the serum ALT was 
lower in the CLEC-2 deficient group (median serum ALT: WT mice 838IU/L vs CLEC-
2 deficient mice 415IU/L) and this correlated with a trend of higher serum TNF 𝛼 





Figure 5.7 CLEC-2 deficient mice exhibit less necrotic damage after chronic CCl4 
administration:  
WT or CLEC-2 deficient mice were injected with twice weekly CCl4 injections or mineral oil 
alone. Mice were sacrificed at the end of 7 weeks (after a total of 14 injections). Groups 
incorporated 3 mice in each, data from individual mice are shown by a single point and 
median values are indicated by horizontal bar. Data are serum level of either TNF- 𝛼 or 






























5.4.4.  Cellular infiltration 
Next, we used our cytometric approach to see if the higher levels of serum TNFa 
observed in CLEC-2-deficient animals influenced hepatic leukocyte recruitment. We 
thus digested murine livers and isolated infiltrating leukocytes as described in chapter 
2. Importantly we also specifically examined the livers for the presence of pro-fibrotic 
(Cd45+Ly6G-Ly6C+ Cd11b+Cd3-), and pro-resolution (Cd45+Ly6G-Ly6C- 
Cd11b+Cd3-) (see gating strategy in fig 5.8). 
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Figure 5.8 Gating strategy used to define restorative and pro-fibrotic macrophages in 
our cytometric analysis of liver digests :  
WT or CLEC-2 deficient mice were injected with twice weekly IP CCl4 injections. Mice were sacrificed 
at the end of 7 weeks (after a total of 14 injections). Livers were digested and leukocytes isolated 
using a gradient separation method. Leukocytes were then stained, analyzed using flow cytometric 
methods and expressed as number of cells per gram of liver tissue. Pro-fibrotic macrophages were 
defined as live dead viability stain followed by CD45+Ly6G-Ly6C+CD11b+CD3-. 'Restorative' or anti-









































We found that although the CLEC-2 deficient animals in general had a tendency to 
have greater numbers of leukocytes after chronic CCl4 intoxication compared to WT 
mice. Thus CLEC-2 deficient mice had larger numbers of intra-hepatic neutrophils 
(median cells per gram of liver tissue: WT mice 7200 cells/gm vs CLEC-2 deficient 
mice 13269 cells/gm) and CD3+ T cells (median cells per gram of liver tissue: WT 
mice 109551 cells/gm vs CLEC-2 deficient mice 154697 cells/gm); owing to the small 
numbers of animals in each arm none of the differences reached significance. 
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Figure 5.9 CLEC-2 deficient and WT mice have similar numbers of liver infiltrating 
leukocytes after chronic CCl4 administration:  
WT or CLEC-2 deficient mice were injected with twice weekly IP CCl4 injections. Mice were sacrificed 
at the end of 7 weeks (after a total of 14 injections). Livers were digested and leukocytes isolated 
using a gradient separation method. Leukocytes were then stained, analyzed using flow cytometric 
methods and expressed as number of cells per gram of liver tissue. Cells defined as per previously 
gating strategies. Groups incorporated 3 mice in each, data from individual mice are shown by a single 







































































































Interestingly however, comparison of numbers of pro fibrotic and pro-resolution 
macrophages (Cd45+Ly6G-Ly6C+ Cd11b+Cd3-, and Cd45+Ly6G-Ly6C- Cd11b+Cd3- 
respectively, Figure 5.10) showed that the CLEC-2 deficient animals had lower 
numbers of both compared to their WT counterparts. 
 
 
Figure 5.10 CLEC-2 deficient mice have lower numbers of both restorative and pro-
fibrotic macrophages after chronic CCl4 administration:  
WT or CLEC-2 deficient mice were injected with twice weekly IP CCl4 injections. Mice were sacrificed 
at the end of 7 weeks (after a total of 14 injections). Livers were digested and leukocytes isolated 
using a gradient separation method. Leukocytes were then stained, analyzed using flow cytometric 
methods and expressed as number of cells per gram of liver tissue. Pro-fibrotic macrophages were 
defined as live dead viability stain followed by CD45+Ly6G-Ly6C+CD11b+CD3-. 'Restorative' or anti-
fibrotic macrophages were defined as CD45+Ly6G-Ly6C-CD11b+CD3-. Groups incorporated 3 mice in 
each, data from individual mice are shown by a single point and median values are indicated by 




































5.5.  Regeneration 
There appeared to be little observable difference in terms of fibrosis development 
between CLEC-2 deficient mice and wild type mice after 7 weeks of biweekly CCl4 
administration. We next examined the CLEC-2 deficient mouse (PF4CreCLEC1bfl/fl) 
to see if there was a difference in resolution from fibrosis. Thus after 7 weeks of CCl4 
administration we stopped the bi-weekly CCl4 dosing to allow the 'resolution from 
fibrosis' phase to begin (fig 5.11). This phase has been well described in WT 






Figure 5.11 Timeline used to allow resolution from chronic CCl4 administration 
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5.5.1.  Minimal resolution from fibrosis is seen after 3 weeks 
We stopped the bi-weekly CCl4 injections at 7 weeks and then culled the mice at 10 
weeks (time allowed for resolution from fibrosis was thus 3 weeks). There were 10 
mice in the wild type group and 3 in the CLEC-2 deficient group. We noted that the 
amounts of hepatic fibrosis as quantified by a hydroxy proline assay remained 
unchanged (compared to the amount seen in mice at the end of 7 weeks of ‘active’ 
injecting) in both the CLEC-2 deficient (PF4CreCLEC1bfl/fl) mice and WT mice. 
 
Figure 5.12 CLEC-2 deficient mice and WT do not exhibit resolution of fibrosis three 
weeks after cessation of IP CCl4:  
WT or CLEC-2 deficient mice were injected with twice weekly CCl4 injections or mineral oil alone for 7 
weeks, some mice were taken at this point (chronic). In the group of mice not culled, injections were 
then stopped. Mice were sacrificed after a further 3 weeks (the mice were not injected during this time-
regen group). The livers were harvested, homogenized and treated with trichloroacetic acid to enable 
protein precipitation. The hydroxyproline concentration of the protein precipitant was then determined 
by colorimetric analysis using 4-(Dimethylamino)benzaldehyde (DMAB). Groups incorporated between 
3 and 10 mice, data from individual mice are shown by a single point and median values are indicated 
by horizontal bar. Data are amount of hydroxy proline per gram of liver tissue, and test Mann-Whitney 
indicated significant differences between groups as indicated (*P < 0.05, **P < 0.01, ***P < 0.001) 
 


























5.5.2.  CLEC-2 deficient mice have altered patterns of injury and inflammation in 
the recovery phase 
Although no difference in terms of hydroxyproline was seen between the groups at 3 
weeks’ post CCl4 cessation, the CLEC-2 deficient mice had lower serum ALT values 
and less hepatic necrosis histologically compared to the WT controls at the same 
timepoint. Again the serum TNFa levels were also higher in the CLEC-2 deficient 
mice but the magnitude of the differences was marginal (fig 5.13) 
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Figure 5.13 CLEC-2 deficient mice have a lower serum transaminase level but higher 
TNF-	𝜶 levels compared to WT mice after chronic CCl4 administration:  
WT or CLEC-2 deficient mice were injected with twice weekly CCl4 injections or mineral oil alone for 7 
weeks. Injections were then stopped. Mice were sacrificed after a further 3 weeks (the mice were not 
injected during the final three weeks). Serum was harvested via cardiac puncture and analyzed for 
TNF-⍺ and serum ALT level. Groups incorporated 3 mice in each, data from individual mice are shown 
by a single point and median values are indicated by horizontal bar. Data are serum level of either 



































5.5.3.  Cellular infiltration 
Overall numbers of intrahepatic leukocytes decreased upon cessation of CCl4 
injections in WT mice (Fig 5.14). In contrast the numbers increased in CLEC-2 
deficient mice (fig 5.14). When comparing by leukocyte subtype, again no major 
differences were seen with similar numbers of lymphoid and myeloid cells seen in 
both WT ad CLEC-2 deficient livers at 10 weeks (fig 5.15). Of note, in contrast to the 
end of the active injury period, when we compared the numbers of pro-fibrotic and 
pro-resolution macrophages, during the resolution phase numbers were comparable 
in WT and KO mice (fig 5.16). 
 
 
Figure 5.14 Numbers of intrahepatic leukocytes increase during the fibrosis resolution 
phase within CLEC-2 deficient mice: 
WT or CLEC-2 deficient mice were injected with twice weekly CCl4 injections or mineral oil alone for 7 
weeks. Injections were then stopped. Mice were sacrificed after a further 3 weeks (the mice were not 
injected during the final three weeks). Livers were digested and leukocytes isolated using a gradient 
separation method. Leukocytes were then stained, analyzed using flow cytometric methods and 
expressed as number of cells per gram of liver tissue. Cells defined as per previously gating strategies 
. Groups incorporated 3 mice in each, data from individual mice are shown by a single point and 
median values are indicated by horizontal bar. Data are cells/ gram of liver tissue. 

















Figure 5.15 CLEC-2 deficient and WT mice have similar numbers of liver infiltrating 
leukocytes during the resolution phase after chronic CCl4 administration:  
WT or CLEC-2 deficient mice were injected with twice weekly CCl4 injections or mineral oil alone for 7 
weeks. Injections were then stopped. Mice were sacrificed after a further 3 weeks (the mice were not 
injected during the final three weeks). Livers were digested and leukocytes isolated using a gradient 
separation method. Leukocytes were then stained, analyzed using flow cytometric methods and 
expressed as number of cells per gram of liver tissue. Cells defined as per previously gating 
strategies. Groups incorporated 3 mice in each, data from individual mice are shown by a single point 


































































































Figure 5.16 CLEC-2 deficient and WT mice have similar numbers of restorative and 
pro-fibrotic macrophages during the resolution phase from chronic liver injury: 
WT or CLEC-2 deficient mice were injected with twice weekly CCl4 injections or mineral oil alone for 7 
weeks. Injections were then stopped. Mice were sacrificed after a further 3 weeks (the mice were not 
injected during the final three weeks). Their livers were digested and leukocytes isolated using a 
gradient separation method. Leukocytes were then stained, analyzed using flow cytometric methods 
and expressed as number of cells per gram of liver tissue. Pro-fibrotic macrophages were defined as 
live dead viability stain followed by CD45+Ly6G-Ly6C+CD11b+CD3-. 'Restorative' or anti-fibrotic 
macrophages were defined as CD45+Ly6G-Ly6C-CD11b+CD3-. Groups incorporated 3 mice in each, 
data from individual mice are shown by a single point and median values are indicated by horizontal 







































5.6.  Methionine choline deficient (MCD) diet 
Platelets have an important role in driving cardiovascular complications of the 
metabolic syndrome(243) ; the various stages of fatty liver disease represent the 
hepatic manifestation of the metabolic syndrome(53). We thus wished to examine the 
role of CLEC-2 mediated platelet activation in driving dietary (MCD) liver damage. As 
per the stipulations of our animal license we had to cull the mice if they lost 35% of 
their pre-diet weight. This resulted in a marked reduction in final numbers of 
particularly wild type mice and podoplanin deficient mice before they developed 
significant liver damage (fig 5.17). The results below thus reflect the mice numbers 
that remained. For this experiment we used both podoplanin deficient (Vav1-
iCre+pdpnfl/fl) and CLEC-2 deficient (PF4CreCLEC1bfl/fl) mice along with wild type 
mice as controls. The majority of WT mice had to be sacrificed before they developed 
significant liver injury as they lost weight at a much greater rate than the mutant mice 
(with CLEC-2 and podoplanin deficient). 
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Figure 5.17 Time line depicting when mice reached license threshold weight: Table 
below gives a breakdown of when mice reached threshold weight and whether any 







1 CLEC-2 deficient 4	weeks Yes
2 CLEC-2 deficient 4	weeks Yes
3 CLEC-2 deficient 4	weeks Yes
4 CLEC-2 deficient 4	weeks Yes
5 CLEC-2 deficient 4	weeks Yes
6 Podoplanin	deficient Day	12 No
7 Podoplanin	deficient Day	12 No
8 Podoplanin	deficient Day	12 No
9 Podoplanin	deficient 4	Weeks Yes
10 Podoplanin	deficient 4	weeks Yes
11 Wild	Type Day	5	 No
12 Wild	Type Day	5	 No
13 Wild	Type Day	5	 No
14 Wild	Type Day	5	 No
15 Wild	Type 4	weeks Yes
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5.6.1.  Podoplanin deficient mice exhibit greater hepatic infiltration by 
macrophages after 4 weeks MCD diet. 
Cytometric analysis revealed that the numbers of infiltrating leukocytes was different 
in WT and mutant mice after administration of the MCD diet. We noted that the 
overall numbers of CD45+ cells were greatest in the podoplanin deficient mice, 
although this information is drawn from only two remaining animals. The CLEC-2-
deficient mice had less CD45+ cells per gram of liver tissue compared to the WT and 
podoplanin-deficient mice, though again these results are from small numbers of 
animals. However further phenotyping of the infiltrating CD45+ cells revealed that 
there were more F4/80+ macrophages within the livers of the podoplanin-deficient 
mice compared to both the CLEC-2-deficient and WT mice. When we assessed the 
murine livers for the numbers of pro-fibrotic and restorative macrophages (defined in 
section 5.4.4), we noted that the CLEC-2 deficient mice had less restorative or 
'fibrosis resolution' macrophages compared to both the WT and podoplanin deficient 
mice. In contrast, the numbers of profibrotic macrophages were similar between the 
CLEC-2 and podoplanin deficient mice, with both greater than the WT mouse. In 
contrast to the pattern of myeloid cell infiltration, the last remaining WT mouse 
exhibited more CD3+, CD4+ and CD8+ lymphocyte infiltration compared to either of 
the mutant strains (fig 5.18). 
 242 
 
Figure 5.18 Podoplanin deficient mice exhibit greater macrophage infiltration whilst 
wild type mice exhibit greater lymphocyte accumulation after 4 weeks of MCD diet:  
12 week old WT, CLEC-2 or podoplanin deficient mice were placed on a methionine choline deficient 
(MCD) diet. Mice had free access to the diet. The mice were sacrificed after 4 weeks. Livers were 
digested and leukocytes isolated using a gradient separation method. Leukocytes were then stained, 
analyzed using flow cytometric methods and expressed as number of cells per gram of liver tissue. 
Cells defined as per previously gating strategies. Groups incorporated between 1 to 3 mice in each, 
data from individual mice are shown by a single point and median values are indicated by horizontal 
bar. Data are cells/ gram of liver tissue. 
 

















































































































Although 4 weeks of MCD diet did induce a degree of liver fibrosis in all three groups 
of mice studied, at this stage no obvious differences were noted between the three 
groups, the median level for hydroxyproline content per gram of liver was marginally 
greater in the podoplanin deficient mice. None of the differences were statistically 
significant. 
 
Figure 5.19 Four weeks of MCD diet induces a small amount of hepatic fibrosis:  
12 week old WT, CLEC-2 or podoplanin deficient mice: were placed on a methionine choline 
deficient (MCD) diet. Mice had free access to the diet. The mice were sacrificed after 4 
weeks. The livers were harvested, homogenized and treated with trichloroacetic acid to 
enable protein precipitation. The hydroxyproline concentration of the protein precipitant was 
then determined by colorimetric analysis using 4-(Dimethylamino)benzaldehyde (DMAB). 
Groups incorporated between 1 and 7 mice, data from individual mice are shown by a single 
point and median values are indicated by horizontal bar. Data are amount of hydroxy proline 































5.6.2.  Serum ALT 
We noted that the podoplanin deficient mice had a slightly lower ALT compared to 
WT or CLEC-2 deficient mice (fig 5.20). None of the differences were statistically 
significant. 
 
Figure 1.20 Four weeks of MCD diet causes hepatic necroinflammation:  
12 week old WT, CLEC-2 or podoplanin deficient mice were placed on a methionine choline deficient 
(MCD) diet. Mice had free access to the diet. The mice were sacrificed after 4 weeks. Serum was 
harvested via cardiac puncture and analyzed for serum ALT level. Groups incorporated between 1 and 
3 mice in each, data from individual mice are shown by a single point and median values are indicated 


















5.7.  Discussion 
Most agents used for the induction of fibrosis in mice including CCl4 are metabolized 
by the hepatocytes present closest to the central vein (centrizonal). Thus hepatocyte 
damage thus starts in this area and mice classically develop centrizonal or 
centrilobular fibrosis. We noted this pattern of in both WT and CLEC-2 deficient mice. 
If the fibrotic reaction is severe enough, it then extends to the portal areas. This 
represents an important point of difference with human liver disease, as fibrosis in 
chronic human liver disease is classically peri-portal. An exception to this is vascular 
or haemodynamic disorders such a Budd-Chiari syndrome where fibrosis occurs in a 
centrizonal distribution(233,244). When examining the role of CLEC-2 mediated 
platelet activation in hepatic fibrosis this fact is particularly relevant as podoplanin 
(the only known ligand for CLEC-2 mediated platelet activation)is upregulated 
predominantly in portal areas in both mice and humans. Thus if any difference is 
seen when blocking the CLEC-2/podoplanin axis it is likely that systemic and 
paracrine effects of podoplanin mediated platelet activation, including endothelial 
activation and release of soluble mediators/platelet cytokines play a role. 
5.7.1.  Carbon tetrachloride induced fibrogenesis 
Our observations demonstrate that there is a slight increase in the amount of fibrosis 
observed at the end of the active period of CCl4 injections in the CLEC-2 deficient 
mice. This would suggest that CLEC-2 driven platelet activation plays a minimal role 
(if any at all) in driving hepatic fibrogenesis or resolution from it. However the small 
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numbers of CLEC-2 deficient animals on the CCl4 protocol made drawing concrete 
conclusions challenging. 
In agreement with the acute injury experiments (chapter 4) we noted that after both 
active (where CCl4 was injected bi-weekly) and passive (where no injections were 
given for three weeks) phases of CCl4 mediated fibrotic liver injury a higher serum 
ALT was noted in WT mice compared to CLEC-2 deficient ones, and this 
corresponded to higher serum TNF- 𝛼 levels in the CLEC-2 deficient mice. Studies 
demonstrate the TNF- 𝛼 is an important driver of liver fibrosis after bile duct ligation in 
mice(245), and high levels of TNF- 𝛼 in both mice and humans with obesity induced 
NAFLD(246). We did see a trend for increased hydroxyproline and PSR staining in 
the CLEC-2 deficient mice that had highest TNFa levels, in agreement with a pro-
fibrogenic role but the data was not significant. Importantly we are unable to 
specifically determine the consequences of platelet activation on HSC function. 
Platelet derived CXCL-4(157), CXCL-7(247) and TGF-b (248) are all implicated as 
cytokines released upon platelet activation with direct effects on the fibrogenic 
potential of HSCs specifically aiding their conversion into collagen depositing 
myofibroblasts. It would therefore be expected that reduced platelet activation as a 
consequence of lack of platelet CLEC-2 would result in less fibrosis. We need further 
experiments to thus definitively determine the effect of CLEC-2 deficiency on fibrosis. 
To ascertain whether the CLEC-2-podoplanin pathway is of direct relevance, we will 
need to assess whether platelets activated by binding to podoplanin on hepatic 
endothelial cells or macrophage populations produce soluble mediators that can 
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activate local HSC to enable a phenotype switch to fibrogenic cells. We noted that 
CLEC-2 deficient mice exhibited reduced pro-fibrotic macrophage recruitment 
compared to WT mice at the end of the active period of CCl4 injections; this is 
conjunction with the lower serum ALT leads us to speculate whether there is perhaps 
a role for CLEC-2 mediated platelet activation in the recruitment of hepatocyte 
damaging immune cells. 
Another point to note when interpreting this data is that little is known about 
lymphangiogenesis(188) within the liver during fibrosis; cirrhotic livers seem to have 
a larger number of lymphatics than non-cirrhotic ones (188). Our data confirms a 
dramatic upregulation of podoplanin (which is used as a marker of lymphatic vessels) 
in cirrhotic human livers (chapter 3), we show that not all podoplanin in these 
damaged livers is exclusively on lymphatic endothelium (figs 3.9, 3,16). We know 
from embryonic studies that the CLEC-2-podoplanin pathway is critical to blood 
lymphatic separation and thus lymphatic vessel formation (70,227). CLEC-2 deficient 
mice may theoretically therefore have an impairment of lymphangiogenesis and as 
these vessels contain collagen, it may be that our data, which suggests no difference 
in hydroxyproline content (which measures hepatic collagen) between CLEC-2 
deficient and WT mice is affected by potentially differing amounts of 
lymphangiogenesis in the two arms, specifically potentially less lymphangiogenesis in 
CLEC-2 deficient animals. We did not assess whether there was a discrepancy in 
lymphatic vessel formation in the CLEC-2 deficient mice and using an alternative 
lymphatic marker such as LYVE-1 to quantify lymphangiogenesis in fibrotic mouse 
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livers will help dissect the contribution (if any) these vessels have to final measured 
hydroxyproline concentrations. 
To minimize the acute necro-inflammatory damage a single dose of CCl4 results in, 
we only sacrificed the mice 96 hours after the last dose of IP CCl4. Although unlikely 
this delay in sacrificing mice from the point of the last injection of CCl4 may have 
influenced the amount of fibrosis we observed. Overall the small numbers in our 
study preclude meaningful conclusions to be drawn. 
5.7.2.  MCD diet 
Owing to the rapid weight loss in mice on the MCD diet we had to cull approximately 
half of the mice on the MCD diet before we could establish the extent of liver injury 
developed. Low final numbers precluded meaningful conclusions to again be drawn 
when examining the role of CLEC-2 mediated platelet activation in MCD diet induced 
liver injury. It is notable however that more of the WT animals reached threshold, 
suggesting that in terms of disease development there was some protective effect of 
the CLEC-2 deficiency. However we did observe that even after 4 weeks of diet mice 
developed hepatic necroinflammation/injury as gauged by serum ALT. Another point 
of note is that most mice reached the 35% weight loss point specified by our license 
and thus had to be culled but remained clinically well, and displayed no other 
features consistent with distress including postural and motion changes, 
overgrooming or reduced feeding. Thus increasing the weight loss limit to 40% would 
allow us to continue mice on the diet for the recommended duration of 6 weeks We 
consider this particularly feasible as once mice reached 35% weight loss in most 
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cases their weight stabilized and they maintained this without much more weight lost 
over the subsequent weeks. Alternately since human fatty liver disease is associated 
with obesity and insulin resistance which are not recreated in the MCD model we 
would consider use of alternate models such as the choline-deficient high fat 
diet(249) to avoid some of the issues we faced with the MCD diet. 
Although our experiments were hindered by low mouse numbers and the fact that the 
mice that were analyzed in the end had only been on the MCD (113) diet for 4 
weeks, which may not a sufficient period of time to induce significant liver fibrosis, we 
feel that further investigation of the role the CLEC-2/podoplanin axis plays in NAFLD 
is warranted. Additionally some of the serum sent was un-analyzable due to the 
sample clotting on the analyzer. This was not an issue we encountered with mouse 
sera obtained from mice that had been on other liver injury protocols. This is likely to 
have been a technical issue with the actual cardiac puncture procedure as the mice 
on the diet were a smaller than the other mice we used and thus obtaining blood 
technically more complicated. This further limited the data available for analysis. 
We have established that that Kupffer cells upregulate podoplanin during liver injury 
and it has been described by various groups how these cells play a crucial role in 
driving insulin resistance in the metabolic syndrome(250–252). Thus abrogating this 
pathway in models of NAFLD may potentially yield clinically important data. The fact 
that soluble CLEC-2 has been shown to manipulate macrophage polarization and 
improve glucose homeostasis(253) supports this. Future work will involve assessing 
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metabolic profiles (including serum glucose and lipids) in mice on dietary protocol, 












6.  Conclusion and future directions 
6.1.  The macrophage:platelet interaction 
Our acute injury model data depends upon macrophage expression of podoplanin to 
provide the ligand for CLEC-2 dependent platelet activation in the injured liver. To 
confirm the role of macrophages in these models the next step would be to deplete 
macrophages thus removing the signal for platelet activation in the injured liver. 
Studies using mice deficient in the macrophage receptor CCR 2 [a key receptor in 
macrophage recruitment to the inflamed liver post APAP overdose(33)] reveals 
delayed healing or recovery from APAP toxicity, but this is in the context of infiltrating 
macrophages not resident Kupffer cells. Encouragingly studies in rats reveal that 
gadolinium mediated Kupffer cell depletion reduces the amount of APAP induced 
liver damage, with the authors speculating that this protective effect may be due to 
modulation of Kupffer cell activation and not infiltrating cells(33) . However APAP 
toxicity in rats is generally mild in comparison to mice or humans(254), so two 
separate experiments depleting both resident and then infiltrating macrophages in 
mice are necessary to accurately attribute which of the two populations is more 
important in APAP induced liver damage. KCs renew themselves from resident stem 
cells and are not replenished by the circulating myeloid monocytic compartment; it is 
however difficult to distinguish between liver resident macrophages and those 
derived from the blood. This is partly due to lack of robust conventional cellular 
phenotype markers to distinguish the two populations (particularly in humans) and 
partly due to the high cellular plasticity these cells exhibit(38). Future studies 
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delineating which of the podoplanin expressing macrophages are derived from local 
precursors and which ones are derived from the bone marrow are necessary. 
It is clear that podoplanin is upregulated within the injured liver. Acutely this 
upregulation is upon hepatic macrophages. In the context of acute toxic liver injury 
we show this upregulation to provide the necessary ligand for CLEC- 2 mediated 
platelet activation, the end result of this interaction is to dampen overall macrophage 
dependent TNF-a production and thus the resultant inflammation. The actual 
mechanism behind this is however less clear. It may be that platelet activation from 
macrophage podoplanin results in production or secretion of platelet cytokines which 
then feedback in a paracrine fashion to the stimulating macrophage eliciting TNF-a 
production. A candidate for such a bioactive mediator is sphingosine-1 phosphate 
(S1P). Platelet derived S1P (released in a CLEC-2/podoplanin dependent fashion) 
has already been shown to be important in the maintenance of high endothelial 
venue integrity during lymphocyte trafficking in lymph nodes(86) . Thus on ligating 
podoplanin, CLEC-2 driven platelet activation could cause the release of S1P which 
would then act on macrophages to dampen TNF-a production. Given the abundant 
potential sources of S1P including the endothelium, plasma, red blood cells, platelets 
and leukocytes(255), much further study including the development and use of 
selective cre mice to delineate a specific contribution (if any) of platelet derived S1P 
to the sterile inflammatory response is necessary. Interestingly, S1P has been shown 
to already ameliorate immune liver injury by recruiting myeloid derived suppressor 
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cells(255,256) and blocking S1P signaling enhances recovery from liver fibrosis in 
mice by enhancing regeneration (257). 
Another mechanism which may account for heightened TNF-a production from 
macrophages when encountering CLEC-2 deficient platelets is the direct effect 
CLEC-2 may have on macrophages via podoplanin ligation (i.e. without any platelet 
released soluble bioactive intermediary molecules). Podoplanin itself is linked to the 
actin cytoskeleton of the cell via the ERM proteins(69). Upregulation of podoplanin 
expression on macrophages (as we observed in vitro  and in vivo) occurs after an 
inflammatory stimulus and is known to phosphorylate the ERM proteins and activate 
the actin cytoskeleton of the cell. Thus ligation of podoplanin by CLEC-2 could 
conceivably have an effect upon TNF-a containing vesicle trafficking to the surface of 
the macrophage. Our data suggests that CLEC-2 ligation here would thus serve to 
dampen TNF-a containing vesicle movement to the surface of the cell. The use of 
intracellular imaging or the experiments using vesicle traffic inhibitors such as 
cytochalasin D would be key to confirming the role of this mechanism. 
6.2.  Hepatic inflammation and liver recovery 
Horiguchi et al report enhanced periportal sequestration of leukocytes after CCl4 
administration in mice that had a selective myeloid specific signal transducer and 
activation of transcription 3 (STAT 3) deficiency (STAT3 Mye-/-). They further report 
reduced hepatic necrosis in these mice albeit with enhanced inflammation(216) . As 
the histological phenotype (enhanced periportal leukocyte sequestration) is similar to 
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our findings in acute carbon tetrachloride intoxication, and STAT 3 is known to be an 
important negative regulator of inflammation it may be that the CLEC-2-podoplanin 
pathway exerts its effects by activating myeloid STAT-3. Further study in this area is 
necessary; the effect wild type and CLEC-2 deficient platelets have on STAT3 
induction in Kupffer cells will help clarify this. Another point Horiguchi et al mention is 
the enhanced production of serum interleukin 6 (IL6) in STAT3 Mye-/-, our data 
suggest that it is TNF-a that is enhanced and it may be that the two cytokines work at 
different points to aid liver recovery(216). 
T cells specifically CD4 T cells were noted in larger amounts in the CLEC-2 deficient 
mice after both APAP and CCl4 mediated liver injury, notable at peak points of injury 
(48 hours after CCl4 injection and at 24 hrs after APAP injection). As not part of the 
innate immune response per se, the traditional thinking suggests that the role for T 
cells in the pathogenesis of an acute toxic liver injury is limited thus we chose to 
focus on the myeloid compartment for our studies. However emerging evidence 
suggests that there may be a role for T helper cells and CD3+CD4-CD8- 
cells(33,258) in modulation of the inflammatory response that follows APAP induced 
liver injury(33). Given that podoplanin has also been described on a subset of T cell 
(th 17)(167) , further studies examining the role of T cells (by using antibody 
mediated depletion in the first instance) in mediating the protective effects that a 
CLEC-2/podoplanin blockade confers during acute toxic liver damage are important. 
We have identified some of the key cells and cytokines that result in the enhanced 
liver healing we noted from a toxic insult. The mechanism of this healing needs to be 
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elucidated next, it seems likely that neutrophil driven debris clearance accounts for 
some of our findings including the reduction in serum transaminase levels and 
restoration in hepatic architecture; the specific aspects of neutrophil function critical 
to this i.e. respiratory burst, phagocytic capacity etc remains to established. Slaba et 
al noted that platelets in fact pave the way into injured livers for neutrophils to enter 
and drive liver recovery(50); blocking integrin mediated neutrophil activation(259) or 
using streptococcal protein M5 to inhibit phagocytic clearance(260) will help us to 
precisely delineate which neutrophil functions are key to driving the liver recovery we 
observe with CLEC-2 blockade. Additionally recent work in oncology(261) has 
defined distinct populations of neutrophils with pro and anti-inflammatory functions, it 
thus become imperative in our future studies for us to further phenotype the nature of 
the neutrophil infiltrate after CLEC-2 blockade in acute liver injury. 
6.3.  Model limitations 
CLEC-2 expression has been described on neutrophils(262) and dendritic cells(182), 
although we used a PF4cre mouse which would theoretically restrict the CLEC-2 
deficiency to cells expressing PF4 i.e. of the megakaryocytic lineage and thus 
platelets; PF4 expression has been noted in haematopoietic stem cells(263). To 
ensure the phenotype we observed was due to platelet activation via CLEC-2, further 
experiments with platelet depletion and flow cytometric phenotyping of liver isolated 
dendritic cells and neutrophils (from the PF4CreCLEC1bfl/f mouse) to ensure CLEC-2 
expression is intact on these cells and thus not contributing to our observed 
phenotype are necessary. 
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For the experiments where we studied podoplanin blockade or deficiency, we either 
used a pan-podoplanin blocking antibody or the VAV1 cre mouse. Although the 
VAV1 cre mouse exhibited reduced injury at key time points after toxic liver injury 
(after both APAP and CCl4), the magnitude of the difference seen was not as 
impressive as what was observed using the podoplanin blocking antibody; it may be 
that the antibody was blocking podoplanin on sources other than just haematopoietic 
cells. Podoplanin is expressed upon lymphatic endothelium(264), and our data [and 
data from other researchers(189)] confirms that podoplanin is also expressed upon 
hepatic vascular endothelium. To delineate the contribution (if any) endothelial 
podoplanin expression has on reduced hepatic injury after toxic insult, we need to 
use a mouse such as the tie2cre where there is selective deficiency of endothelial 
podoplanin expression. 
Owing to mouse numbers available to us and time restrictions, we were unable to 
comprehensively define temporal healing patterns in all the models we used. For 
instance in most of the podoplanin blocking/deficient models of acute toxic injury we 
focused on the time points of maximal injury, so although we demonstrate reduced 
injury at these time points (section 4.9) we do not actually demonstrate enhanced 
recovery which we do with the CLEC-2 deficient mice. Further experiments filling in 
these gaps, thus confirming a single cogent mechanism are necessary. 
Finally alternative methods of blocking platelet activation (including platelet depletion 
and using anti-platelet therapy such as aspirin and clopidogrel) and blocking 
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downstream signaling (of CLEC-2) such as syk, would be ideal to compare whether a 
similar phenotype of enhanced recovery could be achieved. 
6.4.  Future clinical implications 
In murine models we noted that blocking platelet activation therapeutically using a 
podoplanin function blocking antibody enhanced liver healing after a toxic liver injury 
(section 4.9). As we confirm the same axis is present in humans, the ideal next step 
would be to humanize the antibody for potential use in human fulminant liver failure 
due to paracetamol overdose. Further preclinical studies analyzing the stoichiometry 
of podoplanin antibody binding and establishing rates of survival in mice subjected to 
paracetamol overdose and then treated with the antibody are necessary. Additionally 
establishing antibody specificity using western blotting or immunoprecipitation assays 
will be required in the pre-clinical phase. Importantly all of our data was from mice 
treated with the antibody prior to administration of the toxic insult, in order for the 
data to be more relevant to the clinical situation the antibody has to be administered 
after the insult and also be tested in situations of delayed and staggered overdose 
which are common ways in which human paracetamol overdose presents(265). The 
cohort of patients we feel would be most suitable for this therapy are patients with 
acute fulminant liver failure secondary to paracetamol overdose who although meet 
the Kings college criteria for transplantation are not transplantable (for instance due 
to extensive comorbidities). Another cohort of patients who could possibly benefit 
here are patients with acute alcoholic hepatitis, as abrogating TNF-a in these 
patients has been shown to worsen outcomes(220) . 
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In chronic liver disease the pattern of podoplanin expression differed to what was 
noted in acute toxic liver injury as in addition to macrophages we noted that 
podoplanin was now being expressed on vascular endothelium within the liver; 
podoplanin expression has not been noted on vascular endothelium previously. This 
point is particularly poignant as we go on to demonstrate a correlation between the 
development of portal venous thrombosis and hepatic levels of podoplanin (chapter 
3). Thus another potential application for a humanized podoplanin function blocking 
antibody could be in the treatment of portal venous thrombosis. As portal venous 
thrombosis can be associated with portal hypertension and thus bleeding 
oesophageo-gastricl varices-an anti-thrombotic therapy that does not increase 
bleeding risk could potentially be very valuable. Definitively ruling out podoplanin 
expression in vascular endothelium outside the liver would be critical before any such 
treatments could be considered. 
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